Biomarker	Gene	Alteration type	Alteration	Targeting	Drug status	Drug family	Drug	Association	Evidence level	Assay type	Source	Curator	Curation date	Primary Tumor type	Metastatic Tumor Type	TCGI included	Comments	Drug full name
ABL1 (T315I)	ABL1	MUT	ABL1:T315I			VEGFR inhibitor	Axitinib	Responsive	Pre-clinical		PMID:25686603	DTamborero	03/16	CANCER		TRUE		Axitinib (VEGFR inhibitor)
ABL1 (V299L)	ABL1	MUT	ABL1:V299L			Pan-kinase inhibitor	Cabozantinib	Responsive	Pre-clinical		PMID:26924578	DTamborero	03/16	CANCER		TRUE		Cabozantinib (Pan-kinase inhibitor)
ABL1 (V299L)	ABL1	MUT	ABL1:V299L			ALK inhibitor	Crizotinib	Responsive	Pre-clinical		PMID:26924578	DTamborero	03/16	CANCER		TRUE		Crizotinib (ALK inhibitor)
ABL1 (V299L)	ABL1	MUT	ABL1:V299L			MET inhibitor	Foretinib 	Responsive	Pre-clinical		PMID:26924578	DTamborero	03/16	CANCER		TRUE		Foretinib  (MET inhibitor)
ABL1 (V299L)	ABL1	MUT	ABL1:V299L			Pan-TK inhibitor	Vandetanib	Responsive	Pre-clinical		PMID:26924578	DTamborero	03/16	CANCER		TRUE		Vandetanib (Pan-TK inhibitor)
ABL1 (T315I)	ABL1	MUT	ABL1:T315I		Approved	[BCR-ABL inhibitor 2nd gen]	[Nilotinib,Dasatinib]	Resistant	European LeukemiaNet guidelines		PMID:21562040	CRubio-Perez	12/15	CML		TRUE	Has to be rechecked	BCR-ABL inhibitor 2nd gens (Nilotinib,Dasatinib,etc)
ABL1 (T315I)	ABL1	MUT	ABL1:T315I		Approved	BCR-ABL inhibitor  3rd gen	Bosutinib	Resistant	European LeukemiaNet guidelines		PMID:21562040	CRubio-Perez	12/15	CML		TRUE	Has to be rechecked	Bosutinib (BCR-ABL inhibitor  3rd gen)
ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	ABL1	MUT	ABL1:V299L,T315A,F317L,F317V,F317I,F317C		Approved	BCR-ABL inhibitor 2nd gen	Dasatinib	Resistant	European LeukemiaNet guidelines		PMID:21562040	CRubio-Perez	12/15	CML		TRUE	Has to be rechecked	Dasatinib (BCR-ABL inhibitor 2nd gen)
ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	ABL1	MUT	ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	European LeukemiaNet guidelines		PMID:21562040	CRubio-Perez	12/15	CML		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	ABL1	MUT	ABL1:E255K,E255V,Y253H,F359V,F359C,F359I		Approved	BCR-ABL inhibitor 2nd gen	Nilotinib	Resistant	European LeukemiaNet guidelines		PMID:21562040	CRubio-Perez	12/15	CML		TRUE		Nilotinib (BCR-ABL inhibitor 2nd gen)
ABL1 (T315I)	ABL1	MUT	ABL1:T315I		Approved	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann	12/15	CML;ALL		TRUE	REMAP: from T315. to T315I, 12/15 label update states the complete aminoacid change	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)
ABL1-BCR fusion	ABL1	FUS	ABL1__BCR		Approved	BCR-ABL inhibitor  3rd gen	Bosutinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		CML		TRUE		Bosutinib (BCR-ABL inhibitor  3rd gen)
ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	ABL1	MUT	ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I		Approved	BCR-ABL inhibitor  3rd gen	Bosutinib	Responsive	NCCN guidelines		PMID:21562040	RDientsmann		CML		TRUE		Bosutinib (BCR-ABL inhibitor  3rd gen)
ABL1-BCR fusion	ABL1	FUS	ABL1__BCR		Approved	BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		CML;ALL		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	ABL1	MUT	ABL1:F359V,F359C,F359I,Y253H,E255K,E255V		Approved	BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	NCCN guidelines		PMID:21562040	RDientsmann		CML		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
ABL1-BCR fusion	ABL1	FUS	ABL1__BCR		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	FDA guidelines		EMA	CRubio-Perez;DTamborero;RDientsmann		CML;ALL		TRUE	http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
ABL1-BCR fusion	ABL1	FUS	ABL1__BCR		Approved	BCR-ABL inhibitor 2nd gen	Nilotinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		CML		TRUE		Nilotinib (BCR-ABL inhibitor 2nd gen)
ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	ABL1	MUT	ABL1:T315A,F317L,F317V,F317I,F317C,V299L		Approved	BCR-ABL inhibitor 2nd gen	Nilotinib	Responsive	NCCN guidelines		PMID:21562040	RDientsmann		CML		TRUE		Nilotinib (BCR-ABL inhibitor 2nd gen)
ABL1-BCR fusion	ABL1	FUS	ABL1__BCR		Approved	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		CML;ALL		TRUE		Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)
ABL1 (T315I)	ABL1	MUT	ABL1:T315I		Approved	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib	Responsive	NCCN guidelines		PMID:21562040	RDientsmann		CML		TRUE		Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)
ABL1-BCR fusion	ABL1	FUS	ABL1__BCR			BCR-ABL inhibitor 2nd gen;BCL2 inhibitor	Dasatinib;Venetoclax	Responsive	Pre-clinical		PMID:27582059	RDientsmann	12/16	ALL		TRUE		Dasatinib + Venetoclax (BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)
AKT1 (Q79K,E17K)	AKT1	MUT	AKT1:Q79K,E17K			[BRAF inhibitor]	[]	Resistant	Case report		PMID:24265152	RDientsmann;DTamborero	03/16	CM		TRUE		BRAF inhibitors
AKT1 (E17K)	AKT1	MUT	AKT1:E17K			[PI3K pathway inhibitor]	[]	Responsive	Case report		PMID:26763254	RDientsmann	07/16	HNSC		TRUE		PI3K pathway inhibitors
AKT1 (E17K)	AKT1	MUT	AKT1:E17K			MTOR inhibitor	Tensirolimus	Responsive	Early trials		PMID:27016228	RDientsmann	07/16	ED		TRUE		Tensirolimus (MTOR inhibitor)
AKT1 (E17K)	AKT1	MUT	AKT1:E17K		Clinical Trials	[AKT inhibitor]	[]	Responsive	Pre-clinical		PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)	RDientsmann	11/15	CANCER		TRUE		AKT inhibitors
AKT1 (E17K)	AKT1	MUT	AKT1:E17K		Clinical Trials	[non-allosteric AKT inhibitor]	[]	Responsive	Early trials		ENA 2015 (abstract B109)	RDientsmann		CANCER		TRUE		non-allosteric AKT inhibitors
AKT1 (E17K)	AKT1	MUT	AKT1:E17K		Clinical Trials	[allosteric AKT inhibitor]	[]	Responsive	Pre-clinical		PMID:21464312;PMID:17611497	RDientsmann		BRCA		TRUE		allosteric AKT inhibitors
AKT1 (H238Y)	AKT1	MUT	AKT1:H238Y			MTOR inhibitor	Everolimus	Responsive	Case report		ASCO 2015 (abstr 11010)	RDientsmann		FH		TRUE		Everolimus (MTOR inhibitor)
AKT2 amplification	AKT2	CNA	AKT2:amp		Clinical Trials	Allosteric AKT inhibitor	MK2206	Responsive	Pre-clinical		ENA 2014 (abstr 373)	RDientsmann		CANCER		TRUE		MK2206 (Allosteric AKT inhibitor)
AKT3 fusion	AKT3	FUS	AKT3__.	Direct	Clinical Trials;Clinical Trials	[ATP competitive AKT inhibitor]	[AZD5363,GSK2141795]	Responsive	Pre-clinical	Cell line	PMID:22722202	JAlbanell;ARovira;RDientsmann	09/15	BRCA		TRUE		ATP competitive AKT inhibitors (AZD5363,GSK2141795,etc)
ALK fusion	ALK	FUS	ALK__.			[HSP90 inhibitor]	[]	Responsive	Early trials		PMID:23553849	RDientsmann	01/16	LUAD		TRUE		HSP90 inhibitors
ALK fusion	ALK	FUS	ALK__.			[novel ALK inhibitor]	[]	Responsive	Early trials		PMID:23639470	RDientsmann	01/16	LUAD		TRUE		novel ALK inhibitors
ALK (F1174L)	ALK	MUT	ALK:F1174L			[novel ALK inhibitor]	[]	Responsive	Pre-clinical		PMID:24327273	RDientsmann	01/16	LUAD		TRUE		novel ALK inhibitors
ALK fusion	ALK	FUS	ALK__.			[ALK inhibitor;IGF1R inhibitor]	[]	Responsive	Pre-clinical		PMID:25173427	RDientsmann	01/16	LUAD		TRUE		ALK inhibitor + IGF1R inhibitors
ALK fusion	ALK	FUS	ALK__.			[ALK inhibitor;SRC inhibitor]	[]	Responsive	Pre-clinical		PMID:25394791	RDientsmann	01/16	LUAD		TRUE		ALK inhibitor + SRC inhibitors
ALK fusion	ALK	FUS	ALK__.			[ALK inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:26301689	RDientsmann	01/16	LUAD		TRUE		ALK inhibitor + MEK inhibitors
ALK fusion	ALK	FUS	ALK__.			[ALK inhibitor]	[]	Responsive	Case report		PMID:26633560	RDientsmann	01/16	COREAD		TRUE		ALK inhibitors
ALK (I1171T)	ALK	MUT	ALK:I1171T			ALK inhibitor	Alectinib	Resistant	Case report		PMID:25228534	RDientsmann	01/16	LUAD		TRUE		Alectinib (ALK inhibitor)
ALK inframe insertion (1151T)	ALK	MUT	ALK::consequence::inframe_insertion:.1151T.			ALK inhibitor	Ceritinib	Responsive	FDA guidelines		PMID:24670165	RDientsmann	01/16	LUAD		TRUE		Ceritinib (ALK inhibitor)
ALK (L1196M,S1206Y,G1269A,I1171T)	ALK	MUT	ALK:L1196M,S1206Y,G1269A,I1171T			ALK inhibitor	Ceritinib	Responsive	FDA guidelines		PMID:24670165;PMID:24327273	RDientsmann	01/16	LUAD		TRUE		Ceritinib (ALK inhibitor)
ALK (F856S,A348D)	ALK	MUT	ALK:F856S,A348D			ALK inhibitor	Crizotinib	Responsive	Pre-clinical		PMID:26032424	RDientsmann	01/16	AML		TRUE		Crizotinib (ALK inhibitor)
ALK (L1198F)	ALK	MUT	ALK:L1198F			ALK inhibitor	Crizotinib	Responsive	Case report		PMID:26698910	RDientsmann	04/16	LUAD		TRUE		Crizotinib (ALK inhibitor)
ALK (G1123S)	ALK	MUT	ALK:G1123S			ALK inhibitor	Ceritinib	Resistant	Case report		PMID:26134233	EArriola	09/15	LUAD		TRUE		Ceritinib (ALK inhibitor)
ALK (C1156Y,L1196M)	ALK	MUT	ALK:C1156Y,L1196M		Approved	ALK inhibitor	Crizotinib	Resistant	Case report		PMID:20979473	EArriola	09/15	NSCLC		TRUE		Crizotinib (ALK inhibitor)
ALK oncogenic mutation	ALK	MUT	ALK:.		Approved	ALK inhibitor	Crizotinib	Resistant	Clinical trial		PMID:22235099	EArriola	09/15	NSCLC		TRUE		Crizotinib (ALK inhibitor)
ALK amplification	ALK	CNA	ALK:amp		Approved	ALK inhibitor	Crizotinib	Resistant	Clinical trial		PMID:22235099	EArriola	09/15	NSCLC		TRUE		Crizotinib (ALK inhibitor)
ALK fusion	ALK	FUS	ALK__.			ALK inhibitor	Crizotinib	Responsive	Early trials		PMID:24491302;NCT02270034	MMartínez;RDientsmann	09/15	LY;GB		TRUE		Crizotinib (ALK inhibitor)
ALK fusion	ALK	FUS	ALK__.			ALK inhibitor	Alectinib	Responsive	FDA guidelines		FDA	RDientsmann	12/16	LUAD		TRUE		Alectinib (ALK inhibitor)
ALK fusion	ALK	FUS	ALK__.		Approved	ALK inhibitor	Ceritinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann	12/16	NSCLC;LUAD		TRUE		Ceritinib (ALK inhibitor)
ALK fusion	ALK	FUS	ALK__.			ALK inhibitor	Ceritinib	Responsive	Case report		PMID:26633560;PMID:26933125;PMID:27742657	RDientsmann	12/16	COREAD;IM		TRUE		Ceritinib (ALK inhibitor)
ALK fusion	ALK	FUS	ALK__.			Pan-TK inhibitor	Entrictinib	Responsive	Case report		PMID:26633560;PMID:26933125	RDientsmann	12/16	COREAD		TRUE		Entrictinib (Pan-TK inhibitor)
ALK fusion	ALK	FUS	ALK__.		Clinical_Trials	ALK inhibitor	Alectinib	Responsive	FDA guidelines		FDA	EArriola;CRubio-Perez		NSCLC		TRUE		Alectinib (ALK inhibitor)
ALK fusion	ALK	FUS	ALK__.	Direct	Clinical Trials	ALK inhibitor	Ceritinib	Responsive	Early trials		NCT02186821	ECampo		HEMATO		TRUE		Ceritinib (ALK inhibitor)
ALK fusion	ALK	FUS	ALK__.		Approved	ALK inhibitor	Crizotinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		NSCLC;LUAD		TRUE		Crizotinib (ALK inhibitor)
ALK fusion	ALK	FUS	ALK__.			ALK inhibitor	Crizotinib	Responsive	Case report		PMID:20979472;PMID:24687827	RDientsmann		IM;THCA		TRUE		Crizotinib (ALK inhibitor)
ALK (F1174L)	ALK	MUT	ALK:F1174L			ALK inhibitor	Crizotinib	Resistant	Pre-clinical		PMID:22072639	RDientsmann		G		TRUE		Crizotinib (ALK inhibitor)
ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	ALK	MUT	ALK:R1275Q,G1128A,I1171N,R1192P,F1245C			ALK inhibitor	Crizotinib	Responsive	Pre-clinical		PMID:22072639	RDientsmann		G		TRUE		Crizotinib (ALK inhibitor)
ALK inframe insertion (1151T)	ALK	MUT	ALK::consequence::inframe_insertion:.1151T.			ALK inhibitor	Crizotinib	Resistant	Case report		PMID:22277784	RDientsmann		LUAD		TRUE		Crizotinib (ALK inhibitor)
ALK amplification	ALK	CNA	ALK:amp			ALK inhibitor	Crizotinib	Resistant	Case report		PMID:22277784	RDientsmann		LUAD		TRUE		Crizotinib (ALK inhibitor)
ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	ALK	MUT	ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T			ALK inhibitor	Crizotinib	Resistant	Case report		PMID:22277784;PMID:25228534	RDientsmann		LUAD		TRUE		Crizotinib (ALK inhibitor)
APC oncogenic mutation	APC	MUT	APC:.			[Tankyrase inhibitor]	[]	Responsive	Pre-clinical		PMID:22440753;PMID:23539443	RDientsmann		COREAD		TRUE		Tankyrase inhibitors
AR (W741,T878A)	AR	MUT	AR:W741.,T878A			AR inhibitor	Arn-509	Responsive	Pre-clinical		PMID:23779130	RDientsmann	01/16	PRAD		TRUE	REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.	Arn-509 (AR inhibitor)
AR (W741,T878A)	AR	MUT	AR:W741.,T878A			AR inhibitor	Enzalutamide	Responsive	Pre-clinical		PMID:23779130	RDientsmann	01/16	PRAD		TRUE	REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.	Enzalutamide (AR inhibitor)
AR overexpression	AR	EXPR	AR:over	Direct	Clinical Trials	[AR inhibitor]	[Bicalutamide,Enzalutamide,Orterone,4OHtestosterone]	Responsive	Early trials		ASCO 2015 (abstr 1003)	JAlbanell;ARovira	09/15	BRCA		TRUE		AR inhibitors (Bicalutamide,Enzalutamide,Orterone,4OHtestosterone,etc)
AR (F877L)	AR	MUT	AR:F877L			AR inhibitor	Arn-509	Resistant	Case report		PMID:23779130	RDientsmann;ARodriguez-Vida	09/15	PRAD	PRAD	TRUE	REMAP:F876L to F877L the previous mutation was not found in . transcript to our knowledge.	Arn-509 (AR inhibitor)
AR overexpression	AR	EXPR	AR:over	Direct	Approved	AR inhibitor	Enzalutamide	Responsive	Early trials		PMID:24882673	ARodriguez-Vida	09/15	PRAD	PRAD	TRUE		Enzalutamide (AR inhibitor)
AR (F877L)	AR	MUT	AR:F877L			AR inhibitor	Enzalutamide	Resistant	Case report		PMID:23779130	RDientsmann;ARodriguez-Vida	09/15	PRAD	PRAD	TRUE	REMAP:F876L to F877L the previous mutation was not found in . transcript to our knowledge.	Enzalutamide (AR inhibitor)
AR (T878A)	AR	MUT	AR:T878A			AR inhibitor	Flutamide	Resistant	Case report		PMID:2260966	RDientsmann;ARodriguez-Vida	09/15	PRAD	PRAD	TRUE	REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.	Flutamide (AR inhibitor)
AR (L702H,T878A)	AR	MUT	AR:L702H,T878A		Approved	AR inhibitor	Abiraterone	Resistant	Early trials		PMID:26537258	RDientsmann	11/15	PRAD		TRUE	REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.	Abiraterone (AR inhibitor)
AR amplification	AR	CNA	AR:amp		Approved	AR inhibitor	Abiraterone	Resistant	Early trials		PMID:26537258	RDientsmann	11/15	PRAD		TRUE		Abiraterone (AR inhibitor)
AR amplification	AR	CNA	AR:amp			[AR inhibitor next gen]	[]	Responsive	Pre-clinical		PMID:23589709;PMID:21859989	RDientsmann		PRAD		TRUE		AR inhibitor next gens
AR (F877L) + AR (T878A)	AR;AR	MUT;MUT	AR:F877L;AR:T878A			AR inhibitor	Enzalutamide	Responsive	Pre-clinical		PMID:27196756	RDientsmann	12/16	PRAD		TRUE		Enzalutamide (AR inhibitor)
ARAF (S214C)	ARAF	MUT	ARAF:S214C	Direct:primary target	FDA approved	Pan-TK inhibitor	Sorafenib	Responsive	Case report		http://www.jci.org/articles/view/72763;PMID:24569458	JAlbanell;ARovira;RDientsmann	09/15	LUAD		TRUE		Sorafenib (Pan-TK inhibitor)
ARAF oncogenic mutation	ARAF	MUT	ARAF:.			[BRAF inhibitor;EGFR mAb inhibitor]	[]	Resistant	Case report		ENA 2014 (abstr 428)	RDientsmann		COREAD		TRUE		BRAF inhibitor + EGFR mAb inhibitors
ARAF oncogenic mutation	ARAF	MUT	ARAF:.			[BRAF inhibitor;MEK inhibitor]	[]	Resistant	Case report		ENA 2014 (abstr 428)	RDientsmann		COREAD		TRUE		BRAF inhibitor + MEK inhibitors
AREG amplification	AREG	CNA	AREG:amp			[EGFR mAb inhibitor]	[]	Responsive	Early trials		PMID:19738126;PMID:26341080	RDientsmann	04/16	COREAD		TRUE		EGFR mAb inhibitors
ARID1A oncogenic mutation	ARID1A	MUT	ARID1A:.			[EZH2 inhibitor]	[]	Responsive	Pre-clinical		PMID:25686104	RDientsmann	01/16	OV		TRUE		EZH2 inhibitors
ARID1A oncogenic mutation	ARID1A	MUT	ARID1A:.			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:26069190	RDientsmann	11/15	CANCER		TRUE		PARP inhibitors
ARID1A amplification + ANXA1 overexpression	ARID1A;ANXA1	CNA;EXPR	ARID1A:amp;ANXA1:over		FDA approved	ERBB2 mAb inhibitor	Trastuzumab	Resistant	Early trials		PMID:27172896	RDientsmann	12/16	BRCA		TRUE	Anaxa 1 high	Trastuzumab (ERBB2 mAb inhibitor)
ARID1A oncogenic mutation + ANXA1 overexpression	ARID1A;ANXA1	MUT;EXPR	ARID1A:.;ANXA1:over		FDA approved	ERBB2 mAb inhibitor	Trastuzumab	Resistant	Early trials		PMID:27172896	RDientsmann	12/16	BRCA		TRUE	Anaxa 1 high	Trastuzumab (ERBB2 mAb inhibitor)
ATM oncogenic mutation	ATM	MUT	ATM:.			PARP inhibitor	Olaparib	Responsive	Early trials		ENA 2014 (abstr 8LBA);PMID:26510020	RDientsmann	01/16	ST;PRAD		TRUE		Olaparib (PARP inhibitor)
ATM deletion	ATM	CNA	ATM:del	Indirect	Approved	Chemotherapy	Cisplatin	Responsive	Early trials		PMID:26238431	ARodriguez-Vida	09/15	BLCA	BLCA	TRUE		Cisplatin (Chemotherapy)
ATM oncogenic mutation	ATM	MUT	ATM:.	Indirect	Approved	Chemotherapy	Cisplatin	Responsive	Early trials		PMID:26238431	ARodriguez-Vida	09/15	BLCA	BLCA	TRUE		Cisplatin (Chemotherapy)
ATM oncogenic mutation	ATM	MUT	ATM:.			[ATR inhibitor]	[]	Responsive	Case report		ENA 2015 (abstr A48)	RDientsmann	11/15	COREAD		TRUE		ATR inhibitors
ATM deletion	ATM	CNA	ATM:del			[ATR inhibitor]	[]	Responsive	Case report		ENA 2015 (abstr A48)	RDientsmann	11/15	COREAD		TRUE		ATR inhibitors
ATM oncogenic mutation	ATM	MUT	ATM:.			[DNA-PKc inhibitor]	[]	Responsive	Pre-clinical		PMID:23761041	RDientsmann	11/15	LY		TRUE		DNA-PKc inhibitors
ATM deletion	ATM	CNA	ATM:del			[DNA-PKc inhibitor]	[]	Responsive	Pre-clinical		PMID:23761041	RDientsmann	11/15	LY		TRUE		DNA-PKc inhibitors
ATM oncogenic mutation	ATM	MUT	ATM:.			[PARP inhibitor]	[]	Responsive	Early trials		ENA 2014 (abstr 8LBA)	RDientsmann		ST		TRUE		PARP inhibitors
ATM deletion	ATM	CNA	ATM:del			[PARP inhibitor]	[]	Responsive	Early trials		ENA 2014 (abstr 8LBA)	RDientsmann		ST		TRUE		PARP inhibitors
ATM biallelic inactivation	ATM	BIA	ATM:.	Indirect	Clinical Trials	ATR inhibitor	AZD6738	Responsive	Early trials		NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	ECampo		BCL		TRUE		AZD6738 (ATR inhibitor)
ATM oncogenic mutation	ATM	MUT	ATM:.			Chemotherapy	Temozolomide	Responsive	Pre-clinical		PMID:23960094	RDientsmann		G		TRUE		Temozolomide (Chemotherapy)
ATR oncogenic mutation	ATR	MUT	ATR:.	Indirect	Approved	PARP inhibitor	Olaparib	Responsive	Pre-clinical	Cell line	PMID:23548269	CRubio-Perez;ECampo;RDientsmann		OV;CANCER		TRUE		Olaparib (PARP inhibitor)
ATR deletion	ATR	CNA	ATR:del	Indirect	Approved	PARP inhibitor	Olaparib	Responsive	Pre-clinical	Cell line	PMID:23548269	CRubio-Perez;ECampo;RDientsmann		OV;CANCER		TRUE		Olaparib (PARP inhibitor)
ATR oncogenic mutation	ATR	MUT	ATR:.			Chemotherapy	Temozolomide	Responsive	Pre-clinical		PMID:23960094	RDientsmann		G		TRUE		Temozolomide (Chemotherapy)
AURKA amplification	AURKA	CNA	AURKA:amp			[AURK inhibitor]	[]	Responsive	Pre-clinical		PMID:22302096;PMID:22389870	RDientsmann		PRAD;CANCER		TRUE		AURK inhibitors
B2M oncogenic mutation	B2M	MUT	B2M:.			[PD1 Ab inhibitor]	[]	Resistant	Case report		PMID:27433843	RDientsmann	07/16	CM		TRUE		PD1 Ab inhibitors
BAP1 oncogenic mutation	BAP1	MUT	BAP1:.			[EZH2 inhibitor]	[]	Responsive	Pre-clinical		PMID:26437366	RDientsmann	11/15	MESO		TRUE		EZH2 inhibitors
BAP1 deletion	BAP1	CNA	BAP1:del			[EZH2 inhibitor]	[]	Responsive	Pre-clinical		PMID:26437366	RDientsmann	11/15	MESO		TRUE		EZH2 inhibitors
BAP1 oncogenic mutation	BAP1	MUT	BAP1:.			[HDAC inhibitor]	[]	Responsive	Pre-clinical		PMID:22038994	RDientsmann		CM		TRUE		HDAC inhibitors
BAP1 deletion	BAP1	CNA	BAP1:del			[HDAC inhibitor]	[]	Responsive	Pre-clinical		PMID:22038994	RDientsmann		CM		TRUE		HDAC inhibitors
BAP1 oncogenic mutation	BAP1	MUT	BAP1:.			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:22683710	RDientsmann		R;CANCER		TRUE		PARP inhibitors
BAP1 deletion	BAP1	CNA	BAP1:del			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:22683710	RDientsmann		R;CANCER		TRUE		PARP inhibitors
BCL2 amplification	BCL2	CNA	BCL2:amp			[BCL2 inhibitor]	[]	Responsive	Pre-clinical		PMID:22649144	RDientsmann		LY		TRUE		BCL2 inhibitors
BCL overexpression	BCL	EXPR	BCL2:over			BCL2 inhibitor;Proteasome inhibitor	Venetoclax;Bortezomib	Responsive	Early trials		ASH 2015 (Blood 2015 126:2975)	CRubio-Perez	02/17	MM		TRUE		Venetoclax + Bortezomib (BCL2 inhibitor + Proteasome inhibitor)
BCL6 overexpression	BCL6	EXPR	BCL6:over			HSP90 inhibitor	Onalespib	Responsive	Early trials		NCT02572453	CRubio-Perez	02/17	LY		TRUE		Onalespib (HSP90 inhibitor)
BCOR oncogenic mutation	BCOR	MUT	BCOR:.			PKCb inhibitor	Enzastaurin	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	ST		TRUE		Enzastaurin (PKCb inhibitor)
BRAF (V600D,V600K,V600M,V600G,V600R)	BRAF	MUT	BRAF:V600D,V600K,V600M,V600G,V600R		Approved	BRAF inhibitor	Vemurafenib	Responsive	NCCN guidelines		NCCN	CRubio-Perez	16/06	CM		TRUE		Vemurafenib (BRAF inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[BRAF inhibitor;MEK inhibitor]	[]	Responsive	Early trials		ASCO 2013 (abstr 9029)	RDientsmann	01/16	TH		TRUE		BRAF inhibitor + MEK inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[MEK inhibitor]	[]	Responsive	Early trials		PMID:22241789	RDientsmann	01/16	TH		TRUE		MEK inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[BRAF inhibitor;HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:22351686	RDientsmann	01/16	CM		TRUE		BRAF inhibitor + HSP90 inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[BRAF inhibitor;PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:22389471;PMID:21156289	RDientsmann	01/16	CM		TRUE		BRAF inhibitor + PI3K pathway inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[BRAF inhibitor;CDK2/4 inhibitor]	[]	Responsive	Pre-clinical		PMID:22997239	RDientsmann	01/16	CM		TRUE		BRAF inhibitor + CDK2/4 inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[ERK inhibitor]	[]	Responsive	Pre-clinical		PMID:23614898;PMID:22997239	RDientsmann	01/16	CM		TRUE		ERK inhibitors
BRAF (L597R)	BRAF	MUT	BRAF:L597R			[BRAF inhibitor]	[]	Responsive	Case report		PMID:23715574	RDientsmann	01/16	CM		TRUE		BRAF inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			BRAF inhibitor;MEK inhibitor	Dabrafenib;Trametinib	Responsive	Early trials		PMID:26392102;ASCO 2015 (abstr 8006)	RDientsmann	01/16	COREAD		TRUE		Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)
BRAF (V600)	BRAF	MUT	BRAF:V600.	Indirect	Approved; Approved;Clinical Trials	EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor	Panitumumab;Dabrafenib;BYL719	Responsive	Early trials		ENA 2014 (abstr 11LBA)	RDientsmann	01/16	COREAD		TRUE		Panitumumab + Dabrafenib + BYL719 (EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E	Indirect	Approved; Approved;Clinical Trials	EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor	Panitumumab;Dabrafenib;Trametinib	Responsive	Early trials		ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	RDientsmann	01/16	COREAD		TRUE		Panitumumab + Dabrafenib + Trametinib (EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)
BRAF fusion	BRAF	FUS	BRAF__.			MEK inhibitor	Selumetinib	Responsive	Case report		PMID:26324360	RDientsmann	01/16	OV		TRUE		Selumetinib (MEK inhibitor)
BRAF (V600E,G469A)	BRAF	MUT	BRAF:V600E,G469A			[EGFR TK inhibitor]	[]	Resistant	Case report		PMID:22773810	RDientsmann	04/16	LUAD		TRUE	UPDATE: delete G469A mutation in v16 GDKD?	EGFR TK inhibitors
BRAF inframe deletion (L485),inframe deletion (P490)	BRAF	MUT	BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.			[Pan-RAF inhibitor]	[]	Responsive	Pre-clinical		PMID:26732095	RDientsmann	04/16	CANCER		TRUE		Pan-RAF inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			BRAF inhibitor	Dabrafenib	Responsive	Early trials		PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	RDientsmann	04/16	LUAD;TH		TRUE		Dabrafenib (BRAF inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E		Approved	BRAF inhibitor	Vemurafenib	Responsive	Case report		PMID:22743296;PMID:22621641;PMID:23612012	RDientsmann	04/16	LUAD;HCL;MYMA		TRUE		Vemurafenib (BRAF inhibitor)
BRAF inframe deletion (L485),inframe deletion (P490)	BRAF	MUT	BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.		Approved	BRAF inhibitor	Vemurafenib	Resistant	Pre-clinical		PMID:26732095	RDientsmann	04/16	CANCER		TRUE		Vemurafenib (BRAF inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[Pan-RAF inhibitor]	[]	Responsive	Early trials		ESMO 2015 (abstract 300);AACR 2016 (abstr CT005)	RDientsmann	06/16	CM;TH		TRUE		Pan-RAF inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			BRAF inhibitor	Dabrafenib	Responsive	NCCN guidelines		NCCN	CRubio-Perez	06/16	NSCLC		TRUE		Dabrafenib (BRAF inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			BRAF inhibitor;MEK inhibitor	Dabrafenib;Trametinib	Responsive	Case report		PMID:27048246	RDientsmann	07/16	NEU		TRUE		Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			BRAF inhibitor	PLX4720	Responsive	Pre-clinical	Cell line	PMC3638050	MMartínez	09/15	MA		TRUE		PLX4720 (BRAF inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E		Clinical Trials	MEK inhibitor	Selumetinib	Responsive	Early trials		NCT01089101	MMartínez	09/15	PG		TRUE		Selumetinib (MEK inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E		Approved	BRAF inhibitor	Vemurafenib	Responsive	Early trials		PMID:22586120	MMartínez	09/15	MA		TRUE		Vemurafenib (BRAF inhibitor)
BRAF (V600E,V600K)	BRAF	MUT	BRAF:V600E,V600K		Approved	BRAF inhibitor;MEK inhibitor	Vemurafenib;Cobimetinib	Responsive	FDA guidelines		FDA	RDientsmann	11/15	CM		TRUE		Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:19018267	RDientsmann		OV		TRUE		MEK inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[BRAF inhibitor]	[]	Responsive	Pre-clinical		PMID:22038996;PMID:22586120	RDientsmann		G		TRUE		BRAF inhibitors
BRAF (V600E)	BRAF	MUT	BRAF:V600E			[BRAF inhibitor]	[]	Responsive	Case report		PMID:22608338	RDientsmann		OV		TRUE		BRAF inhibitors
BRAF (K601R,L597R,V600R)	BRAF	MUT	BRAF:K601R,L597R,V600R			[MEK inhibitor]	[Trametinib]	Responsive	Case report		PMID:23248257;PMID:22805292;PMID:23248257	RDientsmann		CM		TRUE		MEK inhibitors (Trametinib,etc)
BRAF fusion	BRAF	FUS	BRAF__.			[MEK inhibitor]	[Trametinib]	Responsive	Pre-clinical		PMID:24727320;PMID:24345920;PMID:20526349	RDientsmann		LUAD;CM;PRAD		TRUE		MEK inhibitors (Trametinib,etc)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			EGFR mAb inhibitor	Cetuximab	Resistant	Late trials		PMID:20619739;PMID:21163703;PMID:23325582	RDientsmann		COREAD		TRUE		Cetuximab (EGFR mAb inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E		Approved	BRAF inhibitor	Dabrafenib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		CM		TRUE		Dabrafenib (BRAF inhibitor)
BRAF (V600R)	BRAF	MUT	BRAF:V600R			BRAF inhibitor	Dabrafenib	Responsive	Early trials		PMID:23237741	RDientsmann		CM		TRUE		Dabrafenib (BRAF inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			BRAF inhibitor	Dabrafenib	Responsive	Case report		PMID:23470635;PMID:22608338	RDientsmann		GIST		TRUE		Dabrafenib (BRAF inhibitor)
BRAF (V600E,V600K)	BRAF	MUT	BRAF:V600E,V600K		Approved	BRAF inhibitor;MEK inhibitor	Dabrafenib;Trametinib	Responsive	FDA guidelines		FDA	RDientsmann		CM		TRUE		Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)
BRAF (Y472C)	BRAF	MUT	BRAF:Y472C			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Case report		PMID:22649091	RDientsmann		LUAD		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
BRAF (G466V)	BRAF	MUT	BRAF:G466V			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:22649091	RDientsmann		LUAD		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			EGFR mAb inhibitor	Panitumumab	Resistant	Late trials		PMID:20619739;PMID:21163703;PMID:23325582	RDientsmann		COREAD		TRUE		Panitumumab (EGFR mAb inhibitor)
BRAF (D594G,G469E)	BRAF	MUT	BRAF:D594G,G469E			Pan-TK inhibitor	Sorafenib	Responsive	Pre-clinical		PMID:18794803	RDientsmann		CM		TRUE		Sorafenib (Pan-TK inhibitor)
BRAF fusion	BRAF	FUS	BRAF__.			Pan-TK inhibitor	Sorafenib	Responsive	Pre-clinical		PMID:238900088;PMID:20526349;PMID:24727320	RDientsmann		CM;LUAD;PRAD		TRUE		Sorafenib (Pan-TK inhibitor)
BRAF (V600E,V600K)	BRAF	MUT	BRAF:V600E,V600K		Approved	MEK inhibitor	Trametinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		CM		TRUE		Trametinib (MEK inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E		Approved	BRAF inhibitor	Vemurafenib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		CM		TRUE		Vemurafenib (BRAF inhibitor)
BRAF (V600)	BRAF	MUT	BRAF:V600.		Approved	BRAF inhibitor	Vemurafenib	No Responsive	Early trials		PMID:26287849	DTamborero		COREAD		TRUE		Vemurafenib (BRAF inhibitor)
BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	BRAF	MUT	BRAF:V600E,V600D,V600K,V600M,V600G,V600R	Indirect	Approved	BRAF inhibitor	Vemurafenib	Responsive	NCCN guidelines		PMID:26287849	DTamborero		NSCLC;HISLC;HISEC		TRUE		Vemurafenib (BRAF inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E		Approved	BRAF inhibitor	Vemurafenib	Responsive	Early trials		PMID:22608338;PMID:20818844;PMID:23489023	RDientsmann		THCA		TRUE		Vemurafenib (BRAF inhibitor)
BRAF (V600E)	BRAF	MUT	BRAF:V600E			BRAF inhibitor;MEK inhibitor	Dabrafenib;Trametinib	Responsive	FDA guidelines		PMID:27283860	RDientsmann	12/16	LUAD		TRUE		Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)
BRAF (G469A) + EGFR oncogenic mutation	BRAF;EGFR	MUT;MUT	BRAF:G469A;EGFR:.			[EGFR TK inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:22773810	RDientsmann	01/16	LUAD		TRUE		EGFR TK inhibitor + MEK inhibitors
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			PARP inhibitor	Olaparib	Responsive	Early trials		PMID:26510020	RDientsmann	01/16	PRAD		TRUE		Olaparib (PARP inhibitor)
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			Chemotherapy	Platinum Agent	Responsive	Early trials		PMID:25847936	RDientsmann	01/16	BRCA		TRUE		Platinum Agent (Chemotherapy)
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			[PARP inhibitor;Chemotherapy]	[]	Responsive	Early trials		PMID:22307137;ASCO 2012 (abstr 1009)	RDientsmann	04/16	OV		TRUE		PARP inhibitor + Chemotherapys
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.		Approved	PARP inhibitor	Olaparib	Responsive	FDA guidelines		FDA	RDientsmann	04/16	OV		TRUE		Olaparib (PARP inhibitor)
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			Chemotherapy	Platinum Agent	Responsive	Late trials		PMID:22406760;PMID:22711857	RDientsmann	04/16	OV		TRUE		Platinum Agent (Chemotherapy)
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			PARP inhibitor	Rucaparib	Responsive	FDA guidelines		FDA	RDientsmann	04/16	OV		TRUE		Rucaparib (PARP inhibitor)
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			PARP inhibitor;Chemotherapy	Veliparib;Cisplatin	Responsive	Early trials		PMID:26801247	RDientsmann	07/16	BRCA		TRUE		Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)
BRCA1 deletion	BRCA1	CNA	BRCA1:del			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:22392482	RDientsmann		OV		TRUE		PARP inhibitors
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			[PARP inhibitor]	[]	Responsive	Case report		PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	RDientsmann		PA		TRUE		PARP inhibitors
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			[WEE1 inhibitor]	[]	Responsive	Case report		PMID:25964244	RDientsmann		CANCER		TRUE		WEE1 inhibitors
BRCA1 oncogenic mutation	BRCA1	MUT	BRCA1:.			[PARP inhibitor]	[Olaparib]	Responsive	Early trials		PMID:20609467;PMID:25366685	RDientsmann;JAlbanell		BRCA		TRUE		PARP inhibitors (Olaparib,etc)
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.	Indirect	Approved	PARP inhibitor	Olaparib	Responsive	Early trials		PMID:26510020;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	RDientsmann;ARodriguez-Vida	01/16	PRAD		TRUE		Olaparib (PARP inhibitor)
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.			Chemotherapy	Platinum Agent	Responsive	Early trials		PMID:25847936	RDientsmann	01/16	BRCA		TRUE		Platinum Agent (Chemotherapy)
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.			[PARP inhibitor;Chemotherapy]	[]	Responsive	Early trials		PMID:22307137;ASCO 2012 (abstr 1009)	RDientsmann	04/16	OV		TRUE		PARP inhibitor + Chemotherapys
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.			[PD1 Ab inhibitor]	[]	Responsive	Case report		PMID:26997480	RDientsmann	04/16	CM		TRUE		PD1 Ab inhibitors
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.			Chemotherapy	Platinum Agent	Responsive	Late trials		PMID:22406760;PMID:22711857	RDientsmann	04/16	OV		TRUE		Platinum Agent (Chemotherapy)
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.			PARP inhibitor	Rucaparib	Responsive	FDA guidelines		FDA	RDientsmann	04/16	OV		TRUE		Rucaparib (PARP inhibitor)
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.			PARP inhibitor;Chemotherapy	Veliparib;Cisplatin	Responsive	Early trials		PMID:26801247	RDientsmann	07/16	BRCA		TRUE		Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.	Indirect	Approved	[PARP inhibitor]	[Olaparib]	Responsive	Early trials		PMID:20609467	JAlbanell;ARovira;RDientsmann	09/15	BRCA		TRUE		PARP inhibitors (Olaparib,etc)
BRCA2 deletion	BRCA2	CNA	BRCA2:del			[PARP inhibitor]	[Olaparib]	Responsive	Pre-clinical		PMID:22392482	RDientsmann		OV		TRUE		PARP inhibitors (Olaparib,etc)
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.		Approved	PARP inhibitor	Olaparib	Responsive	FDA guidelines		FDA	RDientsmann		OV		TRUE		Olaparib (PARP inhibitor)
BRCA2 oncogenic mutation	BRCA2	MUT	BRCA2:.			Chemotherapy	Platinum Agent	Responsive	Case report		PMID:25719666	RDientsmann		PA		TRUE		Platinum Agent (Chemotherapy)
BTK (C481S)	BTK	MUT	BTK:C481S			BTK inhibitor	Ibrutinib	Resistant	Early trials		PMID:24869598;PMID:27199251	RDientsmann		CLL		TRUE		Ibrutinib (BTK inhibitor)
BTK (C481)	BTK	MUT	BTK:C481.			BTK inhibitor	Ibrutinib	Resistant	Case report		PMID:25082755	RDientsmann		MCL		TRUE		Ibrutinib (BTK inhibitor)
BRD4-C15orf55 fusion	C15orf55	FUS	BRD4__C15orf55			[BET inhibitor]	[]	Responsive	Case report		ENA 2015 (abstr A49)	RDientsmann	11/15	NMC		TRUE		BET inhibitors
CA9 overexpression	CA9	EXPR	CA9:over	Indirect	Approved	Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical	Cell line	PMID:24086736	ARodriguez-Vida	09/15	R		TRUE		Sunitinib (Pan-TK inhibitor)
CBL (Y371H,C384R)	CBL	MUT	CBL:Y371H,C384R			[JAK inhibitor]	[]	Responsive	Pre-clinical		PMID:23696637	RDientsmann		MDPS		TRUE		JAK inhibitors
CBL (Y371H,C384R)	CBL	MUT	CBL:Y371H,C384R			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:23696637	RDientsmann		MDPS		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
CCND1 amplification	CCND1	CNA	CCND1:amp			[CDK4/6 inhibitor]	[]	Responsive	Case report		ASCO 2014 (abstr 2528)	RDientsmann		CM		TRUE		CDK4/6 inhibitors
CCND1 amplification	CCND1	CNA	CCND1:amp			[CDK4/6 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707	RDientsmann		CANCER		TRUE		CDK4/6 inhibitors
CCND1 amplification	CCND1	CNA	CCND1:amp			[SMO inhibitor]	[]	Resistant	Pre-clinical		PMID:24951114	DTamborero;RDientsmann		MB		TRUE		SMO inhibitors
CCND2 amplification	CCND2	CNA	CCND2:amp			[CDK4/6 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707	RDientsmann		CANCER		TRUE		CDK4/6 inhibitors
CCND2 amplification	CCND2	CNA	CCND2:amp	Indirect	Approved	CDK4/6 inhibitor	Palbociclib	Responsive	Early trials		NCT02154490	CRubio-Perez;DTamborero		L		TRUE		Palbociclib (CDK4/6 inhibitor)
CCND3 amplification	CCND3	CNA	CCND3:amp			[CDK4/6 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707	RDientsmann		CANCER		TRUE		CDK4/6 inhibitors
CCNE1 amplification	CCNE1	CNA	CCNE1:amp			[CDK2 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707	RDientsmann		CANCER		TRUE		CDK2 inhibitors
CD274 overexpression	CD274	EXPR	CD274:over	Direct	Clinical Trials	PDL1 inhibitor	Atezolizumab	Responsive	Early trials		NCT01375842;doi: 10.1093/annonc/mdu337.2	ARodriguez-Vida	09/15	CM;R;CANCER	BLCA	TRUE		Atezolizumab (PDL1 inhibitor)
CD274 overexpression	CD274	EXPR	CD274:over	Indirect	Clinical Trials	PD1 Ab inhibitor	Nivolumab	Responsive	Early trials		PMID:25452452	ARodriguez-Vida	09/15	R	R	TRUE		Nivolumab (PD1 Ab inhibitor)
CD274 overexpression	CD274	EXPR	CD274:over	Indirect	Clinical Trials	PD1 Ab	Pembrolizumab	Responsive	Early trials		NCT01848834	ARodriguez-Vida	09/15	BLCA	BLCA	TRUE		Pembrolizumab (PD1 Ab)
CD274 amplification	CD274	CNA	CD274:amp			[PDL1 inhibitor]	[]	Responsive	Pre-clinical		PMID:25079317	RDientsmann		CANCER		TRUE		PDL1 inhibitors
CD69 undexpression	CD69	EXPR	CD69:under		Approved	Alkylating agent	Bendamustine	Responsive	Pre-clinical	Cell line	PMID:26701728	CRubio-Perez	01/16	CLL		TRUE	Ibrutinib and idelalisib as adjuvants (not added)	Bendamustine (Alkylating agent)
CDH1 oncogenic mutation	CDH1	MUT	CDH1:.			AR inhibitor	Bicalutamide	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	BRCA		TRUE		Bicalutamide (AR inhibitor)
CDK12 amplification	CDK12	CNA	CDK12:amp			[PARP inhibitors]	[]	Responsive	Pre-clinical		PMID:24240700;PMID:24554720	RDientsmann	12/16	OV		TRUE		PARP inhibitorss
CDK12 oncogenic mutation	CDK12	MUT	CDK12:.			[PARP inhibitors]	[]	Responsive	Pre-clinical		PMID:24240700;PMID:24554720	RDientsmann	12/16	OV		TRUE		PARP inhibitorss
CDK4 oncogenic mutation	CDK4	MUT	CDK4:.	Direct	Clinical Trials	CDK4/6 inhibitor	LEE011	Responsive	Early trials		NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	CRubio-Perez;DTamborero		LIP;LY;CANCER		TRUE		LEE011 (CDK4/6 inhibitor)
CDK4 amplification	CDK4	CNA	CDK4:amp	Direct	Clinical Trials	CDK4/6 inhibitor	LEE011	Responsive	Early trials		NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	CRubio-Perez;DTamborero		LIP;LY;CANCER		TRUE		LEE011 (CDK4/6 inhibitor)
CDK4 amplification + RB1 expression	CDK4;RB1	CNA;EXPR	CDK4:amp;RB1:norm			[CDK4 inhibitor]	[]	Responsive	Early trials		PMID:23569312	RDientsmann		LIP		TRUE		CDK4 inhibitors
CDK6 amplification	CDK6	CNA	CDK6:amp			[CDK6 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707	RDientsmann		CANCER		TRUE		CDK6 inhibitors
CDK6 oncogenic mutation	CDK6	MUT	CDK6:.	Direct	Clinical Trials	CDK4/6 inhibitor	LEE011	Responsive	Early trials		NCT02187783;NCT01237236	CRubio-Perez;DTamborero		LIP;LY;CANCER		TRUE		LEE011 (CDK4/6 inhibitor)
CDK6 amplification	CDK6	CNA	CDK6:amp	Direct	Clinical Trials	CDK4/6 inhibitor	LEE011	Responsive	Early trials		NCT02187783;NCT01237236;http://meetinglibrary.asco.org/content/83791-102	CRubio-Perez;DTamborero		LIP;LY;CANCER		TRUE		LEE011 (CDK4/6 inhibitor)
CDKN1A deletion	CDKN1A	CNA	CDKN1A:del			[CDK2/4 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707;PMID:22997239	RDientsmann		CANCER		TRUE		CDK2/4 inhibitors
CDKN1A oncogenic mutation	CDKN1A	MUT	CDKN1A:.			[CDK2/4 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707;PMID:22997239	RDientsmann		CANCER		TRUE		CDK2/4 inhibitors
CDKN1B deletion	CDKN1B	CNA	CDKN1B:del			[CDK2/4 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707	RDientsmann		CANCER		TRUE		CDK2/4 inhibitors
CDKN1B oncogenic mutation	CDKN1B	MUT	CDKN1B:.			[CDK2/4 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707	RDientsmann		CANCER		TRUE		CDK2/4 inhibitors
CDKN2A deletion	CDKN2A	CNA	CDKN2A:del			[CDK4/6 inhibitor]	[]	Responsive	Case report		ASCO 2013 (abstr 2500)	RDientsmann		CM		TRUE		CDK4/6 inhibitors
CDKN2A oncogenic mutation	CDKN2A	MUT	CDKN2A:.			[CDK4/6 inhibitor]	[]	Responsive	Case report		ASCO 2013 (abstr 2500)	RDientsmann		CM		TRUE		CDK4/6 inhibitors
CDKN2A oncogenic mutation	CDKN2A	MUT	CDKN2A:.			[CDK4/6 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707;PMID:22586120;PMID:22711607	RDientsmann		G;CANCER		TRUE		CDK4/6 inhibitors
CDKN2A deletion	CDKN2A	CNA	CDKN2A:del			[CDK4/6 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707;PMID:22586120;PMID:22711607	RDientsmann		G;CANCER		TRUE		CDK4/6 inhibitors
CDKN2A oncogenic mutation	CDKN2A	MUT	CDKN2A:.	Indirect	Clinical Trials	AURKA-VEGF inhibitor	Ilorasertib	Responsive	Early trials		NCT02478320	CRubio-Perez;DTamborero		CANCER		TRUE		Ilorasertib (AURKA-VEGF inhibitor)
CDKN2A deletion	CDKN2A	CNA	CDKN2A:del	Indirect	Clinical Trials	AURKA-VEGF inhibitor	Ilorasertib	Responsive	Early trials		NCT02478320	CRubio-Perez;DTamborero		CANCER		TRUE		Ilorasertib (AURKA-VEGF inhibitor)
CDKN2B oncogenic mutation	CDKN2B	MUT	CDKN2B:.			[CDK4/6 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707;PMID:22711607	RDientsmann		G;CANCER		TRUE		CDK4/6 inhibitors
CDKN2B deletion	CDKN2B	CNA	CDKN2B:del			[CDK4/6 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707;PMID:22711607	RDientsmann		G;CANCER		TRUE		CDK4/6 inhibitors
CDKN2C oncogenic mutation	CDKN2C	MUT	CDKN2C:.			[CDK2 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707;PMID:22997239;PMID:22711607	RDientsmann		G;CANCER		TRUE		CDK2 inhibitors
CDKN2C deletion	CDKN2C	CNA	CDKN2C:del			[CDK2 inhibitor]	[]	Responsive	Pre-clinical		PMID:22471707;PMID:22997239;PMID:22711607	RDientsmann		G;CANCER		TRUE		CDK2 inhibitors
CHEK2 oncogenic mutation	CHEK2	MUT	CHEK2:.			PARP inhibitor	Olaparib	Responsive	Early trials		PMID:26510020;AACR 2015 (abstr CT322)	RDientsmann	01/16	PRAD		TRUE		Olaparib (PARP inhibitor)
CHEK2 deletion	CHEK2	CNA	CHEK2:del			PARP inhibitor	Olaparib	Responsive	Early trials		AACR 2015 (abstr CT322)	RDientsmann		PRAD		TRUE		Olaparib (PARP inhibitor)
CRBN undexpression	CRBN	EXPR	CRBN:under			Immunomodulator	Lenalidomide	Resistant	Case report		PMID:21860026	DTamborero		MYMA		TRUE	several manuscripts reporting that the IMiD resistant patients exhibit lower CRBN expression	Lenalidomide (Immunomodulator)
CRBN (Q100*,R283K)	CRBN	MUT	CRBN:Q100*,R283K			Immunomodulator	Lenalidomide	Resistant	Case report		PMID:23480694	DTamborero		MYMA		TRUE	REMAP:Q99 changed to Q100 (meaning that i change from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C>T chr3:g.3215822G>A)	Lenalidomide (Immunomodulator)
CRBN oncogenic mutation	CRBN	MUT	CRBN:.			Immunomodulator	Lenalidomide	Resistant	Case report		PMID:25108355	DTamborero		MYMA		TRUE	. other mutation disrupting IMID - CRBN or CRBN - ubiqutin complex may confer IMiD resistance	Lenalidomide (Immunomodulator)
CRBN undexpression	CRBN	EXPR	CRBN:under			Immunomodulator	Pomalidomide	Resistant	Case report		PMID:21860026	DTamborero		MYMA		TRUE	several manuscripts reporting that the IMiD resistant patients exhibit lower CRBN expression	Pomalidomide (Immunomodulator)
CRBN (Q100*,R283K)	CRBN	MUT	CRBN:Q100*,R283K			Immunomodulator	Pomalidomide	Resistant	Case report		PMID:23480694	DTamborero		MYMA		TRUE	REMAP:Q99 changed to Q100 (meaning that i changed from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C>T chr3:g.3215822G>A)	Pomalidomide (Immunomodulator)
CRBN oncogenic mutation	CRBN	MUT	CRBN:.			Immunomodulator	Pomalidomide	Resistant	Case report		PMID:25108355	DTamborero		MYMA		TRUE	IMiD-compound pocket in TBD of the CRBN is formed by three tryptophan residues, Trp380, Trp386 and Trp400	Pomalidomide (Immunomodulator)
CRLF2 fusion	CRLF2	FUS	CRLF2__.			[BET inhibitor]	[]	Responsive	Pre-clinical		PMID:22904298	RDientsmann	01/16	ALL		TRUE		BET inhibitors
CRLF2 fusion	CRLF2	FUS	CRLF2__.			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:22955920	RDientsmann	01/16	ALL		TRUE		MTOR inhibitors
CSF1R (Y571D)	CSF1R	MUT	CSF1R:Y571D			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Pre-clinical		PMID:18971950	RDientsmann		MDPS		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
CSF3R (Q741,Y752,W791,T615A,T618I)	CSF3R	MUT	CSF3R:Q741.,Y752.,W791.,T615A,T618I			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:23656643	RDientsmann	01/16	ACML		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
CSF3R frameshift variant (D771),frameshift variant (S783)	CSF3R	MUT	CSF3R::consequence::frameshift_variant:D771.,::frameshift_variant:S783.			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:23656643	RDientsmann	01/16	ACML		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
CTNNB1 oncogenic mutation	CTNNB1	MUT	CTNNB1:.			[Tankyrase inhibitor]	[]	Resistant	Pre-clinical		PMID:23539443	RDientsmann		COREAD		TRUE		Tankyrase inhibitors
CTNNB1 (H36Y,S37C,S37Y,D32V)	CTNNB1	MUT	CTNNB1:H36Y,S37C,S37Y,D32V			MTOR inhibitor;Hormonal therapy	Everolimus;Letrozole	Responsive	Early trials		PMID:25624430	RDientsmann		ED		TRUE		Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)
CYP17A1 expression	CYP17A1	EXPR	CYP17A1:norm	Direct	Approved	AR inhibitor	Abiraterone	Responsive	Early trials		PMID:22184395	ARodriguez-Vida	09/15	PRAD	PRAD	TRUE		Abiraterone (AR inhibitor)
CYP17A1 expression	CYP17A1	EXPR	CYP17A1:norm	Indirect	Approved	AR inhibitor	Enzalutamide	Responsive	Early trials		PMID:24882673	ARodriguez-Vida	09/15	PRAD	PRAD	TRUE		Enzalutamide (AR inhibitor)
DDR2 (S768R)	DDR2	MUT	DDR2:S768R			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Case report		PMID:22328973	RDientsmann		LUSC		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	DDR2	MUT	DDR2:I638F,L239R,G253C,G774V,L63V,G505S			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:22328973	RDientsmann		LUSC		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
DDR2 (S768R)	DDR2	MUT	DDR2:S768R			EGFR inhibitor 1st gen	Erlotinib	Responsive	Case report		PMID:22328973	RDientsmann		LUSC		TRUE		Erlotinib (EGFR inhibitor 1st gen)
DNMT3A oncogenic mutation	DNMT3A	MUT	DNMT3A:.		Approved	Chemotherapy	Daunorubicin	Responsive	FDA guidelines		PMID:22417203	RDientsmann		AML		TRUE		Daunorubicin (Chemotherapy)
DPYD biallelic inactivation	DPYD	BIA	DPYD:.		Approved	Fluoropyrimidine	Capecitabine	Increased Toxicity	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Capecitabine (Fluoropyrimidine)
DPYD splice donor variant	DPYD	MUT	DPYD::consequence::splice_donor_variant:.		Approved	Fluoropyrimidine	Capecitabine	Increased Toxicity	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Capecitabine (Fluoropyrimidine)
DPYD (I560S,D949V)	DPYD	MUT	DPYD:I560S,D949V		Approved	Fluoropyrimidine	Capecitabine	Increased Toxicity	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Capecitabine (Fluoropyrimidine)
DPYD biallelic inactivation	DPYD	BIA	DPYD:.		Approved	Fluoropyrimidine	Flourouracil	Increased Toxicity	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Flourouracil (Fluoropyrimidine)
DPYD splice donor variant	DPYD	MUT	DPYD::consequence::splice_donor_variant:.		Approved	Fluoropyrimidine	Flourouracil	Increased Toxicity	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Flourouracil (Fluoropyrimidine)
DPYD (I560S,D949V)	DPYD	MUT	DPYD:I560S,D949V		Approved	Fluoropyrimidine	Flourouracil	Increased Toxicity	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Flourouracil (Fluoropyrimidine)
DPYD biallelic inactivation	DPYD	BIA	DPYD:.		Approved	Fluoropyrimidine	Tegafur	Increased Toxicity	CPIC guidelines		PMID:23988873	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Tegafur (Fluoropyrimidine)
DPYD splice donor variant	DPYD	MUT	DPYD::consequence::splice_donor_variant:.		Approved	Fluoropyrimidine	Tegafur	Increased Toxicity	CPIC guidelines		PMID:23988873	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Tegafur (Fluoropyrimidine)
DPYD (I560S,D949V)	DPYD	MUT	DPYD:I560S,D949V		Approved	Fluoropyrimidine	Tegafur	Increased Toxicity	CPIC guidelines		PMID:23988873	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Tegafur (Fluoropyrimidine)
EGFR (T790M)	EGFR	MUT	EGFR:T790M			[EGFR inhibitor 1st gen]	[]	Resistant	Late trials		PMID:19680293	DTamborero	01/16	NSCLC		TRUE		EGFR inhibitor 1st gens
EGFR (D761Y)	EGFR	MUT	EGFR:D761Y			[EGFR inhibitor 1st gen]	[]	Resistant	Case report		PMID:19680293	DTamborero		NSCLC		TRUE		EGFR inhibitor 1st gens
EGFR amplification	EGFR	CNA	EGFR:amp			[EGFR inhibitor 1st gen]	[]	No Responsive	Early trials		PMID:16282176;PMID:16278407	RDientsmann		G		TRUE		EGFR inhibitor 1st gens
EGFR inframe deletion (30-336)	EGFR	MUT	EGFR::consequence::inframe_deletion:30-336			[EGFR inhibitor 1st gen]	[]	No Responsive	Early trials		PMID:19204207	RDientsmann		G		TRUE		EGFR inhibitor 1st gens
EGFR exon 20 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:762-823			[EGFR inhibitor 1st gen]	[]	Resistant	Late trials		PMID:21764376;PMID:26773740;PMID:26051236	RDientsmann	12/16	L		TRUE		EGFR inhibitor 1st gens
EGFR (T790M)	EGFR	MUT	EGFR:T790M			[EGFR inhibitor 2nd gen]	[]	Resistant	Late trials		PMID:22452896	DTamborero	01/16	NSCLC		TRUE		EGFR inhibitor 2nd gens
EGFR amplification	EGFR	CNA	EGFR:amp			[EGFR inhibitor 2nd gen]	[]	No Responsive	Early trials		PMID:16282176;PMID:16278407	RDientsmann		G		TRUE		EGFR inhibitor 2nd gens
EGFR inframe deletion (30-336)	EGFR	MUT	EGFR::consequence::inframe_deletion:30-336			[EGFR inhibitor 2nd gen]	[]	No Responsive	Early trials		PMID:19204207	RDientsmann		G		TRUE		EGFR inhibitor 2nd gens
EGFR (T790M)	EGFR	MUT	EGFR:T790M			[EGFR inhibitor 3rd gen]	[]	Responsive	Early trials		ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)	RDientsmann	01/16	L		TRUE		EGFR inhibitor 3rd gens
EGFR amplification	EGFR	CNA	EGFR:amp			[EGFR inhibitor 3rd gen]	[]	No Responsive	Early trials		PMID:16282176;PMID:16278407	RDientsmann		G		TRUE		EGFR inhibitor 3rd gens
EGFR inframe deletion (30-336)	EGFR	MUT	EGFR::consequence::inframe_deletion:30-336			[EGFR inhibitor 3rd gen]	[]	No Responsive	Early trials		PMID:19204207	RDientsmann		G		TRUE		EGFR inhibitor 3rd gens
EGFR (C797S)	EGFR	MUT	EGFR:C797S			[EGFR inhibitor 3rd gen]	[]	Resistant	Early trials		PMID:25939061	RDientsmann		L		TRUE		EGFR inhibitor 3rd gens
EGFR (T790M)	EGFR	MUT	EGFR:T790M			[EGFR inhibitor 3rd gen]	[Rociletinib,HM61713]	Responsive	Late trials		NCT02322281	CRubio-Perez;RDientsmann	01/16	NSCLC		TRUE		EGFR inhibitor 3rd gens (Rociletinib,HM61713,etc)
EGFR amplification	EGFR	CNA	EGFR:amp			[EGFR inhibitor]	[]	Responsive	Case report		PMID:26763254	RDientsmann	07/16	HNSC		TRUE		EGFR inhibitors
EGFR amplification	EGFR	CNA	EGFR:amp			[EGFR mAb inhibitor]	[]	Responsive	Late trials		PMID:18794099;PMID:17664472	RDientsmann		COREAD		TRUE		EGFR mAb inhibitors
EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	EGFR	MUT	EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R			[EGFR TK inhibitor]	[]	Responsive	Late trials		PMID:22753918	RDientsmann	01/16	L		TRUE		EGFR TK inhibitors
EGFR exon 19 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:729-761			[EGFR TK inhibitor]	[]	Responsive	Late trials		PMID:22753918	RDientsmann	01/16	L		TRUE		EGFR TK inhibitors
EGFR exon 20 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:762-823			[HSP90 inhibitor]	[]	Responsive	Case report		ASCO 2014 (abstr 8015)	RDientsmann	01/16	L		TRUE		HSP90 inhibitors
EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	EGFR	MUT	EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R			[HSP90 inhibitor]	[]	Responsive	Early trials		ESMO 2012 (abstr 4380)	RDientsmann	01/16	L		TRUE		HSP90 inhibitors
EGFR (T790M)	EGFR	MUT	EGFR:T790M			[HSP90 inhibitor]	[]	Responsive	Early trials		ESMO 2012 (abstr 4380)	RDientsmann	01/16	L		TRUE		HSP90 inhibitors
EGFR exon 19 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:729-761			[HSP90 inhibitor]	[]	Responsive	Early trials		ESMO 2012 (abstr 4380)	RDientsmann	01/16	L		TRUE		HSP90 inhibitors
EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	EGFR	MUT	EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M			[MEK inhibitor (alone or in combination)]	[]	Responsive	Pre-clinical		PMID:23102728	RDientsmann	01/16	L		TRUE		MEK inhibitor (alone or in combination)s
EGFR exon 19 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:729-761			[MEK inhibitor (alone or in combination)]	[]	Responsive	Pre-clinical		PMID:23102728	RDientsmann	01/16	L		TRUE		MEK inhibitor (alone or in combination)s
EGFR (S492R)	EGFR	MUT	EGFR:S492R			[novel EGFR mAb inhibitor]	[]	Responsive	Early trials		PMID:25962717	RDientsmann	01/16	COREAD		TRUE		novel EGFR mAb inhibitors
EGFR (L798I)	EGFR	MUT	EGFR:L798I			EGFR inhibitor	Rociletinib	Resistant	Case report		PMID:27283993	RDientsmann	07/16	LUAD		TRUE		Rociletinib (EGFR inhibitor)
EGFR (T790M)	EGFR	MUT	EGFR:T790M			EGFR inhibitor 1st gen	Erlotinib	Resistant	NCCN/CAP guidelines		NCCN	RDientsmann	01/16	L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR (S720)	EGFR	MUT	EGFR:S720.			EGFR inhibitor 1st gen	Erlotinib	No Responsive	Case report		PMID:26773740	RDientsmann	12/16	L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR (K757R,E746G)	EGFR	MUT	EGFR:K757R,E746G			EGFR inhibitor 1st gen	Erlotinib	Responsive	Case report		PMID:26773740	RDientsmann	12/16	L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR inframe insertion (769-770)	EGFR	MUT	EGFR::consequence::inframe_insertion:769-770			EGFR inhibitor 1st gen	Erlotinib	Responsive	Case report		PMID:26773740;PMID:23328547	RDientsmann	12/16	L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR-RAD51 fusion	EGFR	FUS	EGFR__RAD51		Approved	EGFR inhibitor 1st gen	Erlotinib	Responsive	Case report		PMID:27102076	EArriola	06/16	NSCLC		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR-RAD51 fusion	EGFR	FUS	EGFR__RAD51			EGFR inhibitor 1st gen	Erlotinib	Responsive	Case report		PMID:27102076	RDientsmann	07/16	L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR amplification	EGFR	CNA	EGFR:amp		Approved	EGFR inhibitor 1st gen	Erlotinib	No Responsive	Early trials		ASCO2015(abstre19028)	RDientsmann		L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR exon 19 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:729-761		Approved	EGFR inhibitor 1st gen	Erlotinib	Responsive	Early trials		PMID:22190593	RDientsmann		L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR exon 19 deletions	EGFR	MUT	EGFR::consequence::inframe_deletion:729-761		Approved	EGFR inhibitor 1st gen	Erlotinib	Responsive	FDA guidelines		FDA	RDientsmann		NSCLC		TRUE	exon 19 deletions	Erlotinib (EGFR inhibitor 1st gen)
EGFR (L858R)	EGFR	MUT	EGFR:L858R		Approved	EGFR inhibitor 1st gen	Erlotinib	Responsive	FDA guidelines		FDA	RDientsmann		NSCLC		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR (L858R,L861,G719,S768I)	EGFR	MUT	EGFR:L858R,L861.,G719.,S768I		Approved	EGFR inhibitor 1st gen	Erlotinib	Responsive	NCCN guidelines		NCCN	RDientsmann		NSCLC		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR (A289V,R108K,G598V,T263P)	EGFR	MUT	EGFR:A289V,R108K,G598V,T263P		Approved	EGFR inhibitor 1st gen	Erlotinib	Responsive	Pre-clinical		PMID:17177598	RDientsmann		G		TRUE		Erlotinib (EGFR inhibitor 1st gen)
EGFR exon 19 deletions	EGFR	MUT	EGFR::consequence::inframe_deletion:729-761		Approved	EGFR inhibitor 1st gen	Gefitinib	Responsive	FDA guidelines		FDA	RDientsmann		NSCLC		TRUE		Gefitinib (EGFR inhibitor 1st gen)
EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	EGFR	MUT	EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R		Approved	EGFR inhibitor 1st gen	Gefitinib	Responsive	FDA guidelines		FDA	RDientsmann		NSCLC		TRUE		Gefitinib (EGFR inhibitor 1st gen)
EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	EGFR	MUT	EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R		Approved	EGFR inhibitor 1st gen	Gefitinib	Responsive	NCCN guidelines		FDA	RDientsmann		NSCLC		TRUE		Gefitinib (EGFR inhibitor 1st gen)
EGFR inframe deletion (L747),inframe insertion (P753PS)	EGFR	MUT	EGFR::consequence::inframe_deletion:L747.,::inframe_insertion:P753PS		Approved	EGFR inhibitor 1st gen	Gefitinib	No Responsive	Case report		PMID:21274259	RDientsmann		HNC		TRUE		Gefitinib (EGFR inhibitor 1st gen)
EGFR (V843I)	EGFR	MUT	EGFR:V843I		Approved	EGFR inhibitor 1st gen	Gefitinib	No Responsive	Case report		PMID:21274259	RDientsmann		HNC		TRUE		Gefitinib (EGFR inhibitor 1st gen)
EGFR amplification	EGFR	CNA	EGFR:amp		Approved	EGFR inhibitor 1st gen	Gefitinib	No Responsive	Early trials		PMID:21274259;PMID:22261807	RDientsmann		HNC		TRUE		Gefitinib (EGFR inhibitor 1st gen)
EGFR amplification	EGFR	CNA	EGFR:amp		Approved	EGFR inhibitor 1st gen	Gefitinib	Responsive	Late trials		PMID:24950987	RDientsmann		ED		TRUE		Gefitinib (EGFR inhibitor 1st gen)
EGFR (L858R)	EGFR	MUT	EGFR:L858R		Approved	EGFR inhibitor 3rd gen	Osimertinib	Responsive	Early trials		NCT02465060	CRubio-Perez	01/16	L		TRUE		Osimertinib (EGFR inhibitor 3rd gen)
EGFR exon 19 deletions	EGFR	MUT	EGFR::consequence::inframe_deletion:729-761		Approved	EGFR inhibitor 3rd gen	Osimertinib	Responsive	Early trials		NCT02465060	CRubio-Perez	01/16	L		TRUE		Osimertinib (EGFR inhibitor 3rd gen)
EGFR (T790M)	EGFR	MUT	EGFR:T790M		Approved	EGFR inhibitor 3rd gen	Osimertinib	Responsive	FDA guidelines		FDA	RDientsmann	01/16	NSCLC		TRUE		Osimertinib (EGFR inhibitor 3rd gen)
EGFR exon 20 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:762-823			EGFR inhibitor 3rd gen	Osimertinib	Responsive	Pre-clinical		PMID:26515464	RDientsmann	12/16	L		TRUE	Insertion exon 20	Osimertinib (EGFR inhibitor 3rd gen)
EGFR (L719Q)	EGFR	MUT	EGFR:L719Q		Approved	EGFR inhibitor 3rd gen	Osimertinib	Resistant	Pre-clinical,Case report		PMID:25948633;PMID:27257132	EArriola	06/16	LUAD		TRUE		Osimertinib (EGFR inhibitor 3rd gen)
EGFR (P546S)	EGFR	MUT	EGFR:P546S			EGFR mAb inhibitor	Cetuximab	Responsive	Case report		PMID:23578570	RDientsmann	01/16	HNC		TRUE		Cetuximab (EGFR mAb inhibitor)
EGFR (S492R,G465R,R451C,K467T)	EGFR	MUT	EGFR:S492R,G465R,R451C,K467T			EGFR mAb inhibitor	Cetuximab	Resistant	Case report		PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	RDientsmann	07/16	COREAD		TRUE		Cetuximab (EGFR mAb inhibitor)
EGFR overexpression	EGFR	EXPR	EGFR:over		Approved	EGFR mAb inhibitor	Cetuximab	Responsive	FDA guidelines		FDA	CRubio-Perez		COREAD		TRUE		Cetuximab (EGFR mAb inhibitor)
EGFR (S464L,G465R,I491M)	EGFR	MUT	EGFR:S464L,G465R,I491M		Approved	EGFR mAb inhibitor	Cetuximab	Resistant	Pre-clinical		PMID:25623215	RDientsmann		COREAD		TRUE		Cetuximab (EGFR mAb inhibitor)
EGFR (S492R)	EGFR	MUT	EGFR:S492R			EGFR mAb inhibitor	Panitumumab	Responsive	Case report		PMID:22270724	RDientsmann	01/16	COREAD		TRUE		Panitumumab (EGFR mAb inhibitor)
EGFR (G465R)	EGFR	MUT	EGFR:G465R			EGFR mAb inhibitor	Panitumumab	Resistant	Case report		PMID:26059438	RDientsmann	01/16	COREAD		TRUE		Panitumumab (EGFR mAb inhibitor)
EGFR overexpression	EGFR	EXPR	EGFR:over		Approved	EGFR mAb inhibitor	Panitumumab	Resistant	FDA guidelines		FDA guidelines	CRubio-Perez;RDientsmann		COREAD		TRUE		Panitumumab (EGFR mAb inhibitor)
EGFR (P753S)	EGFR	MUT	EGFR:P753S			EGFR mAb inhibitor;MTOR inhibitor	Cetuximab;Sirolimus	Responsive	Case report		PMID:24934779	RDientsmann	01/16	HNC		TRUE		Cetuximab + Sirolimus (EGFR mAb inhibitor + MTOR inhibitor)
EGFR (E690K)	EGFR	MUT	EGFR:E690K		Approved	ERBB2 inhibitor	Lapatinib	Responsive	Case report		PMID:22885469	RDientsmann		ED		TRUE		Lapatinib (ERBB2 inhibitor)
EGFR (T790M)	EGFR	MUT	EGFR:T790M			ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib	Resistant	NCCN/CAP guidelines		NCCN	RDientsmann	01/16	L		TRUE		Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)
EGFR exon 19 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:729-761			ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib	Responsive	Late trials		PMID:22753918;PMID:25589191	RDientsmann	01/16	L		TRUE		Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)
EGFR exon 19 deletions	EGFR	MUT	EGFR::consequence::inframe_deletion:729-761		Approved	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib	Responsive	FDA guidelines		FDA	RDientsmann		NSCLC		TRUE		Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)
EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	EGFR	MUT	EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R		Approved	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib	Responsive	FDA guidelines		FDA	RDientsmann		NSCLC		TRUE		Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)
EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	EGFR	MUT	EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R		Approved	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib	Responsive	NCCN guidelines		FDA	RDientsmann		NSCLC		TRUE		Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)
EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	EGFR	MUT	EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R			ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib;Cetuximab	Responsive	Early trials		ESMO 2012 (abstr 1289)	RDientsmann	01/16	L		TRUE		Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)
EGFR exon 19 insertions	EGFR	MUT	EGFR::consequence::inframe_insertion:729-761			ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib;Cetuximab	Responsive	Early trials		ESMO 2012 (abstr 1289)	RDientsmann	01/16	L		TRUE		Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)
EGFR (T790M)	EGFR	MUT	EGFR:T790M			ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib;Cetuximab	Responsive	Early trials		PMID:25074459	RDientsmann	01/16	L		TRUE		Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)
EGFR (T790M)	EGFR	MUT	EGFR:T790M			ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib;Nimotuzumab	Responsive	Early trials		PMID:26667485	RDientsmann	06/16	L		TRUE		Afatinib + Nimotuzumab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)
EGFR inframe deletion (6-273)	EGFR	MUT	EGFR::consequence::inframe_deletion:6-273	Indirect	Clinical Trials	Vaccine	Rindopepimut	Responsive	Late trials		NCT01480479	MMartínez	09/15	GB		TRUE	he EGFRvIII variant receptor is characterized by a deletion of exons 2–7 of the wild type (Wt) EGFR gene. This results in an in-frame truncation of amino acids (AA) 6 to 273 in the extracellular domain of the full length protein,	Rindopepimut (Vaccine)
EPHA2 (G391R)	EPHA2	MUT	EPHA2:G391R			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:20360610	RDientsmann	01/16	LUSC		TRUE		MTOR inhibitors
EPHA2 amplification	EPHA2	CNA	EPHA2:amp			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:18047674;PMID:19010823;PMID:19861960	RDientsmann	01/16	CANCER		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
EPHA2 (G391R)	EPHA2	MUT	EPHA2:G391R			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:20360610	RDientsmann	01/16	LUSC		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
EPHA2 (G391R)	EPHA2	MUT	EPHA2:G391R			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:20360610	RDientsmann		LUSC		TRUE		MTOR inhibitors
EPHA2 amplification	EPHA2	CNA	EPHA2:amp			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:18047674;PMID:19010823;PMID:19861960	RDientsmann		CANCER		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
EPHA2 (G391R)	EPHA2	MUT	EPHA2:G391R			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:20360610	RDientsmann		LUSC		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
EPHA3 amplification	EPHA3	CNA	EPHA3:amp			[EPHA3 inhibitor]	[]	Responsive	Pre-clinical		PMID:25125683	RDientsmann	01/16	CANCER		TRUE		EPHA3 inhibitors
EPHA3 amplification	EPHA3	CNA	EPHA3:amp			[EPHA3 inhibitor]	[]	Responsive	Pre-clinical		PMID:25125683	RDientsmann		CANCER		TRUE		EPHA3 inhibitors
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2&EGFR inhibitor 2nd gen	Afatinib	Responsive	Case report		AACR 2014 (abstr CT228)	RDientsmann	01/16	ST		TRUE		Afatinib (ERBB2&EGFR inhibitor 2nd gen)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 inhibitor;Chemotherapy	Lapatinib;Chemotherapy	Responsive	Early trials		PMID:25694417;NCT02015169	RDientsmann	01/16	ST		TRUE		Lapatinib + Chemotherapy (ERBB2 inhibitor + Chemotherapy)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Pertuzumab	Responsive	Early trials		PMID:24960402	RDientsmann	01/16	ST		TRUE		Pertuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab;Lapatinib	Responsive	Late trials		ASCO 2015 (abstr 3508);NCT01104571;EBCC10	RDientsmann	01/16	COREAD		TRUE		Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab;Lapatinib	Responsive	Pre-clinical		PMID:25294905	RDientsmann	01/16	ED		TRUE		Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			[ERBB2 inhibitor;CDK4/6 inhibitor]	[]	Responsive	Pre-clinical		PMID:26977878	RDientsmann	04/16	BRCA		TRUE		ERBB2 inhibitor + CDK4/6 inhibitors
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			EGFR mAb inhibitor	Ado-Trastuzumab Emtansine	Responsive	FDA guidelines		FDA	RDientsmann	04/16	BRCA		TRUE		Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2&EGFR inhibitor 2nd gen	Afatinib	Responsive	Late trials		PMID:20142587;PMID:22418700;PMID:23632474	RDientsmann	04/16	BRCA		TRUE		Afatinib (ERBB2&EGFR inhibitor 2nd gen)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 inhibitor	Lapatinib	Responsive	FDA guidelines		FDA	RDientsmann;CRubio-Perez	04/16	BRCA		TRUE		Lapatinib (ERBB2 inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 inhibitor	Neratinib	Responsive	Late trials		PMID:20142587;PMID:22418700;PMID:23632474	RDientsmann	04/16	BRCA		TRUE		Neratinib (ERBB2 inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Pertuzumab	Responsive	FDA guidelines		FDA	RDientsmann;CRubio-Perez	04/16	BRCA		TRUE		Pertuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	Responsive	FDA guidelines		FDA	CRubio-Perez	04/16	ST;GEJA		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	Responsive	FDA guidelines		FDA	RDientsmann;CRubio-Perez	04/16	BRCA		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy	Trastuzumab;Everolimus;Chemotherapy	Responsive	Early trials		PMID:21107682;PMID:20975068	RDientsmann	04/16	BRCA		TRUE		Trastuzumab + Everolimus + Chemotherapy (ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor;HSP90 inhibitor	Trastuzumab;HSP90 inhibitor	Responsive	Early trials		PMID:21558407	RDientsmann	04/16	BRCA		TRUE		Trastuzumab + HSP90 inhibitor (ERBB2 mAb inhibitor + HSP90 inhibitor)
ERBB2 (K753E)	ERBB2	MUT	ERBB2:K753E			ERBB2 inhibitor	Neratinib	Responsive	Pre-clinical		PMID:27697991	RDientsmann	12/16	BRCA		TRUE		Neratinib (ERBB2 inhibitor)
ERBB2 (K753E)	ERBB2	MUT	ERBB2:K753E			ERBB2 inhibitor	Lapatinib	Resistant	Pre-clinical		PMID:27697991	RDientsmann	12/16	BRCA		TRUE		Lapatinib (ERBB2 inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			[EGFR inhibitor]	[]	Resistant	Pre-clinical		PMID:22956644	EArriola	06/16	LUAD		TRUE		EGFR inhibitors
ERBB2 oncogenic mutation	ERBB2	MUT	ERBB2:.			Pan ERBB inhibitor	Dacomitinib	Responsive	Early trials		PMID:25899785	EArriola	06/16	NSCLC		TRUE		Dacomitinib (Pan ERBB inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp		Approved	3rd generation EGFR inhibitor	Osimertinib	Resistant	Case report		PMID:27252416	EArriola	06/16	LUAD		TRUE		Osimertinib (3rd generation EGFR inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			3rd generation EGFR inhibitor	Rociletinib	Resistant	Case report		PMID:27252416	EArriola	06/16	LUAD		TRUE		Rociletinib (3rd generation EGFR inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2&EGFR inhibitor 2nd gen	Afatinib	Responsive	Case report		PMID:27044931	RDientsmann	07/16	BLCA		TRUE		Afatinib (ERBB2&EGFR inhibitor 2nd gen)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 inhibitor	Lapatinib	Responsive	Early trials		ASCO 2015 (abstr e15137)	RDientsmann	11/15	BT		TRUE		Lapatinib (ERBB2 inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Pertuzumab	Responsive	Early trials		ASCO 2015 (abstr e15137)	RDientsmann	11/15	BT		TRUE		Pertuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	Responsive	Early trials		ASCO 2015 (abstr e15137)	RDientsmann	11/15	BT		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			[EGFR mAb inhibitor]	[]	Resistant	Early trials		PMID:22586653;PMID:23348520	RDientsmann		COREAD		TRUE		EGFR mAb inhibitors
ERBB2 inframe insertion (775-881)	ERBB2	MUT	ERBB2::consequence::inframe_insertion:775-881			[ERBB2 inhibitor]	[Afatinib,Lapatinib,Neratinib]	Responsive	Early trials		PMID:26598547	RDientsmann		LUAD		TRUE		ERBB2 inhibitors (Afatinib,Lapatinib,Neratinib,etc)
ERBB2 inframe insertion (775-881)	ERBB2	MUT	ERBB2::consequence::inframe_insertion:775-881			[ERBB2 mAb inhibitor]	[Trastuzumab]	Responsive	Early trials		PMID:26598547	RDientsmann		LUAD		TRUE		ERBB2 mAb inhibitors (Trastuzumab,etc)
ERBB2 overexpression	ERBB2	EXPR	ERBB2:over		Approved	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine	Responsive	FDA guidelines		FDA	CRubio-Perez		BRCA		TRUE		Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)
ERBB2 overexpression	ERBB2	EXPR	ERBB2:over		Approved	ERBB2 inhibitor	Lapatinib	Responsive	FDA guidelines		FDA	CRubio-Perez		BRCA		TRUE		Lapatinib (ERBB2 inhibitor)
ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	ERBB2	MUT	ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A			ERBB2 inhibitor	Lapatinib	Responsive	Pre-clinical		PMID:23220880	RDientsmann		BRCA		TRUE		Lapatinib (ERBB2 inhibitor)
ERBB2 (V659E)	ERBB2	MUT	ERBB2:V659E			ERBB2 inhibitor	Lapatinib	Responsive	Case report		PMID:23950206	RDientsmann		BRCA;LUAD		TRUE		Lapatinib (ERBB2 inhibitor)
ERBB2 overexpression	ERBB2	EXPR	ERBB2:over			Allosteric AKT inhibitor;ERBB2 mAb inhibitor	MK2206;Trastuzumab	Responsive	Early trials		ASCO 2013 (abstr 2605);PMID:26104654	DCasadevall		SOLID		TRUE		MK2206 + Trastuzumab (Allosteric AKT inhibitor + ERBB2 mAb inhibitor)
ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	ERBB2	MUT	ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I			ERBB2 inhibitor	Neratinib	Responsive	Pre-clinical		PMID:23220880	RDientsmann		BRCA		TRUE		Neratinib (ERBB2 inhibitor)
ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	ERBB2	MUT	ERBB2::consequence::inframe_deletion:755-759,::inframe_insertion:.780GSP,::inframe_insertion:.781GSP			ERBB2 inhibitor	Neratinib	Responsive	Pre-clinical		PMID:23220880	RDientsmann		BRCA		TRUE		Neratinib (ERBB2 inhibitor)
ERBB2 oncogenic mutation	ERBB2	MUT	ERBB2:.			ERBB2 inhibitor	Neratinib	Responsive	Early trials		ESMO 2014 (abstr LBA39_PR)	RDientsmann		LUAD		TRUE		Neratinib (ERBB2 inhibitor)
ERBB2 overexpression	ERBB2	EXPR	ERBB2:over		Approved	ERBB2 mAb inhibitor	Pertuzumab	Responsive	FDA guidelines		FDA	CRubio-Perez		BRCA		TRUE		Pertuzumab (ERBB2 mAb inhibitor)
ERBB2 oncogenic mutation	ERBB2	MUT	ERBB2:.			MTOR inhibitor	Tensirolimus	Responsive	Early trials		ESMO 2014 (abstr LBA39_PR)	RDientsmann		LUAD		TRUE		Tensirolimus (MTOR inhibitor)
ERBB2 overexpression	ERBB2	EXPR	ERBB2:over		Approved	ERBB2 mAb inhibitor	Trastuzumab	Responsive	FDA guidelines		FDA	CRubio-Perez		BRCA		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 overexpression	ERBB2	EXPR	ERBB2:over		Approved	ERBB2 mAb inhibitor	Trastuzumab	Responsive	FDA guidelines		FDA	CRubio-Perez		ST;GEJA		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	No Responsive	Early trials		PMID:26099744;PMID:19840887	DTamborero;RDientsmann		ED		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	ERBB2	MUT	ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R			ERBB2 mAb inhibitor	Trastuzumab	Responsive	Pre-clinical		PMID:23220880;PMID:22908275	RDientsmann		BRCA;CANCER		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	ERBB2	MUT	ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S			ERBB2 mAb inhibitor	Trastuzumab	Responsive	Pre-clinical		PMID:22908275	RDientsmann		CANCER		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	Responsive	Case report		PMID:21380780	RDientsmann		HNC		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 (G776L)	ERBB2	MUT	ERBB2:G776L			ERBB2 mAb inhibitor	Trastuzumab	Responsive	Case report		PMID:16775247	RDientsmann		LUAD		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 amplification	ERBB2	CNA	ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	Responsive	Early trials		PMID:20003286;PMID:12525520	RDientsmann		OV		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB2 expression + ESR1 overexpression	ERBB2;ESR1	EXPR;EXPR	ERBB2:norm;ESR1:over			CDK4/6 inhibitor	Abemaciclib	Responsive	Early trials		PMID:26658964	DTamborero;CRubio-Perez	04/16	BRCA		TRUE		Abemaciclib (CDK4/6 inhibitor)
ERBB2 expression + ESR1 overexpression	ERBB2;ESR1	EXPR;EXPR	ERBB2:norm;ESR1:over		Approved	[Hormonal therapy]	[Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist]	Responsive	FDA guidelines		FDA	JAlbanell;ARovira	09/15	BRCA		TRUE		Hormonal therapys (Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist,etc)
ERBB2 expression + ESR1 overexpression	ERBB2;ESR1	EXPR;EXPR	ERBB2:norm;ESR1:over		Approved	MTOR inhibitor	Everolimus	Responsive	FDA guidelines		FDA	JAlbanell;ARovira	09/15	BRCA		TRUE	HER2- (not overexpressed and not amplified) and ER+ (>1% positive tumor cells)	Everolimus (MTOR inhibitor)
ERBB2 expression + ESR1 overexpression	ERBB2;ESR1	EXPR;EXPR	ERBB2:norm;ESR1:over		Approved	CDK4/6 inhibitor	Palbociclib	Responsive	FDA guidelines		FDA	CRubio-Perez		BRCA		TRUE	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf	Palbociclib (CDK4/6 inhibitor)
ERBB3 (G284R,V104M,R103G)	ERBB3	MUT	ERBB3:G284R,V104M,R103G			ERBB2&EGFR inhibitor 2nd gen	Afatinib	Responsive	Case report		PMID:27044931	RDientsmann	07/16	BLCA		TRUE		Afatinib (ERBB2&EGFR inhibitor 2nd gen)
ERBB3 (P262H,G284R)	ERBB3	MUT	ERBB3:P262H,G284R			[ERBB3 mAb inhibitor]	[]	Responsive	Pre-clinical		PMID:23680147	RDientsmann		CANCER		TRUE		ERBB3 mAb inhibitors
ERBB3 (P262H,G284R,Q809R)	ERBB3	MUT	ERBB3:P262H,G284R,Q809R			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:23680147	RDientsmann		CANCER		TRUE		PI3K pathway inhibitor + MEK inhibitors
ERBB3 amplification	ERBB3	CNA	ERBB3:amp			[EGFR mAb inhibitor]	[]	Resistant	Early trials		PMID:25520391	RDientsmann		COREAD		TRUE		EGFR mAb inhibitors
ERBB3 (G284R,R103G)	ERBB3	MUT	ERBB3:G284R,R103G			ERBB2&EGFR inhibitor 2nd gen	Afatinib	Responsive	Case report		ASCO 2015 (abstr e15516)	RDientsmann		BLCA		TRUE		Afatinib (ERBB2&EGFR inhibitor 2nd gen)
ERBB3 (P262H,G284R,Q809R)	ERBB3	MUT	ERBB3:P262H,G284R,Q809R			ERBB2 inhibitor	Lapatinib	Responsive	Pre-clinical		PMID:23680147	RDientsmann		CANCER		TRUE		Lapatinib (ERBB2 inhibitor)
ERBB3 (P262H,G284R)	ERBB3	MUT	ERBB3:P262H,G284R			ERBB2 mAb inhibitor	Pertuzumab	Responsive	Pre-clinical		PMID:23680147	RDientsmann		CANCER		TRUE		Pertuzumab (ERBB2 mAb inhibitor)
ERBB3 (P262H,G284R,Q809R)	ERBB3	MUT	ERBB3:P262H,G284R,Q809R			ERBB2 mAb inhibitor	Trastuzumab	Responsive	Pre-clinical		PMID:23680147	RDientsmann		CANCER		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
ERBB4 (H809G)	ERBB4	MUT	ERBB4:H809G			[ERBB2 inhibitor]	[Lapatinib]	Resistant	Case report		PMID:26530965	RDientsmann	11/15	BRCA		TRUE		ERBB2 inhibitors (Lapatinib,etc)
ERBB4 (E317K,E452K,R544W,R393W,E872K)	ERBB4	MUT	ERBB4:E317K,E452K,R544W,R393W,E872K			ERBB2 inhibitor	Lapatinib	Responsive	Pre-clinical		PMID:19718025	RDientsmann		CM		TRUE		Lapatinib (ERBB2 inhibitor)
ERBB4 fusion	ERBB4	FUS	ERBB4__.			ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen	Lapatinib;Afatinib	Responsive	Pre-clinical		PMID:24727320	RDientsmann		LUAD		TRUE		Lapatinib + Afatinib (ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)
ERCC1 oncogenic mutation	ERCC1	MUT	ERCC1:.			Chemotherapy	Cisplatin	Responsive	Pre-clinical		PMID:23275151;PMID:23934192	RDientsmann	01/16	L		TRUE		Cisplatin (Chemotherapy)
ERCC1 deletion	ERCC1	CNA	ERCC1:del			Chemotherapy	Cisplatin	Responsive	Pre-clinical		PMID:23275151;PMID:23934192	RDientsmann	01/16	L		TRUE		Cisplatin (Chemotherapy)
ERCC1 overexpression	ERCC1	EXPR	ERCC1:over		Approved	Chemotherapy	Cisplatin	Resistant	Pre-clinical		PMID:20846399;PMID:21177407	ARodriguez-Vida	09/15	BLCA	BLCA	TRUE		Cisplatin (Chemotherapy)
ERCC1 oncogenic mutation	ERCC1	MUT	ERCC1:.			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:23934192	RDientsmann		L		TRUE		PARP inhibitors
ERCC1 deletion	ERCC1	CNA	ERCC1:del			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:23934192	RDientsmann		L		TRUE		PARP inhibitors
ERCC2 oncogenic mutation	ERCC2	MUT	ERCC2:.			Chemotherapy	Cisplatin	Responsive	Early trials		PMID:25096233	RDientsmann		BLCA		TRUE		Cisplatin (Chemotherapy)
ERCC4 oncogenic mutation	ERCC4	MUT	ERCC4:.			Chemotherapy	Cisplatin	Responsive	Pre-clinical		PMID:25634215	RDientsmann		OV		TRUE		Cisplatin (Chemotherapy)
ERCC6 oncogenic mutation	ERCC6	MUT	ERCC6:.			Chemotherapy	Cisplatin	Responsive	Pre-clinical		PMID:25634215	RDientsmann		OV		TRUE		Cisplatin (Chemotherapy)
EREG amplification	EREG	CNA	EREG:amp			[EGFR mAb inhibitor]	[]	Responsive	Early trials		PMID:19738126;PMID:26341080	RDientsmann	04/16	COREAD		TRUE		EGFR mAb inhibitors
ESR1 (E380Q,537,538,L536,P535H)	ESR1	MUT	ESR1:E380Q,.537.,.538.,L536.,P535H			[novel ER degrader]	[GDC-0810]	Responsive	Case report		AACR 2015 (abstr CT231)	RDientsmann	01/16	BRCA		TRUE		novel ER degraders (GDC-0810,etc)
ESR1 oncogenic mutation	ESR1	MUT	ESR1:.			Hormonal therapy	Exemestane	Resistant	Late trials		PMID:27269946	RDientsmann	06/16	BRCA		TRUE		Exemestane (Hormonal therapy)
ESR1 oncogenic mutation	ESR1	MUT	ESR1:.			Hormonal therapy	Fluvestrant	Responsive	Late trials		PMID:27269946	RDientsmann	06/16	BRCA		TRUE		Fluvestrant (Hormonal therapy)
ESR1-YAP1 fusion	ESR1	FUS	ESR1__YAP1			[ESR1 inhibitor]	[]	Resistant	Pre-clinical		PMID:24055055	RDientsmann		BRCA		TRUE		ESR1 inhibitors
ESR1 (E380Q,537,538,L536,P535H)	ESR1	MUT	ESR1:E380Q,.537.,.538.,L536.,P535H			Hormonal therapy	Tamoxifen	Resistant	Early trials		PMID:24185512;PMID:24185510;PMID:24398047	RDientsmann		BRCA		TRUE		Tamoxifen (Hormonal therapy)
EZH2 (Y641,A677)	EZH2	MUT	EZH2:Y641.,A677.	Direct	Pre-clinical	[EZH2 inhibitor]	[EPZ-005687,EPZ-6438]	Responsive	Pre-clinical	Cell line	PMID:23023262;PMID:24563539	RDientsmann;ECampo		LY		TRUE		EZH2 inhibitors (EPZ-005687,EPZ-6438,etc)
FANCA oncogenic mutation	FANCA	MUT	FANCA:.			PARP inhibitor	Olaparib	Responsive	Case report		PMID:26510020	RDientsmann	01/16	PRAD		TRUE		Olaparib (PARP inhibitor)
FANCA deletion	FANCA	CNA	FANCA:del			PARP inhibitor	Olaparib	Responsive	Case report		PMID:26510020	RDientsmann	01/16	PRAD		TRUE		Olaparib (PARP inhibitor)
FANCC oncogenic mutation	FANCC	MUT	FANCC:.	Indirect	Approved	Chemotherapy	Cisplatin	Responsive	Early trials		PMID:26238431	ARodriguez-Vida	09/15	BLCA	BLCA	TRUE		Cisplatin (Chemotherapy)
FANCC deletion	FANCC	CNA	FANCC:del	Indirect	Approved	Chemotherapy	Cisplatin	Responsive	Early trials		PMID:26238431	ARodriguez-Vida	09/15	BLCA	BLCA	TRUE		Cisplatin (Chemotherapy)
FAT1 oncogenic mutation	FAT1	MUT	FAT1:.			[BET inhibitor]	[]	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	HNSC		TRUE		BET inhibitors
FBXW7 oncogenic mutation	FBXW7	MUT	FBXW7:.			[Steroid]	[]	Responsive	Late trials		PMID:20861909	RDientsmann	01/16	ALL		TRUE		Steroids
FBXW7 deletion	FBXW7	CNA	FBXW7:del			[Tubulin inhibitor]	[]	Resistant	Pre-clinical		PMID:21368834	RDientsmann		CANCER		TRUE		Tubulin inhibitors
FBXW7 oncogenic mutation	FBXW7	MUT	FBXW7:.			[Tubulin inhibitor]	[]	Resistant	Pre-clinical		PMID:21368834	RDientsmann		CANCER		TRUE		Tubulin inhibitors
FBXW7 deletion	FBXW7	CNA	FBXW7:del	Indirect	Approved	MTOR inhibitor	Sirolimus	Responsive	Pre-clinical	Cell line	PMID:23558291	CRubio-Perez		COREAD		TRUE		Sirolimus (MTOR inhibitor)
FGF3 amplification	FGF3	CNA	FGF3:amp	Indirect	Clinical Trials	FGFR inhibitor	Lucitanib	Responsive	Early trials		PMID:25193991	JAlbanell;ARovira	09/15	BRCA		TRUE		Lucitanib (FGFR inhibitor)
FGF3 amplification	FGF3	CNA	FGF3:amp			FGFR inhibitor	Dovitinib	Responsive	Early trials		PMID:23658459	RDientsmann		BRCA		TRUE		Dovitinib (FGFR inhibitor)
FGF4 amplification	FGF4	CNA	FGF4:amp	Indirect	Clinical Trials	FGFR inhibitor	Lucitanib	Responsive	Early trials		PMID:25193991	JAlbanell;ARovira	09/15	BRCA		TRUE		Lucitanib (FGFR inhibitor)
FGF4 amplification	FGF4	CNA	FGF4:amp			FGFR inhibitor	Dovitinib	Responsive	Early trials		PMID:23658459	RDientsmann		BRCA		TRUE		Dovitinib (FGFR inhibitor)
FGFR1 amplification	FGFR1	CNA	FGFR1:amp			[FGFR inhibitor]	[]	Responsive	Early trials		AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)	RDientsmann		LUSC		TRUE		FGFR inhibitors
FGFR1 amplification	FGFR1	CNA	FGFR1:amp			[FGFR inhibitor]	[]	Responsive	Pre-clinical		PMID:23418312	RDientsmann		HNC		TRUE		FGFR inhibitors
FGFR1 amplification	FGFR1	CNA	FGFR1:amp			[FGFR inhibitor]	[Lucitanib]	Responsive	Early trials		PMID:25193991	RDientsmann;JAlbanell		BRCA		TRUE		FGFR inhibitors (Lucitanib,etc)
FGFR2 amplification	FGFR2	CNA	FGFR2:amp			[FGFR inhibitor]	[]	Responsive	Early trials		ASCO 2015 (abstr 2508)	RDientsmann	01/16	ST		TRUE		FGFR inhibitors
FGFR2 (V565I)	FGFR2	MUT	FGFR2:V565I			[FGFR inhibitor]	[]	Responsive	Pre-clinical		ENA 2014 (abstr 381)	RDientsmann	01/16	ED		TRUE		FGFR inhibitors
FGFR2 amplification	FGFR2	CNA	FGFR2:amp			[FGFR inhibitor]	[]	Responsive	Case report		PMID:25193991	RDientsmann	01/16	BRCA		TRUE		FGFR inhibitors
FGFR2 inframe insertion (A266),inframe insertion (S267)	FGFR2	MUT	FGFR2::consequence::inframe_insertion:A266.,::inframe_insertion:S267.			[FGFR inhibitor]	[]	Responsive	Pre-clinical		PMID:26048680	RDientsmann	01/16	L		TRUE		FGFR inhibitors
FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	FGFR2	MUT	FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E			BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib	Responsive	Pre-clinical		PMID:23908597	RDientsmann	01/16	ED		TRUE		Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)
FGFR2 fusion	FGFR2	FUS	FGFR2__.			[FGFR inhibitor]	[]	Responsive	Early trials		ASCO 2016 (abstr 109)	RDientsmann		BT		TRUE		FGFR inhibitors
FGFR2 (S252W,N550K)	FGFR2	MUT	FGFR2:S252W,N550K			[FGFR inhibitor]	[]	Responsive	Pre-clinical		PMID:18552176;PMID:22238366;PMID:23002168	RDientsmann		ED		TRUE	REMAP: N549K to N500K to have all mutations in same transcript (ENST00000457416)	FGFR inhibitors
FGFR2 (W290C,S320C,K660N)	FGFR2	MUT	FGFR2:W290C,S320C,K660N			[FGFR inhibitor]	[]	Responsive	Pre-clinical		PMID:23786770;PMID:25035393	RDientsmann		LUSC		TRUE		FGFR inhibitors
FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	FGFR2	MUT	FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E			FGFR inhibitor	Dovitinib	Resistant	Pre-clinical		PMID:23908597	RDientsmann		ED		TRUE		Dovitinib (FGFR inhibitor)
FGFR3 oncogenic mutation	FGFR3	MUT	FGFR3:.			[FGFR inhibitor]	[]	Responsive	Early trials		AACR 2014 (abstr CT326)	RDientsmann	01/16	BLCA		TRUE		FGFR inhibitors
FGFR3 (K650,Y373C)	FGFR3	MUT	FGFR3:K650.,Y373C			[FGFR inhibitor]	[]	Responsive	Pre-clinical		PMID:16091734;PMID:20439987;PMID:22869148	RDientsmann	01/16	MYMA		TRUE		FGFR inhibitors
FGFR3 fusion	FGFR3	FUS	FGFR3__.			[FGFR inhibitor]	[]	Responsive	Case report		PMID:26324363	RDientsmann	01/16	BLCA		TRUE		FGFR inhibitors
FGFR3 fusion	FGFR3	FUS	FGFR3__.			[FGFR inhibitor]	[]	Responsive	Early trials		PMID:26324363	RDientsmann	01/16	G		TRUE		FGFR inhibitors
FGFR3-TACC3 fusion	FGFR3	FUS	FGFR3__TACC3			[FGFR inhibitor]		Responsive	Pre-clinical		PMID:25294908	EArriola	06/16	NSCLC		TRUE		FGFR inhibitors (,etc)
FGFR3 (V555M)	FGFR3	MUT	FGFR3:V555M			[FGFR inhibitor]	[]	Resistant	Pre-clinical		PMID:22869148	RDientsmann		MYMA		TRUE		FGFR inhibitors
FGFR3 (Y373C)	FGFR3	MUT	FGFR3:Y373C			Proteasome inhibitor	Bortezomib	Resistant	Pre-clinical		PMID:19331127;PMID:21273588	RDientsmann		MYMA		TRUE		Bortezomib (Proteasome inhibitor)
FGFR3 (K650)	FGFR3	MUT	FGFR3:K650.			Proteasome inhibitor	Bortezomib	Responsive	Pre-clinical		PMID:19331127;PMID:21273588	RDientsmann		MYMA		TRUE		Bortezomib (Proteasome inhibitor)
FGFR4 (N535,V550)	FGFR4	MUT	FGFR4:N535.,V550.			[FGFR inhibitor]	[]	Responsive	Pre-clinical		PMID:19809159;PMID:24124571	RDientsmann	04/16	RHBDS		TRUE	REMAP:changed N535 and V550 from K535 and E550. Reference added by carlota	FGFR inhibitors
FLCN oncogenic mutation	FLCN	MUT	FLCN:.			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:23995526	RDientsmann	01/16	R		TRUE		Everolimus (MTOR inhibitor)
FLCN deletion	FLCN	CNA	FLCN:del			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:25295501	RDientsmann	01/16	TH		TRUE		Everolimus (MTOR inhibitor)
FLT1 overexpression	FLT1	EXPR	VEGFR1:over	Direct	Approved	Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical	Cell line	PMID:24086736;PMID:21478036	ARodriguez-Vida	09/15	R		TRUE		Sunitinib (Pan-TK inhibitor)
FLT1 overexpression	FLT1	EXPR	VEGFR2:over	Direct	Approved	Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical	Cell line	PMID:24086736;PMID:21478036	ARodriguez-Vida	09/15	R		TRUE		Sunitinib (Pan-TK inhibitor)
FLT3-ITD	FLT3	MUT	FLT3::consequence::inframe_variant:572-603			[FLT3 inhibitor]	[]	Responsive	Early trials		PMID:16857985	RDientsmann	01/16	AML		TRUE	ITD (codified as inframe) in Juxtamembrane domain	FLT3 inhibitors
FLT3 (F691)	FLT3	MUT	FLT3:F691.			[novel FLT3 inhibitor]	[]	Responsive	Pre-clinical		PMID:25847190	RDientsmann	01/16	AML		TRUE		novel FLT3 inhibitors
FLT3 (N676)	FLT3	MUT	FLT3:N676.			FLT3 inhibitor	Crenolanib	Responsive	Pre-clinical		PMID:24619500	RDientsmann	01/16	AML		TRUE		Crenolanib (FLT3 inhibitor)
FLT3 (D835)	FLT3	MUT	FLT3:D835.			Pan-TK inhibitor	Lestaurtinib	Responsive	Case report		PMID:16857985	RDientsmann	01/16	AML		TRUE		Lestaurtinib (Pan-TK inhibitor)
FLT3 (D835)	FLT3	MUT	FLT3:D835.			Pan-TK inhibitor	Midostaurin	Responsive	Case report		PMID:20733134	RDientsmann	01/16	AML		TRUE		Midostaurin (Pan-TK inhibitor)
FLT3 (N676)	FLT3	MUT	FLT3:N676.			Pan-TK inhibitor	Midostaurin	Responsive	Pre-clinical		PMID:24619500	RDientsmann	01/16	AML		TRUE		Midostaurin (Pan-TK inhibitor)
FLT3 (D835,Y842)	FLT3	MUT	FLT3:D835.,Y842.			BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib	Resistant	Pre-clinical		PMID:23430109	RDientsmann	01/16	AML		TRUE		Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)
FLT3-ITD	FLT3	MUT	FLT3::consequence::inframe_variant:572-603			Pan-TK inhibitor	Quizartinib	Responsive	Early trials		ASH 2012 (abstr 673);ASH 2012 (abstr 48)	RDientsmann	01/16	AML		TRUE	ITD (codified as inframe) in Juxtamembrane domain	Quizartinib (Pan-TK inhibitor)
FLT3-ITD	FLT3	MUT	FLT3::consequence::inframe_variant:572-603			Pan-TK inhibitor	Sorafenib	Responsive	Early trials		PMID:19389879;PMID:22368270	RDientsmann	01/16	AML		TRUE	ITD (codified as inframe) in Juxtamembrane domain	Sorafenib (Pan-TK inhibitor)
FLT3-ITD	FLT3	MUT	FLT3::consequence::inframe_variant:572-603			Pan-TK inhibitor;Chemotherapy	Sorafenib;Azacytidine	Responsive	Early trials		PMID:23613521	RDientsmann	01/16	AML		TRUE	ITD (codified as inframe) in Juxtamembrane domain	Sorafenib + Azacytidine (Pan-TK inhibitor + Chemotherapy)
FLT3-ITD	FLT3	MUT	FLT3::consequence::inframe_variant:572-603			BCL2 inhibitor	Venetoclax	Resistant	Early trials		PMID:27520294	DTamborero;CRubio-Perez	10/16	AML		TRUE	ITD (codified as inframe) in Juxtamembrane domain	Venetoclax (BCL2 inhibitor)
FLT3 (F691,D835,N676,Y842)	FLT3	MUT	FLT3:F691.,D835.,N676.,Y842.			Pan-TK inhibitor	Quizartinib	Resistant	Pre-clinical		PMID:22504184;PMID:23878140	RDientsmann		AML		TRUE		Quizartinib (Pan-TK inhibitor)
FOXA1 amplification	FOXA1	CNA	FOXA1:amp			[BCL2 inhibitor]	[]	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	COREAD		TRUE		BCL2 inhibitors
FRS2 amplification	FRS2	CNA	FRS2:amp			[FGFR inhibitor]	[]	Responsive	Pre-clinical		PMID:23393200	RDientsmann		LIP		TRUE		FGFR inhibitors
G6PD biallelic inactivation	G6PD	BIA	G6PD:.		Approved	BRAF inhibitor	Dabrafenib	Increased Toxicity (Haemolytic Anemia)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Dabrafenib (BRAF inhibitor)
G6PD (S218F)	G6PD	MUT	G6PD:S218F		Approved	BRAF inhibitor	Dabrafenib	Increased Toxicity (Haemolytic Anemia)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Dabrafenib (BRAF inhibitor)
G6PD (V98M) + G6PD (N156D)	G6PD;G6PD	MUT;MUT	G6PD:V98M;G6PD:N156D		Approved	BRAF inhibitor	Dabrafenib	Increased Toxicity (Haemolytic Anemia)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Dabrafenib (BRAF inhibitor)
GATA3 oncogenic mutation	GATA3	MUT	GATA3:.			[Aromatase ihibitor]	[]	Responsive	Pre-clinical		PMID:24758297	RDientsmann		BRCA		TRUE		Aromatase ihibitors
GLI2 amplification	GLI2	CNA	GLI2:amp			[SMO inhibitor]	[]	Resistant	Pre-clinical		PMID:24951114	DTamborero;RDientsmann		MB		TRUE		SMO inhibitors
GNA11 (Q209L,Q209P)	GNA11	MUT	GNA11:Q209L,Q209P			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:22733540;PMID:22808163	RDientsmann	01/16	CM		TRUE		PI3K pathway inhibitor + MEK inhibitors
GNA11 (Q209L,Q209P)	GNA11	MUT	GNA11:Q209L,Q209P			MEK inhibitor	Selumetinib	Responsive	Early trials		ASCO 2013 (abstr CRA9003)	RDientsmann	01/16	CM		TRUE		Selumetinib (MEK inhibitor)
GNA11 (Q209L,Q209P)	GNA11	MUT	GNA11:Q209L,Q209P			HDAC inhibitor	Vorinostat	Responsive	Pre-clinical		NCT01587352	RDientsmann	01/16	CM		TRUE		Vorinostat (HDAC inhibitor)
GNAQ (Q209)	GNAQ	MUT	GNAQ:Q209.			[HDAC inhibitor]	[]	Responsive	Pre-clinical		NCT01587352	RDientsmann	01/16	CM		TRUE		HDAC inhibitors
GNAQ (Q209)	GNAQ	MUT	GNAQ:Q209.			[PKC inhibitor]	[]	Responsive	Pre-clinical		PMID:22653968;PMID:22253748	RDientsmann	01/16	CM		TRUE		PKC inhibitors
GNAQ (Q209)	GNAQ	MUT	GNAQ:Q209.			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:22733540;PMID:22808163	RDientsmann	01/16	CM		TRUE		PI3K pathway inhibitor + MEK inhibitors
GNAQ (Q209)	GNAQ	MUT	GNAQ:Q209.			MEK inhibitor	Selumetinib	Responsive	Early trials		ASCO 2013 (abstr CRA9003)	RDientsmann	01/16	CM		TRUE		Selumetinib (MEK inhibitor)
GNAS (R201)	GNAS	MUT	GNAS:R201.			[JAK inhibitor]	[]	Responsive	Pre-clinical		PMID:21835143	RDientsmann		CANCER		TRUE		JAK inhibitors
HDAC2 biallelic inactivation	HDAC2	BIA	HDAC2:.			PARP inhibitor	Olaparib	Responsive	Case report		PMID:26510020	RDientsmann;CRubio-Perez	01/16	PRAD		TRUE		Olaparib (PARP inhibitor)
HGF overexpression	HGF	EXPR	HGF:over	Indirect	Approved	Pan-kinase inhibitor	Cabozantinib	Responsive	Pre-clinical	Xenograft	PMID:25534569	CRubio-Perez;ARodriguez-Vida		UTC		TRUE		Cabozantinib (Pan-kinase inhibitor)
HGF amplification + ERBB2 amplification	HGF;ERBB2	CNA;CNA	HGF:amp;ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	Resistant	Early trials		PMID:22850551	RDientsmann;CRubio-Perez		BRCA		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
HIF1A overexpression	HIF1A	EXPR	HIF1A:over	Indirect	Approved	Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical	Cell line	PMID:24086736	ARodriguez-Vida	09/15	R		TRUE		Sunitinib (Pan-TK inhibitor)
HRAS oncogenic mutation	HRAS	MUT	HRAS:.			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:22345164	RDientsmann	01/16	CESC		TRUE		MTOR inhibitors
HRAS oncogenic mutation	HRAS	MUT	HRAS:.			Farnesyltransferase inhibitor	Tipifarnib	Responsive	Early trials		NCT02383927	RDientsmann	01/16	CANCER		TRUE		Tipifarnib (Farnesyltransferase inhibitor)
HRAS oncogenic mutation	HRAS	MUT	HRAS:.		Clinical Trials	Farnesyltransferase inhibitor	Tipifarnib	Responsive	Early trials		NCT02383927	RDientsmann	11/15	CANCER		TRUE		Tipifarnib (Farnesyltransferase inhibitor)
HRAS oncogenic mutation	HRAS	MUT	HRAS:.			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:15950068	RDientsmann		CER		TRUE		PI3K pathway inhibitor + MEK inhibitors
HRAS oncogenic mutation	HRAS	MUT	HRAS:.			[MEK inhibitor +/- MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:22399013;PMID:22507781	RDientsmann		AML		TRUE		MEK inhibitor +/- MTOR inhibitors
IDH1 oncogenic mutation	IDH1	MUT	IDH1:.			[IDH1 inhibitor]	[]	Responsive	Early trials		ENA 2014 (abstr 1LBA)	RDientsmann	01/16	AML		TRUE		IDH1 inhibitors
IDH1 oncogenic mutation	IDH1	MUT	IDH1:.			[BCL2 inhibitor]	[]	Responsive	Pre-clinical		PMID:25599133	RDientsmann	01/16	AML		TRUE		BCL2 inhibitors
IDH1 (R132)	IDH1	MUT	IDH1:R132.			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:27231123	RDientsmann	07/16	BT		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
IDH1 oncogenic mutation	IDH1	MUT	IDH1:.	Direct	Clinical Trials	IDH1 inhibitor	AG-120	Responsive	Early trials		NCT02073994;PMID:23558169	MMartínez;RDientsmann;CRubio-Perez	09/15	G		TRUE		AG-120 (IDH1 inhibitor)
IDH1 oncogenic mutation	IDH1	MUT	IDH1:.			BCL2 inhibitor	Venetoclax	Responsive	Early trials		PMID:27520294	DTamborero;CRubio-Perez	10/16	AML		TRUE	ITD (codified as inframe) in Juxtamembrane domain	Venetoclax (BCL2 inhibitor)
IDH1 oncogenic mutation	IDH1	MUT	IDH1:.	Indirect	Clinical Trials	BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Early trials		NCT02428855	CRubio-Perez		CH		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
IDH2 (R172)	IDH2	MUT	IDH2:R172.			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:27231123	RDientsmann	07/16	BT		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
IDH2 oncogenic mutation	IDH2	MUT	IDH2:.			BCL2 inhibitor	Venetoclax	Responsive	Early trials		PMID:27520294	DTamborero;CRubio-Perez	10/16	AML		TRUE	ITD (codified as inframe) in Juxtamembrane domain	Venetoclax (BCL2 inhibitor)
IDH2 (R140K,R172K)	IDH2	MUT	IDH2:R140K,R172K	Direct	Clinical Trials	IDH2 inhibitor	AG-221	Responsive	Early trials		AACR 2014 (abstr CT103)	RDientsmann		HEMATO		TRUE		AG-221 (IDH2 inhibitor)
IDH2 oncogenic mutation	IDH2	MUT	IDH2:.	Indirect	Clinical Trials	BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Early trials		NCT02428855	CRubio-Perez		CH		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
IGF1R amplification	IGF1R	CNA	IGF1R:amp			EGFR inhibitor 1st gen	Erlotinib	Resistant	Pre-clinical		PMID:24458568	RDientsmann		LUAD		TRUE		Erlotinib (EGFR inhibitor 1st gen)
IGF2 amplification	IGF2	CNA	IGF2:amp			[EGFR mAb inhibitor]	[]	Resistant	Early trials		PMID:25632036	RDientsmann		COREAD		TRUE		EGFR mAb inhibitors
IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion	IL7R;SH2B3	MUT;CNA	IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:22955920	RDientsmann	01/16	ALL		TRUE		MTOR inhibitors
IL7R (S185C) + SH2B3 deletion	IL7R;SH2B3	MUT;CNA	IL7R:S185C;SH2B3:del			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:22955920	RDientsmann	01/16	ALL		TRUE		MTOR inhibitors
IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion	IL7R;SH2B3	MUT;CNA	IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del			JAK inhibitor	Ruxolitinib	Responsive	Pre-clinical		PMID:22897847;PMID:22955920	RDientsmann	01/16	ALL		TRUE		Ruxolitinib (JAK inhibitor)
IL7R (S185C) + SH2B3 deletion	IL7R;SH2B3	MUT;CNA	IL7R:S185C;SH2B3:del			JAK inhibitor	Ruxolitinib	Responsive	Pre-clinical		PMID:22897847;PMID:22955920	RDientsmann	01/16	ALL		TRUE		Ruxolitinib (JAK inhibitor)
INPP4B deletion	INPP4B	CNA	INPP4B:del			[PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:23551093	RDientsmann		BRCA		TRUE		PI3K pathway inhibitors
INPP4B oncogenic mutation	INPP4B	MUT	INPP4B:.			[PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:23551093	RDientsmann		BRCA		TRUE		PI3K pathway inhibitors
JAK1 (S646F;R683)	JAK1	MUT	JAK1:S646F;R683.			JAK inhibitor	Ruxolitinib	Responsive	Pre-clinical		PMID:22955920;PMID:18805579	RDientsmann	01/16	ALL		TRUE		Ruxolitinib (JAK inhibitor)
JAK1 oncogenic mutation	JAK1	MUT	JAK1:.			[PD1 inhibitor]	[]	Resistant	Case report		PMID:27433843	RDientsmann	07/16	CM		TRUE		PD1 inhibitors
JAK2 (V617F)	JAK2	MUT	JAK2:V617F			[JAK inhibitor (alone or in combination)]	[]	Responsive	Pre-clinical		PMID:22829971	RDientsmann	01/16	AML		TRUE		JAK inhibitor (alone or in combination)s
JAK2 (V617F)	JAK2	MUT	JAK2:V617F			JAK inhibitor	Ruxolitinib	Responsive	Early trials		PMID:22422826	RDientsmann	01/16	AML		TRUE		Ruxolitinib (JAK inhibitor)
JAK2-BRAF fusion	JAK2	FUS	JAK2__BRAF			JAK inhibitor	Ruxolitinib	Responsive	Pre-clinical		PMID:22875628;PMID:22899477	RDientsmann	01/16	ALL		TRUE		Ruxolitinib (JAK inhibitor)
JAK2 amplification	JAK2	CNA	JAK2:amp			[JAK inhibitor]	[]	Responsive	Pre-clinical		PMID:27075627	RDientsmann	06/16	BRCA		TRUE		JAK inhibitors
JAK2 oncogenic mutation	JAK2	MUT	JAK2:.			[PD1 inhibitor]	[]	Resistant	Case report		PMID:27433843	RDientsmann	07/16	CM		TRUE		PD1 inhibitors
JAK2 (V617F)	JAK2	MUT	JAK2:V617F		Approved	JAK inhibitor	Ruxolitinib	Responsive	FDA guidelines		FDA	RDientsmann		MY		TRUE		Ruxolitinib (JAK inhibitor)
JAK3 (R657Q,I87T,Q501H)	JAK3	MUT	JAK3:R657Q,I87T,Q501H			[JAK inhibitor]	[]	Responsive	Pre-clinical		PMID:18397343	RDientsmann		MKB		TRUE		JAK inhibitors
JAK3 (A572V,A573V)	JAK3	MUT	JAK3:A572V,A573V			[JAK inhibitor]	[]	Responsive	Pre-clinical		PMID:22705984	RDientsmann		LY		TRUE		JAK inhibitors
KCNJ5 (L168R)	KCNJ5	MUT	KCNJ5:L168R	Indirect	Approved	Na-Ca chanel blocker	Amiloride	Responsive	Pre-clinical	Cell line	PMID:24506072	ECampo		AA		TRUE		Amiloride (Na-Ca chanel blocker)
KCNJ5 (L168R)	KCNJ5	MUT	KCNJ5:L168R	Indirect	Approved	Na-Ca chanel blocker	Verapamil	Responsive	Pre-clinical	Cell line	PMID:24506072	ECampo		AA		TRUE		Verapamil (Na-Ca chanel blocker)
KDR (A1065T)	KDR	MUT	KDR:A1065T			[VEGFR inhibitor]	[]	Responsive	Pre-clinical		PMID:24569783	RDientsmann		CANCER		TRUE		VEGFR inhibitors
KIT mutation in exon 9 or 17	KIT	MUT	KIT:788-828,449-514			[HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:21737509	RDientsmann	01/16	GIST		TRUE		HSP90 inhibitors
KIT mutation in exon 11	KIT	MUT	KIT:550-592			[HSP90 inhibitor]	[]	Responsive	Early trials		PMID:22898035	RDientsmann	01/16	GIST		TRUE		HSP90 inhibitors
KIT wildtype	KIT	MUT	KIT::wildtype:.			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:16397263	RDientsmann	01/16	GIST		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
KIT (D816V)	KIT	MUT	KIT:D816V			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Early trials		PMID:18559612	RDientsmann	01/16	SM		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
KIT (D816V)	KIT	MUT	KIT:D816V			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Case report		PMID:18986703	RDientsmann	01/16	AML		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
KIT mutation in exon 9,11,13,14 or 17	KIT	MUT	KIT:550-592,627-664			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Case report		PMID:19671763	RDientsmann	01/16	CM		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
KIT inframe deletion (V560)	KIT	MUT	KIT::consequence::inframe_deletion:V560.			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Case report		PMID:15201427	RDientsmann	01/16	THYM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT mutation in exon 9,11,13,14 or 17	KIT	MUT	KIT:550-592,627-664			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Late trials		PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	RDientsmann	01/16	CM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT (627-664,664-714,449-514)	KIT	MUT	KIT:627-664,664-714,449-514			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Late trials		PMID:18955458;PMID:18955451;PMID:16624552	RDientsmann	01/16	GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT (Y553N)	KIT	MUT	KIT:Y553N			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Case report		PMID:21969494	RDientsmann	01/16	THYM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT (D820Y)	KIT	MUT	KIT:D820Y			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Case report		PMID:23775962	RDientsmann	01/16	CM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT mutation in exon 17	KIT	MUT	KIT:788-828			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Pre-clinical		PMID:23840364	RDientsmann	01/16	GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT mutation in exon 9,11,13,14 or 17	KIT	MUT	KIT:550-592,627-664			BCR-ABL inhibitor 2nd gen	Nilotinib	Responsive	Early trials		PMID:22068222;PMID:25695690	RDientsmann	01/16	CM		TRUE		Nilotinib (BCR-ABL inhibitor 2nd gen)
KIT mutation in exon 17	KIT	MUT	KIT:788-828			BCR-ABL inhibitor 2nd gen	Nilotinib	Responsive	Early trials		PMID:22119758;PMID:21456006	RDientsmann	01/16	GIST		TRUE		Nilotinib (BCR-ABL inhibitor 2nd gen)
KIT (D820Y)	KIT	MUT	KIT:D820Y			BCR-ABL inhibitor 2nd gen	Nilotinib	Responsive	Case report		PMID:25695690	RDientsmann	01/16	CM		TRUE		Nilotinib (BCR-ABL inhibitor 2nd gen)
KIT (788-828,829-860,550-592)	KIT	MUT	KIT:788-828,829-860,550-592			BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib	Responsive	Early trials		ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)	RDientsmann	01/16	GIST		TRUE		Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)
KIT wildtype	KIT	MUT	KIT::wildtype:.			Pan-TK inhibitor	Sorafenib	Responsive	Early trials		ASCO 2011 (abstr 10009)	RDientsmann	01/16	GIST		TRUE		Sorafenib (Pan-TK inhibitor)
KIT (550-592,627-664,788-828,829-860)	KIT	MUT	KIT:550-592,627-664,788-828,829-860			Pan-TK inhibitor	Sorafenib	Responsive	Case report		PMID:18936790;PMID:20372153	RDientsmann	01/16	CM		TRUE		Sorafenib (Pan-TK inhibitor)
KIT (D820E)	KIT	MUT	KIT:D820E			Pan-TK inhibitor	Sorafenib	Responsive	Case report		PMID:19461405	RDientsmann	01/16	THYM		TRUE		Sorafenib (Pan-TK inhibitor)
KIT inframe deletion (577-579)	KIT	MUT	KIT::consequence::inframe_deletion:577-579			Pan-TK inhibitor	Sorafenib	Responsive	Case report		PMID:20970876	RDientsmann	01/16	THYM		TRUE		Sorafenib (Pan-TK inhibitor)
KIT mutation in exon 9 or 11	KIT	MUT	KIT:550-592,449-514			Pan-TK inhibitor	Sorafenib	Responsive	Early trials		PMID:22270258	RDientsmann	01/16	GIST		TRUE		Sorafenib (Pan-TK inhibitor)
KIT mutation in exon 17	KIT	MUT	KIT:788-828			Pan-TK inhibitor	Sorafenib	Responsive	Pre-clinical		PMID:23840364	RDientsmann	01/16	GIST		TRUE		Sorafenib (Pan-TK inhibitor)
KIT mutation in exon 9,11,13,14 or 17	KIT	MUT	KIT:550-592,627-664			Pan-TK inhibitor	Sunitinib	Responsive	Late trials		PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	RDientsmann	01/16	CM		TRUE		Sunitinib (Pan-TK inhibitor)
KIT mutation in exon 11	KIT	MUT	KIT:550-592			Pan-TK inhibitor	Sunitinib	Resistant	Late trials		PMID:18955458	RDientsmann	01/16	GIST		TRUE		Sunitinib (Pan-TK inhibitor)
KIT wildtype	KIT	MUT	KIT::wildtype:.			Pan-TK inhibitor	Sunitinib	Responsive	Late trials		PMID:18955458	RDientsmann	01/16	GIST		TRUE		Sunitinib (Pan-TK inhibitor)
KIT (H697Y)	KIT	MUT	KIT:H697Y			Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical		PMID:19861435	RDientsmann	01/16	THYM		TRUE		Sunitinib (Pan-TK inhibitor)
KIT amplification	KIT	CNA	KIT:amp			Pan-TK inhibitor	Sunitinib	No Responsive	Early trials		PMID:22261812	RDientsmann	01/16	CM		TRUE		Sunitinib (Pan-TK inhibitor)
KIT (Y553N)	KIT	MUT	KIT:Y553N			Pan-TK inhibitor	Sunitinib	Responsive	Case report		PMID:23375402	RDientsmann	01/16	THYM		TRUE		Sunitinib (Pan-TK inhibitor)
KIT mutation in exon 17	KIT	MUT	KIT:788-828			Pan-TK inhibitor	Sunitinib	Resistant	Pre-clinical		PMID:23840364	RDientsmann	01/16	GIST		TRUE		Sunitinib (Pan-TK inhibitor)
KIT (D816Y,D816F,D816V)	KIT	MUT	KIT:D816Y,D816F,D816V			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:16397263	CRubio-Perez;RDientsmann		CANCER		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
KIT (N822K)	KIT	MUT	KIT:N822K			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:23149070	RDientsmann		AML		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
KIT mutation in exon 9,11,13,14 or 17	KIT	MUT	KIT:449-514,550-592,627-664,664-714,788-828		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT (D816)	KIT	MUT	KIT:D816.		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	FDA guidelines		FDA	CRubio-Perez;DTamborero;RDientsmann		GIST;MDS;MDPS;HES;ECL;CML;ALL;SM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT mutation in exon 9,11,13,14 or 17	KIT	MUT	KIT:550-592,627-664		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	NCCN guidelines		NCCN	RDientsmann		CM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT inframe deletion (416-422),inframe insertion (416-422)	KIT	MUT	KIT::consequence::inframe_deletion:416-422,::inframe_insertion:416-422			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Pre-clinical		PMID:15618474	RDientsmann		AML		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT wildtype	KIT	MUT	KIT::wildtype:.			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Late trials		PMID:18955458	RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT mutation in exon 17 or 18	KIT	MUT	KIT:788-828,829-860			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Early trials		PMID:21690468;PMID:21642685	RDientsmann		CM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	KIT	MUT	KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Pre-clinical		PMID:23582185;PMID:21689725;PMID:17259998	RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT amplification	KIT	CNA	KIT:amp			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	No Responsive	Early trials		PMID:23775962	RDientsmann		CM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT (T670I)	KIT	MUT	KIT:T670I			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Case report		PMID:24687822	RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KIT (A829P,V654A,T670I)	KIT	MUT	KIT:A829P,V654A,T670I			BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib	Responsive	Pre-clinical		PMID:25239608	RDientsmann		GIST		TRUE		Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)
KIT mutation in exon 9,11,13,14 or 17	KIT	MUT	KIT:449-514,550-592,627-664,664-714,788-828		Approved	Pan-kinase inhibitor	Regorafenib	Responsive	FDA guidelines		FDA	RDientsmann		GIST		TRUE	Exon 9,11,14,17	Regorafenib (Pan-kinase inhibitor)
KIT mutation in exon 9,11,13,14 or 17	KIT	MUT	KIT:449-514,550-592,627-664,664-714,788-828		Approved	Pan-TK inhibitor	Sunitinib	Responsive	FDA guidelines		FDA	RDientsmann		GIST		TRUE		Sunitinib (Pan-TK inhibitor)
KIT (H697Y)	KIT	MUT	KIT:H697Y			Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical		PMID:19861435	RDientsmann		THYM		TRUE		Sunitinib (Pan-TK inhibitor)
KMT2D oncogenic mutation	KMT2D	MUT	KMT2D:.			AR inhibitor	Bicalutamide	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	LUSC		TRUE		Bicalutamide (AR inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[PI3K pathway inhibitor;MEK inhibitor]	[]	No Responsive	Early trials		ASCO 2015 (abstr 4119)	RDientsmann	01/16	PA		TRUE		PI3K pathway inhibitor + MEK inhibitors
KRAS (G12)	KRAS	MUT	KRAS:G12.			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:18701506	RDientsmann	01/16	ALL		TRUE		MEK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:21984976;PMID:22662154;PMID:22985491	RDientsmann	01/16	ED;MYMA		TRUE		PI3K pathway inhibitor + MEK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[MEK inhibitor;PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:22392911	RDientsmann	01/16	COREAD		TRUE		MEK inhibitor + PI3K pathway inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[MEK inhibitor;BCL-XL inhibitor]	[]	Responsive	Pre-clinical		PMID:23245996	RDientsmann	01/16	COREAD		TRUE		MEK inhibitor + BCL-XL inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[ERK inhibitor]	[]	Responsive	Pre-clinical		PMID:23614898	RDientsmann	01/16	COREAD		TRUE		ERK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[MEK inhibitor;IGF1R inhibitor]	[]	Responsive	Pre-clinical		PMID:24045180	RDientsmann	01/16	COREAD		TRUE		MEK inhibitor + IGF1R inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[MTOR inhibitor;BH3 mimetics]	[]	Responsive	Pre-clinical		PMID:24163374	RDientsmann	01/16	COREAD		TRUE		MTOR inhibitor + BH3 mimeticss
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[EGFR mAb inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:24553387	RDientsmann	01/16	COREAD		TRUE		EGFR mAb inhibitor + MEK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[EZH2 inhibitor]	[]	Resistant	Pre-clinical		PMID:26552009	RDientsmann	01/16	CANCER		TRUE		EZH2 inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			Chemotherapy;BCL2 inhibitor	Decitabine;BCL2 inhibitor	Responsive	Pre-clinical		PMID:25968887	RDientsmann	01/16	OV		TRUE		Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			Chemotherapy;MEK inhibitor	Gemcitabine;MEK inhibitor	Responsive	Early trials		PMID:23583440	RDientsmann	01/16	PA		TRUE		Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			Pan-TK inhibitor;MEK inhibitor	Sorafenib;MEK inhibitor	Responsive	Early Trials,Case Report		PMID:25294897	RDientsmann	01/16	HC		TRUE		Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab;Lapatinib	Resistant	Late trials		ASCO 2015 (abstr 3508);NCT01104571;EBCC10	RDientsmann	01/16	COREAD		TRUE		Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[FAS inhibitor]	[]	Responsive	Case report		AACR 2016;abstr	RDientsmann	04/16	L		TRUE		FAS inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[CDK4 inhibitor]	[]	Responsive	Pre-clinical		PMID:20609353	RDientsmann	04/16	L		TRUE		CDK4 inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[HSP90 inhibitor (in combination)]	[]	Responsive	Pre-clinical		PMID:23012248;PMID:21907929	RDientsmann	04/16	L		TRUE		HSP90 inhibitor (in combination)s
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[BET inhibitor]	[]	Responsive	Pre-clinical		PMID:23129625;PMID:24045185	RDientsmann	04/16	L		TRUE		BET inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[MEK inhibitor]	[]	Responsive	Early trials		PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	RDientsmann	04/16	L;BT		TRUE		MEK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[FAK inhibitor]	[]	Responsive	Pre-clinical		PMID:23358651	RDientsmann	04/16	L		TRUE		FAK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[JAK/TBK1/IKKε inhibitor]	[]	Responsive	Pre-clinical		PMID:24444711	RDientsmann	04/16	L		TRUE		JAK/TBK1/IKKε inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Early trials		PMID:25516890	RDientsmann	04/16	L		TRUE		PI3K pathway inhibitor + MEK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[CDK4/6 inhibitor]	[Palbociclib,Abemaciclib]	Responsive	Early trials		PMID:26658964;NCT01291017	DTamborero;CRubio-Perez	04/16	NSCLC		TRUE		CDK4/6 inhibitors (Palbociclib,Abemaciclib,etc)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			MEK inhibitor	Selumetinib	No Responsive	Early trials		PMID:26802155	RDientsmann	04/16	L		TRUE		Selumetinib (MEK inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[pan-RAF inhibitor]	[]	Responsive	Case report		AACR 2016 (abstr CT005)	RDientsmann	06/16	ED;L		TRUE		pan-RAF inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[FAS inhibitor]	[]	Responsive	Case report		AACR 2016, abstr LB214	RDientsmann	06/16	L		TRUE		FAS inhibitors
KRAS (G13D)	KRAS	MUT	KRAS:G13D			EGFR mAb inhibitor	Cetuximab	No Responsive	Late trials		PMID:27114605	RDientsmann	06/16	COREAD		TRUE		Cetuximab (EGFR mAb inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			CDK4/6 inhibitor	Abemaciclib	Responsive	Early trials		PMID:27231123	RDientsmann	07/16	LUAD		TRUE		Abemaciclib (CDK4/6 inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			MEK inhibitor;BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Trametinib;Ponatinib	Responsive	Pre-clinical		PMID:27338794	RDientsmann	07/16	LUAD		TRUE		Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.		Clinical Trials	MEK inhibitor	Selumetinib	Responsive	Early trials		NCT00890825	EArriola	09/15	NSCLC		TRUE		Selumetinib (MEK inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[EGFR inhibitor]	[]	Resistant	Pre-clinical		PMID:19238210	DTamborero		NSCLC		TRUE		EGFR inhibitors
KRAS amplification	KRAS	CNA	KRAS:amp			[BRAF inhibitor;EGFR mAb inhibitor]	[]	Resistant	Case report		ENA 2014 (abstr 428)	RDientsmann		COREAD		TRUE		BRAF inhibitor + EGFR mAb inhibitors
KRAS amplification	KRAS	CNA	KRAS:amp			[BRAF inhibitor;MEK inhibitor]	[]	Resistant	Case report		ENA 2014 (abstr 428)	RDientsmann		COREAD		TRUE		BRAF inhibitor + MEK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[EGFR inhibitor 1st gen]	[]	Resistant	NCCN guidelines		PMID:20921461	RDientsmann		L		TRUE		EGFR inhibitor 1st gens
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[EGFR inhibitor 2nd gen]	[]	Resistant	NCCN guidelines		PMID:20921461	RDientsmann		L		TRUE		EGFR inhibitor 2nd gens
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:22507781;PMID:22169769;PMID:19018267	RDientsmann		AML;CER;OV		TRUE		MEK inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[EGFR mAb inhibitor]	[]	Resistant	Pre-clinical		PMID:22614881;PMID:22290393	RDientsmann		ST		TRUE		EGFR mAb inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			[PI3K pathway inhibitor]	[]	Resistant	Pre-clinical		PMID:22662154	RDientsmann		ED		TRUE		PI3K pathway inhibitors
KRAS oncogenic mutation	KRAS	MUT	KRAS:.		Approved	EGFR mAb inhibitor	Cetuximab	Resistant	FDA guidelines		FDA guidelines	CRubio-Perez;RDientsmann		COREAD		TRUE	KRAS:.; no seria tambe NRAS??	Cetuximab (EGFR mAb inhibitor)
KRAS (G12)	KRAS	MUT	KRAS:G12.			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Case report		PMID:24687822	RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.		Approved	EGFR mAb inhibitor	Panitumumab	Resistant	FDA guidelines		FDA guidelines	CRubio-Perez;RDientsmann		COREAD		TRUE		Panitumumab (EGFR mAb inhibitor)
KRAS oncogenic mutation	KRAS	MUT	KRAS:.			Pan-kinase inhibitor	Regorafenib	Resistant	FDA guidelines		FDA guidelines	CRubio-Perez;RDientsmann		COREAD	COREAD	TRUE		Regorafenib (Pan-kinase inhibitor)
LRP1B oncogenic mutation	LRP1B	MUT	LRP1B:.			Chemotherapy	Liposomal Doxorubicin	Resistant	Early trials		PMID:22896685	RDientsmann		OV		TRUE		Liposomal Doxorubicin (Chemotherapy)
LRP1B deletion	LRP1B	CNA	LRP1B:del			Chemotherapy	Liposomal Doxorubicin	Resistant	Early trials		PMID:22896685	RDientsmann		OV		TRUE		Liposomal Doxorubicin (Chemotherapy)
MAP2K1 (F129L,L215P,I103N,P124)	MAP2K1	MUT	MAP2K1:F129L,L215P,I103N,P124.			[ERK inhibitor]	[]	Responsive	Pre-clinical		PMID:23614898	RDientsmann	01/16	CANCER		TRUE		ERK inhibitors
MAP2K1 (C121S)	MAP2K1	MUT	MAP2K1:C121S			[novel MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:24448821	RDientsmann	01/16	CM		TRUE		novel MEK inhibitors
MAP2K1 (P124)	MAP2K1	MUT	MAP2K1:P124.			[ERK inhibitor]	[]	Responsive	Pre-clinical		PMID:25370473	RDientsmann	01/16	CM		TRUE		ERK inhibitors
MAP2K1 inframe deletion (56-60)	MAP2K1	MUT	MAP2K1::consequence::inframe_deletion:56-60			MEK inhibitor	Selumetinib	Responsive	Case report		PMID:26324360	RDientsmann	01/16	OV		TRUE		Selumetinib (MEK inhibitor)
MAP2K1 (Q56P,P124S,P124L)	MAP2K1	MUT	MAP2K1:Q56P,P124S,P124L			[MEK inhibitor]	[]	Resistant	Case report		PMID:19915144	DTamborero	03/16	CM		TRUE		MEK inhibitors
MAP2K1 (Q56P,P124S,P124L;C121S)	MAP2K1	MUT	MAP2K1:Q56P,P124S,P124L;C121S			[BRAF inhibitor]	[]	Resistant	Case report		PMID:19915144;PMID:21383288	RDientsmann;DTamborero	03/16	CM		TRUE		BRAF inhibitors
MAP2K1 (K57T)	MAP2K1	MUT	MAP2K1:K57T			EGFR mAb inhibitor;MEK inhibitor	Panitumumab;Trametinib	Responsive	Case report		PMID:26644315	RDientsmann	04/16	COREAD		TRUE		Panitumumab + Trametinib (EGFR mAb inhibitor + MEK inhibitor)
MAP2K1 (Q56P)	MAP2K1	MUT	MAP2K1:Q56P			MEK inhibitor	Trametinib	Responsive	Pre-clinical		PMID:26582713	RDientsmann	04/16	CANCER		TRUE		Trametinib (MEK inhibitor)
MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	MAP2K1	MUT	MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N			[MEK inhibitor]	[]	Resistant	Pre-clinical		PMID:19915144	RDientsmann		CANCER		TRUE	Reference added by carlota	MEK inhibitors
MAP2K1 (P124L,K57N,C121S)	MAP2K1	MUT	MAP2K1:P124L,K57N,C121S			[MEK inhibitor]	[]	Resistant	Case report		PMID:19915144;PMID:23444215;PMID:21383288	RDientsmann		CM		TRUE		MEK inhibitors
MAP2K1 (P124)	MAP2K1	MUT	MAP2K1:P124.			[BRAF inhibitor]	[]	Resistant	Early trials		PMID:25370473	RDientsmann		CM		TRUE		BRAF inhibitors
MAP2K1 oncogenic mutation	MAP2K1	MUT	MAP2K1:.			[EGFR mAb inhibitor]	[]	Resistant	Case report		PMID:26030179	RDientsmann		COREAD		TRUE		EGFR mAb inhibitors
MAP2K1 (E203K,Q56P,K57E)	MAP2K1	MUT	MAP2K1:E203K,Q56P,K57E			BRAF inhibitor	Vemurafenib	Resistant	Case report		PMID:23569304	RDientsmann		CM		TRUE		Vemurafenib (BRAF inhibitor)
MAP2K1 (P124S,I111S) + BRAF oncogenic mutation	MAP2K1;BRAF	MUT;MUT	MAP2K1:P124S,I111S;BRAF:.			[BRAF inhibitor]	[]	Responsive	Case report		PMID:22588879	RDientsmann	01/16	CM		TRUE		BRAF inhibitors
MAP2K2 (V35M,L46F,N126D,C125S)	MAP2K2	MUT	MAP2K2:V35M,L46F,N126D,C125S			[BRAF inhibitor]	[]	Resistant	Pre-clinical		PMID:24265153	RDientsmann		CM		TRUE		BRAF inhibitors
MAP2K2 (V35M,L46F,N126D,C125S)	MAP2K2	MUT	MAP2K2:V35M,L46F,N126D,C125S			[MEK inhibitor]	[]	Resistant	Pre-clinical		PMID:24265153	RDientsmann		CM		TRUE		MEK inhibitors
MAP2K2 (Q60P)	MAP2K2	MUT	MAP2K2:Q60P			[BRAF inhibitor]	[]	Resistant	Case report		PMID:24265154	RDientsmann		CM		TRUE		BRAF inhibitors
MAP2K2 (Q60P)	MAP2K2	MUT	MAP2K2:Q60P			[MEK inhibitor]	[]	Resistant	Case report		PMID:24265154	RDientsmann		CM		TRUE		MEK inhibitors
MCL1 amplification	MCL1	CNA	MCL1:amp			[Tubulin inhibitor]	[]	Resistant	Pre-clinical		PMID:21368834	RDientsmann		CANCER		TRUE		Tubulin inhibitors
MDM2 amplification	MDM2	CNA	MDM2:amp			[MDM2 inhibitor]	[]	Responsive	Early trials		PMID:23084521;ASCO 2015 (abstr 10564)	RDientsmann	01/16	LIP		TRUE		MDM2 inhibitors
MDM2 amplification	MDM2	CNA	MDM2:amp			Chemotherapy	Cisplatin	Resistant	Early trials		PMID:27646943	RDientsmann	12/16	MGCT		TRUE		Cisplatin (Chemotherapy)
MDM4 amplification	MDM4	CNA	MDM4:amp			[MDM2/MDMX inhibitor]	[]	Responsive	Pre-clinical		PMID:24336067	RDientsmann		S		TRUE		MDM2/MDMX inhibitors
MET amplification	MET	CNA	MET:amp			[MET inhibitor]	[]	Responsive	Case report		ENA 2015 (abstract A55)	RDientsmann	01/16	HC		TRUE		MET inhibitors
MET amplification	MET	CNA	MET:amp			[MET inhibitor]	[]	Responsive	Pre-clinical		PMID:22729845;PMID:23327903	RDientsmann	01/16	ST		TRUE		MET inhibitors
MET (H1112R)	MET	MUT	MET:H1112R			[MET inhibitor]	[]	Responsive	Early trials		PMID:23213094	RDientsmann	01/16	R		TRUE	REMAP:H1094r changed to H1112R	MET inhibitors
MET (M1268T)	MET	MUT	MET:M1268T			[MET inhibitor]	[]	Responsive	Case report		PMID:23610116	RDientsmann	01/16	R		TRUE		MET inhibitors
MET amplification	MET	CNA	MET:amp		Clinical Trials	ALK inhibitor	Crizotinib	Responsive	Early trials		NCT02499614;ASCO 2015 (abstr 2595)	EArriola;CRubio-Perez	01/16	NSCLC		TRUE		Crizotinib (ALK inhibitor)
MET amplification	MET	CNA	MET:amp			ALK inhibitor	Crizotinib	Responsive	Early trials		ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	RDientsmann	01/16	LUAD;ST		TRUE		Crizotinib (ALK inhibitor)
MET amplification	MET	CNA	MET:amp			ALK inhibitor	Crizotinib	Responsive	Case report		PMID:22162573	RDientsmann	01/16	G		TRUE		Crizotinib (ALK inhibitor)
MET fusion	MET	FUS	MET__.			ALK inhibitor	Crizotinib	Responsive	Case report		PMID:27748748	RDientsmann	12/16	G		TRUE		Crizotinib (ALK inhibitor)
MET amplification	MET	CNA	MET:amp			[MET inhibitor]	[]	Responsive	Early trials		PMID:23213094;AACR 2016 (abstr CT2006)	RDientsmann	06/16	R		TRUE		MET inhibitors
MET mutation in exon 16-19	MET	MUT	MET:1132-1330			ALK inhibitor	Crizotinib	Responsive	Early trials		AACR 2016 (abstr CT2006)	RDientsmann	06/16	R		TRUE	EXON 16-19	Crizotinib (ALK inhibitor)
MET amplification	MET	CNA	MET:amp		Approved	[EGFR inhibitor 3rd gen]	Osimertinib	Resistant	Case report		PMID:27252416	EArriola	06/16	LUAD		TRUE		EGFR inhibitor 3rd gens (Osimertinib,etc)
MET amplification	MET	CNA	MET:amp			[EGFR inhibitor 3rd gen]	Rociletinib	Resistant	Case report		PMID:27252416	EArriola	06/16	LUAD		TRUE		EGFR inhibitor 3rd gens (Rociletinib,etc)
MET amplification	MET	CNA	MET:amp			[BCL2 inhibitor]	[]	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	COREAD		TRUE		BCL2 inhibitors
MET amplification	MET	CNA	MET:amp		Clinical Trials	Pan-kinase inhibitor;EGFR mAb inhibitor	Cabozantinib;Panitumumab	Responsive	Case report		ENA 2015 (abstr A52)	RDientsmann	11/15	COREAD		TRUE		Cabozantinib + Panitumumab (Pan-kinase inhibitor + EGFR mAb inhibitor)
MET amplification	MET	CNA	MET:amp			[EGFR inhibitor 1st gen]	[]	Resistant	Early trials		PMID:22189054;PMID:23729478	DTamborero		NSCLC;COREAD		TRUE		EGFR inhibitor 1st gens
MET amplification	MET	CNA	MET:amp			[EGFR mAb inhibitor]	[]	Resistant	Early trials		PMID:23729478	RDientsmann		COREAD		TRUE		EGFR mAb inhibitors
MET (H1112L)	MET	MUT	MET:H1112L			[MET inhibitor]	[Crizotinib]	Responsive	Pre-clinical		AACR 2012 (abstr 1786)	RDientsmann		CANCER		TRUE		MET inhibitors (Crizotinib,etc)
MET (V1110I,H1112R,M1268T,R988C,T1010I)	MET	MUT	MET:V1110I,H1112R,M1268T,R988C,T1010I			ALK inhibitor	Crizotinib	Responsive	Pre-clinical		PMID:17483355	RDientsmann		CANCER		TRUE	REMAP:H1094R changed to H1112R, v1092i changed to v1110i (all mutations annotated in same transcript ENST00000318493; these mutations where from ENST00000397752)	Crizotinib (ALK inhibitor)
MET (Y1230C;Y1235D)	MET	MUT	MET:Y1230C;Y1235D			ALK inhibitor	Crizotinib	Resistant	Pre-clinical		PMID:17483355	RDientsmann		CANCER		TRUE		Crizotinib (ALK inhibitor)
MET amplification + BRAF (V600E)	MET;BRAF	CNA;MUT	MET:amp;BRAF:V600E			BRAF inhibitor;EGFR mAb inhibitor	Vemurafenib;Panitumumab	Resistant	Case report		PMID:27325282	RDientsmann	12/16	COREAD		TRUE		Vemurafenib + Panitumumab (BRAF inhibitor + EGFR mAb inhibitor)
MET amplification + BRAF (V600E)	MET;BRAF	CNA;MUT	MET:amp;BRAF:V600E			ALK inhibitor;BRAF inhibitor	Crizotinib;Vemurafenib	Responsive	Case report		PMID:27325282	RDientsmann	12/16	COREAD		TRUE		Crizotinib + Vemurafenib (ALK inhibitor + BRAF inhibitor)
MET amplification + EGFR oncogenic mutation	MET;EGFR	CNA;MUT	MET:amp;EGFR:.			[EGFR TK inhibitor]	[]	Resistant	Early trials		ASCO 2015 (abstr 8089)	RDientsmann	01/16	LUAD		TRUE		EGFR TK inhibitors
MET amplification + ERBB2 amplification	MET;ERBB2	CNA;CNA	MET:amp;ERBB2:amp			ALK inhibitor;ERBB2 mAb inhibitor	Crizotinib;Trastuzumab	Responsive	Case report		PMID:26432108	RDientsmann	01/16	ST		TRUE		Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)
MET amplification + ERBB2 amplification	MET;ERBB2	CNA;CNA	MET:amp;ERBB2:amp			ALK inhibitor;ERBB2 mAb inhibitor	Crizotinib;Trastuzumab	Responsive	Case report		PMID:26432108	RDientsmann	01/16	ST		TRUE		Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)
MET amplification + ERBB2 amplification	MET;ERBB2	CNA;CNA	MET:amp;ERBB2:amp			ERBB2 inhibitor	Lapatinib	Resistant	Pre-clinical		PMID:22238368	RDientsmann	01/16	ST		TRUE		Lapatinib (ERBB2 inhibitor)
MET amplification + ERBB2 amplification	MET;ERBB2	CNA;CNA	MET:amp;ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	Resistant	Early trials		PMID:22850551	RDientsmann	01/16	BRCA		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
MET amplification + ERBB2 amplification	MET;ERBB2	CNA;CNA	MET:amp;ERBB2:amp			ERBB2 mAb inhibitor	Trastuzumab	Resistant	Early trials		PMID:22850551; PMID:26432108	RDientsmann	01/16	BRCA;ST		TRUE		Trastuzumab (ERBB2 mAb inhibitor)
MITF amplification	MITF	CNA	MITF:amp			[BRAF inhibitor]	[]	Resistant	Case report		PMID:24265153	RDientsmann	01/16	CM		TRUE		BRAF inhibitors
MITF amplification	MITF	CNA	MITF:amp			[BRAF inhibitor]	[]	Resistant	Case report		PMID:24265153	RDientsmann		CM		TRUE		BRAF inhibitors
MKI67 overexpression	MKI67	EXPR	MKI67:over	Indirect	Approved	Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical	Cell line	PMID:24086736	ARodriguez-Vida	09/15	R		TRUE		Sunitinib (Pan-TK inhibitor)
MLL fusion	MLL	FUS	MLL__.			[BET inhibitor]	[]	Responsive	Pre-clinical		PMID:21964340	RDientsmann	01/16	AML		TRUE		BET inhibitors
MLL fusion	MLL	FUS	MLL__.	Indirect	Approved	HDAC inhibitor	Belinostat	Responsive	Early trials		NCT00351975;NCT00357032;PMID:22015773	ECampo;RDientsmann		AML		TRUE		Belinostat (HDAC inhibitor)
MLL fusion	MLL	FUS	MLL__.		Approved	Chemotherapy	Daunorubicin	Responsive	FDA guidelines		PMID:22417203	RDientsmann		AML		TRUE		Daunorubicin (Chemotherapy)
MLL fusion	MLL	FUS	MLL__.	Indirect	Clinical Trials	DOTL1 inhibitor	EPZ-5676	Responsive	Early trials		NCT02141828;NCT01684150;PMID:21741596	ECampo;RDientsmann		AML;ALL;MDS		TRUE		EPZ-5676 (DOTL1 inhibitor)
MPL (W515F)	MPL	MUT	MPL:W515F			[JAK inhibitor]	[]	Responsive	Pre-clinical		PMID:16834459	RDientsmann		MDPS		TRUE		JAK inhibitors
MSH3 oncogenic mutation	MSH3	MUT	MSH3:.			[DNA-PKc inhibitor]	[]	Responsive	Pre-clinical		PMID:24556366	RDientsmann		CANCER		TRUE		DNA-PKc inhibitors
MTOR (F2108L)	MTOR	MUT	MTOR:F2108L			[MTOR kinase inhibitor]	[]	Responsive	Pre-clinical		PMID:25295501	RDientsmann	01/16	CANCER		TRUE		MTOR kinase inhibitors
MTOR (K1771R)	MTOR	MUT	MTOR:K1771R			MTOR inhibitor	Everolimus	Responsive	Case report		ASCO 2015 (abstr 11010);PMID:26859683	RDientsmann	01/16	ST;AG		TRUE		Everolimus (MTOR inhibitor)
MTOR (Q2223K)	MTOR	MUT	MTOR:Q2223K			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:24622468	RDientsmann	01/16	R		TRUE		Everolimus (MTOR inhibitor)
MTOR (E2014K,E2419K,N1421D)	MTOR	MUT	MTOR:E2014K,E2419K,N1421D			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:24625776	RDientsmann	01/16	BLCA		TRUE		Everolimus (MTOR inhibitor)
MTOR (I1973F)	MTOR	MUT	MTOR:I1973F			MTOR inhibitor	Everolimus	Responsive	Case report		ASCO 2015 (abstr 11010);PMID:26859683	RDientsmann	06/16	AS;R		TRUE		Everolimus (MTOR inhibitor)
MTOR (N1421D)	MTOR	MUT	MTOR:N1421D			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:26859683	RDientsmann	06/16	ST		TRUE		Everolimus (MTOR inhibitor)
MTOR (F2108L)	MTOR	MUT	MTOR:F2108L			MTOR inhibitor	Everolimus	Resistant	Case report		PMID:25295501	DTamborero;RDientsmann		THCA		TRUE	Metastatic THCA with superresponse putatively assoiated with TSC2 nonsense mutation developing resistance associated with MTOR mutation after 18months	Everolimus (MTOR inhibitor)
MTOR (L1460P,S2215Y,R2505P)	MTOR	MUT	MTOR:L1460P,S2215Y,R2505P			MTOR inhibitor	Sirolimus	Responsive	Pre-clinical		PMID:24631838	RDientsmann		CANCER		TRUE		Sirolimus (MTOR inhibitor)
MYC amplification	MYC	CNA	MYC:amp			Chemotherapy	Temozolomide	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	COREAD		TRUE		Temozolomide (Chemotherapy)
MYC amplification	MYC	CNA	MYC:amp			[FACT inhibitor]	[]	Responsive	Pre-clinical		PMID:26537256	RDientsmann	11/15	NB		TRUE		FACT inhibitors
MYC amplification	MYC	CNA	MYC:amp			[BET inhibitor]	[]	Responsive	Pre-clinical		PMID:21889194;PMID:23430699	RDientsmann		MYMA;NB		TRUE		BET inhibitors
MYC amplification	MYC	CNA	MYC:amp			[CDK7 inhibitor]	[]	Responsive	Pre-clinical		PMID:25416950	RDientsmann		NB		TRUE		CDK7 inhibitors
MYC amplification	MYC	CNA	MYC:amp			[PIM inhibitor]	[]	Responsive	Pre-clinical		PMID:25505253	RDientsmann		PRAD		TRUE		PIM inhibitors
MYCN amplification	MYCN	CNA	MYCN:amp			[SMO inhibitor]	[]	Resistant	Pre-clinical		PMID:24951114	DTamborero;RDientsmann		MB		TRUE		SMO inhibitors
MYD88 (L265P)	MYD88	MUT	MYD88:L265P			BTK inhibitor	Ibrutinib	Responsive	FDA guidelines		PMID:25853747	RDientsmann	12/16	WM		TRUE		Ibrutinib (BTK inhibitor)
NF1 (D1644A)	NF1	MUT	NF1:D1644A			MTOR inhibitor	Everolimus	Responsive	Case report		ASCO 2015 (abstr 11010);PMID:26859683	RDientsmann	06/16	HNC		TRUE		Everolimus (MTOR inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:23221341	RDientsmann	07/16	MPN		TRUE		MEK inhibitors
NF1 deletion	NF1	CNA	NF1:del			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:23221341	RDientsmann	07/16	MPN		TRUE		MEK inhibitors
NF1 deletion	NF1	CNA	NF1:del			[AURK inhibitor]	[]	Responsive	Pre-clinical		PMID:24373973	RDientsmann	07/16	MPN		TRUE	germline	AURK inhibitors
NF1 oncogenic mutation	NF1	MUT	NF1:.			[AURK inhibitor]	[]	Responsive	Pre-clinical		PMID:24373973	RDientsmann	07/16	MPN		TRUE	germline	AURK inhibitors
NF1 deletion	NF1	CNA	NF1:del			[BRD4 inhibitor]	[]	Responsive	Pre-clinical		PMID:24373973	RDientsmann	07/16	MPN		TRUE	germline	BRD4 inhibitors
NF1 oncogenic mutation	NF1	MUT	NF1:.			[BRD4 inhibitor]	[]	Responsive	Pre-clinical		PMID:24373973	RDientsmann	07/16	MPN		TRUE	germline	BRD4 inhibitors
NF1 deletion	NF1	CNA	NF1:del			[MTOR inhibitor;HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:21907929	RDientsmann	07/16	MPN		TRUE	germline	MTOR inhibitor + HSP90 inhibitors
NF1 oncogenic mutation	NF1	MUT	NF1:.			[MTOR inhibitor;HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:21907929	RDientsmann	07/16	MPN		TRUE	germline	MTOR inhibitor + HSP90 inhibitors
NF1 deletion	NF1	CNA	NF1:del			[PD1 Ab inhibitor]	[]	Responsive	Early trials		ASCO 2016 (abstr 105)	RDientsmann	07/16	CM		TRUE	, PD1 expression higher in NF1 mutant melanoma (PMID 26960397)	PD1 Ab inhibitors
NF1 oncogenic mutation	NF1	MUT	NF1:.			[PD1 Ab inhibitor]	[]	Responsive	Early trials		ASCO 2016 (abstr 105)	RDientsmann	07/16	CM		TRUE		PD1 Ab inhibitors
NF1 deletion	NF1	CNA	NF1:del			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	RDientsmann	07/16	G;MPN;LK		TRUE		MTOR inhibitors
NF1 oncogenic mutation	NF1	MUT	NF1:.			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	RDientsmann	07/16	G;MPN;LK		TRUE		MTOR inhibitors
NF1 deletion	NF1	CNA	NF1:del			[KIT inhibitor;MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:24718867	RDientsmann	07/16	MPN		TRUE	germline	KIT inhibitor + MTOR inhibitors
NF1 oncogenic mutation	NF1	MUT	NF1:.			[KIT inhibitor;MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:24718867	RDientsmann	07/16	MPN		TRUE	germline	KIT inhibitor + MTOR inhibitors
NF1 deletion	NF1	CNA	NF1:del			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:22573716;PMID:19727076	RDientsmann	07/16	G;LK		TRUE		MEK inhibitors
NF1 oncogenic mutation	NF1	MUT	NF1:.			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:22573716;PMID:19727076	RDientsmann	07/16	G;LK		TRUE		MEK inhibitors
NF1 deletion	NF1	CNA	NF1:del			[Pan-RAF inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:26351322	RDientsmann	07/16	CM		TRUE		Pan-RAF inhibitor + MEK inhibitors
NF1 oncogenic mutation	NF1	MUT	NF1:.			[Pan-RAF inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:26351322	RDientsmann	07/16	CM		TRUE		Pan-RAF inhibitor + MEK inhibitors
NF1 deletion	NF1	CNA	NF1:del			[Retinoic Acid]	[]	Resistant	Pre-clinical		PMID:20655465	RDientsmann	07/16	NB		TRUE		Retinoic Acids
NF1 oncogenic mutation	NF1	MUT	NF1:.			[Retinoic Acid]	[]	Resistant	Pre-clinical		PMID:20655465	RDientsmann	07/16	NB		TRUE		Retinoic Acids
NF1 deletion	NF1	CNA	NF1:del			VEGFR mAb inhibitor	Bevacizumab	Responsive	Case report		PMID:24232489;PMID:2485933	RDientsmann	07/16	G		TRUE	germline	Bevacizumab (VEGFR mAb inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			VEGFR mAb inhibitor	Bevacizumab	Responsive	Case report		PMID:24232489;PMID:2485933	RDientsmann	07/16	G		TRUE	germline	Bevacizumab (VEGFR mAb inhibitor)
NF1 deletion	NF1	CNA	NF1:del			ALK inhibitor	Cediranib	No Responsive	Early trials		NCT00326872	RDientsmann	07/16	PLEN		TRUE	germline NCT00326872 (trial results section)	Cediranib (ALK inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			ALK inhibitor	Cediranib	No Responsive	Early trials		NCT00326872	RDientsmann	07/16	PLEN		TRUE	germline	Cediranib (ALK inhibitor)
NF1 deletion	NF1	CNA	NF1:del			BCR-ABL inhibitor 2nd gen	Dasatinib	Resistant	Pre-clinical		PMID:24296828	RDientsmann	07/16	L		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
NF1 oncogenic mutation	NF1	MUT	NF1:.			BCR-ABL inhibitor 2nd gen	Dasatinib	Resistant	Pre-clinical		PMID:24296828	RDientsmann	07/16	L		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
NF1 deletion	NF1	CNA	NF1:del			EGFR inhibitor 1st gen	Erlotinib	Resistant	Pre-clinical		PMID:24535670	RDientsmann	07/16	L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
NF1 oncogenic mutation	NF1	MUT	NF1:.			EGFR inhibitor 1st gen	Erlotinib	Resistant	Pre-clinical		PMID:24535670	RDientsmann	07/16	L		TRUE		Erlotinib (EGFR inhibitor 1st gen)
NF1 deletion	NF1	CNA	NF1:del			MTOR inhibitor	Everolimus	No Responsive	Early trials		NCT01365468	RDientsmann	07/16	MPN		TRUE	germline	Everolimus (MTOR inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MTOR inhibitor	Everolimus	No Responsive	Early trials		NCT01365468	RDientsmann	07/16	MPN		TRUE	germline	Everolimus (MTOR inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:26859683;ASCO 2016 (abstr e17557)	RDientsmann	07/16	HNC;SG		TRUE		Everolimus (MTOR inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:26859683;ASCO 2016 (abstr e17557)	RDientsmann	07/16	HNC;SG		TRUE		Everolimus (MTOR inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MTOR inhibitor;VEGFR mAb inhibitor	Everolimus;Bevacizumab	No Responsive	Early trials		ASCO 2016 (abstr 11053)	RDientsmann	07/16	MPN		TRUE	germline	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MTOR inhibitor;VEGFR mAb inhibitor	Everolimus;Bevacizumab	No Responsive	Early trials		ASCO 2016 (abstr 11053)	RDientsmann	07/16	MPN		TRUE	germline	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MTOR inhibitor;EGFR inhibitor 1st gen	Everolimus;Erlotinib	No Responsive	Case report		PMID:24634382	RDientsmann	07/16	G		TRUE		Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MTOR inhibitor;EGFR inhibitor 1st gen	Everolimus;Erlotinib	No Responsive	Case report		PMID:24634382	RDientsmann	07/16	G		TRUE		Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MTOR inhibitor;VEGFR inhibitor	Everolimus;Pazopanib	Responsive	Case report		PMID:24931142	RDientsmann	07/16	HC		TRUE		Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)
NF1 deletion	NF1	CNA	NF1:del			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Early trials		PMID:23099009	RDientsmann	07/16	PLEN		TRUE	germline	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Early trials		PMID:23099009	RDientsmann	07/16	PLEN		TRUE	germline	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
NF1 deletion	NF1	CNA	NF1:del			BCR-ABL inhibitor 2nd gen	Nilotinib	Responsive	Pre-clinical		PMID:24173684	RDientsmann	07/16	PLEN;MPN		TRUE	germline	Nilotinib (BCR-ABL inhibitor 2nd gen)
NF1 oncogenic mutation	NF1	MUT	NF1:.			BCR-ABL inhibitor 2nd gen	Nilotinib	Responsive	Pre-clinical		PMID:24173684	RDientsmann	07/16	PLEN;MPN		TRUE	germline	Nilotinib (BCR-ABL inhibitor 2nd gen)
NF1 deletion	NF1	CNA	NF1:del			Pan-TK inhibitor	PLX3397	Responsive	Pre-clinical		PMID:23099891	RDientsmann	07/16	PLEN		TRUE	germline	PLX3397 (Pan-TK inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			Pan-TK inhibitor	PLX3397	Responsive	Pre-clinical		PMID:23099891	RDientsmann	07/16	PLEN		TRUE	germline	PLX3397 (Pan-TK inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MEK inhibitor	Selumetinib	Responsive	Early trials		ASCO 2014 (abstr 10018)	RDientsmann	07/16	PLEN		TRUE	germline	Selumetinib (MEK inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MEK inhibitor	Selumetinib	Responsive	Early trials		ASCO 2014 (abstr 10018)	RDientsmann	07/16	PLEN		TRUE	germline	Selumetinib (MEK inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MTOR inhibitor	Sirolimus	Responsive	Early trials		PMID:25314964	RDientsmann	07/16	PLEN		TRUE	germline	Sirolimus (MTOR inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MTOR inhibitor	Sirolimus	Responsive	Early trials		PMID:25314964	RDientsmann	07/16	PLEN		TRUE	germline	Sirolimus (MTOR inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MTOR inhibitor;EGFR inhibitor 1st gen	Sirolimus;Erlotinib	Responsive	Case report		PMID:22434731	RDientsmann	07/16	G		TRUE	germline, rampamycin = sirolimus	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MTOR inhibitor;EGFR inhibitor 1st gen	Sirolimus;Erlotinib	Responsive	Case report		PMID:22434731	RDientsmann	07/16	G		TRUE	germline, rampamycin = sirolimus	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)
NF1 deletion	NF1	CNA	NF1:del			Pan-TK inhibitor;MTOR inhibitor	Sorafenib;Sirolimus	Responsive	Pre-clinical		PMID:25810463	RDientsmann	07/16	MPN		TRUE	germline	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			Pan-TK inhibitor;MTOR inhibitor	Sorafenib;Sirolimus	Responsive	Pre-clinical		PMID:25810463	RDientsmann	07/16	MPN		TRUE	germline	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)
NF1 deletion	NF1	CNA	NF1:del			Hormonal therapy	Tamoxifen	Responsive	Pre-clinical		PMID:21075781	RDientsmann	07/16	MPN		TRUE	germline	Tamoxifen (Hormonal therapy)
NF1 oncogenic mutation	NF1	MUT	NF1:.			Hormonal therapy	Tamoxifen	Responsive	Pre-clinical		PMID:21075781	RDientsmann	07/16	MPN		TRUE	germline	Tamoxifen (Hormonal therapy)
NF1 deletion	NF1	CNA	NF1:del			Farnesyltransferase inhibitor	Tipifarnib	No Responsive	Early trials		PMID:24500418	RDientsmann	07/16	PLEN		TRUE	germline	Tipifarnib (Farnesyltransferase inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			Farnesyltransferase inhibitor	Tipifarnib	No Responsive	Early trials		PMID:24500418	RDientsmann	07/16	PLEN		TRUE	germline	Tipifarnib (Farnesyltransferase inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MEK inhibitor	Trametinib	Responsive	Case report		PMID:26936308	RDientsmann	07/16	G		TRUE	germline	Trametinib (MEK inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MEK inhibitor	Trametinib	Responsive	Case report		PMID:26936308	RDientsmann	07/16	G		TRUE	germline	Trametinib (MEK inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MEK inhibitor	Trametinib	Responsive	Pre-clinical		PMID:24576830;PMID:2524381	RDientsmann	07/16	CM		TRUE		Trametinib (MEK inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MEK inhibitor	Trametinib	Responsive	Pre-clinical		PMID:24576830;PMID:2524381	RDientsmann	07/16	CM		TRUE		Trametinib (MEK inhibitor)
NF1 deletion	NF1	CNA	NF1:del			MEK inhibitor	Trametinib	No Responsive	Case report		PMID:26325560	RDientsmann	07/16	OS		TRUE		Trametinib (MEK inhibitor)
NF1 oncogenic mutation	NF1	MUT	NF1:.			MEK inhibitor	Trametinib	No Responsive	Case report		PMID:26325560	RDientsmann	07/16	OS		TRUE		Trametinib (MEK inhibitor)
NF1 deletion	NF1	CNA	NF1:del			Chemotherapy	Vinblastine	Responsive	Early trials		ASCO 2016 (abstr 2019)	RDientsmann	07/16	G		TRUE	germline	Vinblastine (Chemotherapy)
NF1 oncogenic mutation	NF1	MUT	NF1:.			Chemotherapy	Vinblastine	Responsive	Early trials		ASCO 2016 (abstr 2019)	RDientsmann	07/16	G		TRUE	germline	Vinblastine (Chemotherapy)
NF1 deletion	NF1	CNA	NF1:del			Chemotherapy;BCR-ABL inhibitor 2nd gen	Vinblastine;Nilotinib	Responsive	Case report		ASCO 2016 (abstr 10555)	RDientsmann	07/16	G		TRUE	germline	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)
NF1 oncogenic mutation	NF1	MUT	NF1:.			Chemotherapy;BCR-ABL inhibitor 2nd gen	Vinblastine;Nilotinib	Responsive	Case report		ASCO 2016 (abstr 10555)	RDientsmann	07/16	G		TRUE	germline	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)
NF1 oncogenic mutation	NF1	MUT	NF1:.	Indirect	Approved	MTOR inhibitor	Everolimus	Responsive	Late trials		NCT01365468	MMartínez	09/15	NF		TRUE	benign	Everolimus (MTOR inhibitor)
NF1 biallelic inactivation	NF1	BIA	NF1:.			BRAF inhibitor	Vemurafenib	Resistant	Pre-clinical		PMID:23171796	DTamborero		CM		TRUE		Vemurafenib (BRAF inhibitor)
NF1 deletion + BRAF oncogenic mutation	NF1;BRAF	CNA;MUT	NF1:del;BRAF:.			MEK inhibitor	Selumetinib	Resistant	Case report		PMID:23444215	RDientsmann	07/16	CM		TRUE		Selumetinib (MEK inhibitor)
NF1 oncogenic mutation + BRAF oncogenic mutation	NF1;BRAF	MUT;MUT	NF1:.;BRAF:.			MEK inhibitor	Selumetinib	Resistant	Case report		PMID:23444215	RDientsmann	07/16	CM		TRUE		Selumetinib (MEK inhibitor)
NF1 deletion + BRAF oncogenic mutation	NF1;BRAF	CNA;MUT	NF1:del;BRAF:.			BRAF inhibitor	Vemurafenib	Resistant	Case report		PMID:23288408;PMID:231718	RDientsmann	07/16	CM		TRUE		Vemurafenib (BRAF inhibitor)
NF1 oncogenic mutation + BRAF oncogenic mutation	NF1;BRAF	MUT;MUT	NF1:.;BRAF:.			BRAF inhibitor	Vemurafenib	Resistant	Case report		PMID:23288408;PMID:231718	RDientsmann	07/16	CM		TRUE		Vemurafenib (BRAF inhibitor)
SLC44A4 overexpression	SLC44A4	EXPR	SLC44A4:over			[SLC44A4 inhibitor]	[]	Responsive	Pre-clinical		PMID:27550944 	CRubio-Perez	02/17	PRAD;PAAD		TRUE		SLC44A4 inhibitors
NF2 deletion	NF2	CNA	NF2:del			[FAK inhibitor]	[]	Responsive	Early trials		ENA 2012 (abstr 610)	RDientsmann	07/16	MESO		TRUE		FAK inhibitors
NF2 oncogenic mutation	NF2	MUT	NF2:.			[FAK inhibitor]	[]	Responsive	Early trials		ENA 2012 (abstr 610)	RDientsmann	07/16	MESO		TRUE		FAK inhibitors
NF2 deletion	NF2	CNA	NF2:del			[FAK inhibitor]	[]	Responsive	Pre-clinical		PMID:24848258;PMID:24786638	RDientsmann	07/16	MESO;OV		TRUE		FAK inhibitors
NF2 oncogenic mutation	NF2	MUT	NF2:.			[FAK inhibitor]	[]	Responsive	Pre-clinical		PMID:24848258;PMID:24786638	RDientsmann	07/16	MESO;OV		TRUE		FAK inhibitors
NF2 deletion	NF2	CNA	NF2:del			[HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:23714726	RDientsmann	07/16	MEN		TRUE	germline	HSP90 inhibitors
NF2 oncogenic mutation	NF2	MUT	NF2:.			[HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:23714726	RDientsmann	07/16	MEN		TRUE	germline	HSP90 inhibitors
NF2 deletion	NF2	CNA	NF2:del			[PAK inhibitor]	[]	Responsive	Pre-clinical		PMID:23960073;PMID:25596744	RDientsmann	07/16	SCHW;MEN		TRUE	germline	PAK inhibitors
NF2 oncogenic mutation	NF2	MUT	NF2:.			[PAK inhibitor]	[]	Responsive	Pre-clinical		PMID:23960073;PMID:25596744	RDientsmann	07/16	SCHW;MEN		TRUE	germline	PAK inhibitors
NF2 deletion	NF2	CNA	NF2:del			[PDK1 inhibitor]	[]	Responsive	Pre-clinical		PMID:19359162	RDientsmann	07/16	SCHW		TRUE	germline	PDK1 inhibitors
NF2 oncogenic mutation	NF2	MUT	NF2:.			[PDK1 inhibitor]	[]	Responsive	Pre-clinical		PMID:19359162	RDientsmann	07/16	SCHW		TRUE	germline	PDK1 inhibitors
NF2 deletion	NF2	CNA	NF2:del			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:26359368	RDientsmann	07/16	TH		TRUE		MEK inhibitors
NF2 oncogenic mutation	NF2	MUT	NF2:.			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:26359368	RDientsmann	07/16	TH		TRUE		MEK inhibitors
NF2 deletion	NF2	CNA	NF2:del			HDAC inhibitor	AR42	Responsive	Pre-clinical		PMID:21778190	RDientsmann	07/16	SCHW		TRUE	germline	AR42 (HDAC inhibitor)
NF2 oncogenic mutation	NF2	MUT	NF2:.			HDAC inhibitor	AR42	Responsive	Pre-clinical		PMID:21778190	RDientsmann	07/16	SCHW		TRUE	germline	AR42 (HDAC inhibitor)
NF2 deletion	NF2	CNA	NF2:del			HDAC inhibitor	AR42	Responsive	Early trials		ASCO 2016 (abstr 2558)	RDientsmann	07/16	MEN		TRUE	germline,minor response	AR42 (HDAC inhibitor)
NF2 oncogenic mutation	NF2	MUT	NF2:.			HDAC inhibitor	AR42	Responsive	Early trials		ASCO 2016 (abstr 2558)	RDientsmann	07/16	MEN		TRUE	germline,minor response	AR42 (HDAC inhibitor)
NF2 deletion	NF2	CNA	NF2:del			VEGFR mAb inhibitor	Bevacizumab	Responsive	Early trials		PMID:19587327;PMID:22805104;PMID:26022982	RDientsmann	07/16	SCHW		TRUE	germline	Bevacizumab (VEGFR mAb inhibitor)
NF2 oncogenic mutation	NF2	MUT	NF2:.			VEGFR mAb inhibitor	Bevacizumab	Responsive	Early trials		PMID:19587327;PMID:22805104;PMID:26022982	RDientsmann	07/16	SCHW		TRUE	germline	Bevacizumab (VEGFR mAb inhibitor)
NF2 deletion	NF2	CNA	NF2:del			EGFR inhibitor 1st gen	Erlotinib	No Responsive	Early trials		PMID:20736812	RDientsmann	07/16	SCHW		TRUE	germline	Erlotinib (EGFR inhibitor 1st gen)
NF2 oncogenic mutation	NF2	MUT	NF2:.			EGFR inhibitor 1st gen	Erlotinib	No Responsive	Early trials		PMID:20736812	RDientsmann	07/16	SCHW		TRUE	germline	Erlotinib (EGFR inhibitor 1st gen)
NF2 deletion	NF2	CNA	NF2:del			MTOR inhibitor	Everolimus	Responsive	Early trials		PMID:24311643;2556735	RDientsmann	07/16	SCHW		TRUE	germline, minor responsiv	Everolimus (MTOR inhibitor)
NF2 oncogenic mutation	NF2	MUT	NF2:.			MTOR inhibitor	Everolimus	Responsive	Early trials		PMID:24311643;2556735	RDientsmann	07/16	SCHW		TRUE	germline, minor responsiv	Everolimus (MTOR inhibitor)
NF2 deletion	NF2	CNA	NF2:del			MTOR inhibitor;Somatostatin analog	Everolimus;Octreotide	Responsive	Pre-clinical		PMID:26015296	RDientsmann	07/16	MEN		TRUE		Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)
NF2 oncogenic mutation	NF2	MUT	NF2:.			MTOR inhibitor;Somatostatin analog	Everolimus;Octreotide	Responsive	Pre-clinical		PMID:26015296	RDientsmann	07/16	MEN		TRUE		Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)
NF2 deletion	NF2	CNA	NF2:del			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Pre-clinical		PMID:19509233;PMID:2290085	RDientsmann	07/16	SCHW		TRUE	germline	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
NF2 oncogenic mutation	NF2	MUT	NF2:.			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Pre-clinical		PMID:19509233;PMID:2290085	RDientsmann	07/16	SCHW		TRUE	germline	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
NF2 deletion	NF2	CNA	NF2:del			ERBB2 inhibitor	Lapatinib	Responsive	Early trials		PMID:22844108;NCT00973739	RDientsmann;MMartínez	07/16	SCHW;NF		TRUE	germline	Lapatinib (ERBB2 inhibitor)
NF2 oncogenic mutation	NF2	MUT	NF2:.			ERBB2 inhibitor	Lapatinib	Responsive	Early trials		PMID:22844108;NCT00973739	RDientsmann;MMartínez	07/16	SCHW;NF		TRUE	germline	Lapatinib (ERBB2 inhibitor)
NF2 deletion	NF2	CNA	NF2:del			MTOR inhibitor;Chemotherapy	Tensirolimus;Chemotherapy	Responsive	Case report		PMID:25878190	RDientsmann	07/16	BRCA		TRUE		Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)
NF2 oncogenic mutation	NF2	MUT	NF2:.			MTOR inhibitor;Chemotherapy	Tensirolimus;Chemotherapy	Responsive	Case report		PMID:25878190	RDientsmann	07/16	BRCA		TRUE		Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)
NF2 deletion	NF2	CNA	NF2:del			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:19451225;PMID:2242646	RDientsmann	07/17	MEN		TRUE		MTOR inhibitors
NF2 oncogenic mutation	NF2	MUT	NF2:.			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:19451225;PMID:2242646	RDientsmann	07/18	MEN		TRUE		MTOR inhibitors
NF2 deletion + EGFR oncogenic mutation	NF2;EGFR	CNA;MUT	NF2:del;EGFR:.			EGFR inhibitor 1st gen;EGFR mAb inhibitor	Erlotinib;Cetuximab	Resistant	Case report		PMID:24813888	RDientsmann	07/16	L		TRUE	 In Egfr Mutant Tumors	Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)
NF2 oncogenic mutation + EGFR oncogenic mutation	NF2;EGFR	MUT;MUT	NF2:.;EGFR:.			EGFR inhibitor 1st gen;EGFR mAb inhibitor	Erlotinib;Cetuximab	Resistant	Case report		PMID:24813888	RDientsmann	07/16	L		TRUE	 In Egfr Mutant Tumors	Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	MUT	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536			[Gamma secretase inhibitor]	[]	Responsive	Early trials		ASCO 2006 (abstr 6585)	RDientsmann	01/16	ALL		TRUE		Gamma secretase inhibitors
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	MUT	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536			[Gamma secretase inhibitor]	[]	Responsive	Pre-clinical		PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	RDientsmann	01/16	ALL		TRUE		Gamma secretase inhibitors
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	FUS	NOTCH1__.			[Gamma secretase inhibitor]	[]	Responsive	Pre-clinical		PMID:16688224;PMID:23033986	RDientsmann	01/16	ALL		TRUE		Gamma secretase inhibitors
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	MUT	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536			[Gamma secretase inhibitor;MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:19246562	RDientsmann	01/16	ALL		TRUE		Gamma secretase inhibitor + MTOR inhibitors
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	MUT	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536			[Gamma secretase inhibitor;CDK4 inhibitor]	[]	Responsive	Pre-clinical		PMID:19318552	RDientsmann	01/16	ALL		TRUE		Gamma secretase inhibitor + CDK4 inhibitors
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	FUS	NOTCH1__.			[Gamma secretase inhibitor]	[]	Responsive	Pre-clinical		PMID:22101766	RDientsmann		BRCA		TRUE		Gamma secretase inhibitors
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	MUT	NOTCH1:.			[Gamma secretase inhibitor]	[]	Responsive	Pre-clinical		PMID:22210878	RDientsmann		MCL		TRUE		Gamma secretase inhibitors
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	MUT	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536			[Gamma secretase inhibitor]	[]	Responsive	Pre-clinical		PMID:25564152	RDientsmann		BRCA		TRUE		Gamma secretase inhibitors
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	MUT	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536	Indirect	Clinical Trials	[Gamma secretase inhibitor]	[Ro4929097,Pf-03084014,Mk-0752]	Responsive	Early trials		NCT01703572;NCT01778439; NCT01098344; NCT01981551	ECampo		CANCER		TRUE		Gamma secretase inhibitors (Ro4929097,Pf-03084014,Mk-0752,etc)
NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH1	MUT	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536	Direct	Clinical Trials	NOTCH1 inhibitor	OMP-52M51	Responsive	Early trials		NCT01703572;NCT01778439	ECampo		CANCER		TRUE		OMP-52M51 (NOTCH1 inhibitor)
NOTCH2 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH2	FUS	NOTCH2__.			[Gamma secretase inhibitor]	[]	Responsive	Pre-clinical		PMID:22101766	RDientsmann		BRCA		TRUE		Gamma secretase inhibitors
NOTCH2 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH2	MUT	NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420	Direct	Clinical Trials	Gamma secretase inhibitor	Mk-0752	Responsive	Early trials		PMID:25564152	KKarube;RDientsmann		BRCA;AML;ALL		TRUE		Mk-0752 (Gamma secretase inhibitor)
NOTCH2 activating mutation (missense in TAD or truncating in Cterm domain)	NOTCH2	MUT	NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420	Direct	Clinical Trials	NOTCH2 inhibitor	OMP-59R5	Responsive	Early trials		NCT01859741;NCT01277146	ECampo		SOLID		TRUE		OMP-59R5 (NOTCH2 inhibitor)
NPM1 oncogenic mutation	NPM1	MUT	NPM1:.			[DOT1L inhibitors;MLL1 inhibitors]	[]	Responsive	Pre-clinical		PMID:27535106	RDientsmann	12/16	AML		TRUE		DOT1L inhibitors + MLL1 inhibitorss
NPM1 oncogenic mutation	NPM1	MUT	NPM1:.		Approved	Chemotherapy	Daunorubicin	Responsive	FDA guidelines		PMID:22417203	RDientsmann		AML		TRUE		Daunorubicin (Chemotherapy)
NRAS (Q61)	NRAS	MUT	NRAS:Q61.			[Pan-RAF inhibitor]	[]	Responsive	Case report		ESMO 2015 (abstract 300)	RDientsmann	01/16	CM		TRUE		Pan-RAF inhibitors
NRAS oncogenic mutation	NRAS	MUT	NRAS:.			[MEK inhibitor +/- PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:23274911;PMID:22392911	RDientsmann	01/16	COREAD		TRUE		MEK inhibitor +/- PI3K pathway inhibitors
NRAS (Q61)	NRAS	MUT	NRAS:Q61.			[HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:23538902	RDientsmann	01/16	CM		TRUE		HSP90 inhibitors
NRAS (Q61)	NRAS	MUT	NRAS:Q61.			[BRAF inhibitor]	[]	Resistant	Early trials		PMID:23569304;PMID:24265153	RDientsmann	01/16	CM		TRUE		BRAF inhibitors
NRAS (Q61)	NRAS	MUT	NRAS:Q61.			[ERK inhibitor]	[]	Responsive	Pre-clinical		PMID:23614898	RDientsmann	01/16	CM		TRUE		ERK inhibitors
NRAS oncogenic mutation	NRAS	MUT	NRAS:.			Pan-TK inhibitor;MEK inhibitor	Sorafenib;MEK inhibitor	Responsive	Early trials,Case report		PMID:25294897	RDientsmann	01/16	HC		TRUE		Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)
NRAS (Q61)	NRAS	MUT	NRAS:Q61.			[MEK inhibitor]	[]	Responsive	Late trials		PMID:23414587,ASCO 2016 (abstr 9500)	RDientsmann	06/16	CM		TRUE		MEK inhibitors
NRAS oncogenic mutation	NRAS	MUT	NRAS:.	Indirect	Approved	[CDK4/6 inhibitor;MEK inhibitor]	[]	Responsive	Early trials		PMID:26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009)	DTamborero;CRubio-Perez;RDientsmann		CM		TRUE		CDK4/6 inhibitor + MEK inhibitors
NRAS oncogenic mutation	NRAS	MUT	NRAS:.			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:22507781;PMID:23515407;PMID:18701506	RDientsmann		AML;LUAD;ALL		TRUE		MEK inhibitors
NRAS oncogenic mutation	NRAS	MUT	NRAS:.			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:22985491	RDientsmann		MYMA		TRUE		PI3K pathway inhibitor + MEK inhibitors
NRAS (G12C)	NRAS	MUT	NRAS:G12C			[ERK inhibitor]	[]	Responsive	Pre-clinical		PMID:23614898	RDientsmann		CANCER		TRUE		ERK inhibitors
NRAS oncogenic mutation	NRAS	MUT	NRAS:.		Approved	EGFR mAb inhibitor	Cetuximab	Resistant	NCCN guidelines		PMID:24024839;PMID:20619739;PMID:23325582	RDientsmann		COREAD		TRUE		Cetuximab (EGFR mAb inhibitor)
NRAS oncogenic mutation	NRAS	MUT	NRAS:.		Approved	EGFR mAb inhibitor	Panitumumab	Resistant	NCCN guidelines		PMID:24024839;PMID:20619739;PMID:23325582	RDientsmann		COREAD		TRUE		Panitumumab (EGFR mAb inhibitor)
NRAS oncogenic mutation	NRAS	MUT	NRAS:.			BRAF inhibitor	Vemurafenib	Resistant	Pre-clinical		PMID:20179705	DTamborero		CM		TRUE	there is also some report in real patients with resistance, but not clear association	Vemurafenib (BRAF inhibitor)
NRG1 fusion	NRG1	FUS	NRG1__.			ERBB2&EGFR inhibitor 2nd gen	Afatinib	Responsive	Case report		AACR 2016 (abstr 2631)	RDientsmann	06/16	LUAD		TRUE		Afatinib (ERBB2&EGFR inhibitor 2nd gen)
NRG1 fusion	NRG1	FUS	NRG1__.			ERBB2 inhibitor	Lapatinib	Responsive	Pre-clinical		PMID:24727320	RDientsmann		LUAD		TRUE		Lapatinib (ERBB2 inhibitor)
NTRK1 fusion	NTRK1	FUS	NTRK1__.			[Pan-TK inhibitor]	[]	Responsive	Pre-clinical		PMID:24162815	RDientsmann	01/16	LUAD		TRUE		Pan-TK inhibitors
NTRK1 fusion	NTRK1	FUS	NTRK1__.			ALK inhibitor	Crizotinib	Responsive	Case report		ASCO 2013 (abstr 8023)	RDientsmann	01/16	LUAD		TRUE		Crizotinib (ALK inhibitor)
NTRK1 fusion	NTRK1	FUS	NTRK1__.			[Pan-TKR inhibitor]	[]	Responsive	Early trials		AACR 2016 (abstr CT007), AACR 2016 (abstr CT008)	RDientsmann	06/16	CANCER		TRUE		Pan-TKR inhibitors
NTRK1 fusion	NTRK1	FUS	NTRK1__.			[Pan-TK inhibitor]	[Entrectinib]	Responsive	Case report		PMID:26546295	RDientsmann	11/15	COREAD		TRUE		Pan-TK inhibitors (Entrectinib,etc)
NTRK1 (G595R,G667C)	NTRK1	MUT	NTRK1:G595R,G667C			[Pan-TK inhibitor]	[Entrectinib]	Resistant	Case report		PMID:26546295	RDientsmann	11/15	COREAD		TRUE		Pan-TK inhibitors (Entrectinib,etc)
NTRK3 fusion	NTRK3	FUS	NTRK3__.			[IGF1R inhibitor]	[]	Responsive	Pre-clinical		PMID:21148487;PMID:23131561	RDientsmann		BRCA		TRUE		IGF1R inhibitors
NTRK3 fusion	NTRK3	FUS	NTRK3__.			[PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:21148487;PMID:23131561	RDientsmann		BRCA		TRUE		PI3K pathway inhibitors
NTRK3 fusion	NTRK3	FUS	NTRK3__.			Pan-TK inhibitor	Midostaurin	Responsive	Pre-clinical		PMID:21148487;PMID:23131561	RDientsmann		BRCA		TRUE		Midostaurin (Pan-TK inhibitor)
PAK1 amplification	PAK1	CNA	PAK1:amp			[PAK inhibitor]	[]	Responsive	Pre-clinical		PMID:23535073	RDientsmann		CM		TRUE		PAK inhibitors
PALB2 oncogenic mutation	PALB2	MUT	PALB2:.			[PARP inhibitor]	[]	Responsive	Early trials		AACR 2015 (abstr CT322);PMID:26510020	RDientsmann	01/16	PRAD		TRUE		PARP inhibitors
PALB2 deletion	PALB2	CNA	PALB2:del			[PARP inhibitor]	[]	Responsive	Early trials		AACR 2015 (abstr CT322);PMID:26510020	RDientsmann	01/16	PRAD		TRUE		PARP inhibitors
PALB2 oncogenic mutation	PALB2	MUT	PALB2:.			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:25263539;NCT01585805	RDientsmann	01/16	PA		TRUE		PARP inhibitors
PALB2 deletion	PALB2	CNA	PALB2:del			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:25263539;NCT01585805	RDientsmann	01/16	PA		TRUE		PARP inhibitors
PALB2 oncogenic mutation	PALB2	MUT	PALB2:.			Chemotherapy	Mytomycin C	Responsive	Case report		PMID:21135251	RDientsmann	01/16	PA		TRUE		Mytomycin C (Chemotherapy)
PALB2 deletion	PALB2	CNA	PALB2:del			Chemotherapy	Mytomycin C	Responsive	Case report		PMID:21135251	RDientsmann	01/16	PA		TRUE		Mytomycin C (Chemotherapy)
PALB2 oncogenic mutation	PALB2	MUT	PALB2:.			Chemotherapy	Platinum Agent	Responsive	Case report		PMID:25719666	RDientsmann	01/16	PA		TRUE		Platinum Agent (Chemotherapy)
PALB2 deletion	PALB2	CNA	PALB2:del			Chemotherapy	Platinum Agent	Responsive	Case report		PMID:25719666	RDientsmann	01/16	PA		TRUE		Platinum Agent (Chemotherapy)
PBRM1 deletion	PBRM1	CNA	PBRM1:del			[EZH2 inhibitor]	[]	Responsive	Pre-clinical		PMID:26552009	RDientsmann	01/16	CANCER		TRUE		EZH2 inhibitors
PBRM1 oncogenic mutation	PBRM1	MUT	PBRM1:.			[EZH2 inhibitor]	[]	Responsive	Pre-clinical		PMID:26552009	RDientsmann	01/16	CANCER		TRUE		EZH2 inhibitors
PBRM1 undexpression	PBRM1	EXPR	PBRM1:under		Approved	MTOR inhibitor	Everolimus	Responsive	Pre-clinical	Cell line	PMID:25997916	ARodriguez-Vida	09/15	R		TRUE		Everolimus (MTOR inhibitor)
PDGFRA (D842V)	PDGFRA	MUT	PDGFRA:D842V			[HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:18794084	RDientsmann	01/16	GIST		TRUE		HSP90 inhibitors
PDGFRA wildtype	PDGFRA	MUT	PDGFRA::wildtype:.			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:16397263	RDientsmann	01/16	GIST		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
PDGFRA (D842V)	PDGFRA	MUT	PDGFRA:D842V			BCR-ABL inhibitor 2nd gen	Dasatinib	Responsive	Pre-clinical		PMID:18794084	RDientsmann	01/16	GIST		TRUE		Dasatinib (BCR-ABL inhibitor 2nd gen)
PDGFRA (D842V)	PDGFRA	MUT	PDGFRA:D842V			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Late trials,Pre-clinical		PMID:22718859;PMID:16638875	RDientsmann	01/16	GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA wildtype	PDGFRA	MUT	PDGFRA::wildtype:.			Pan-TK inhibitor	Sorafenib	Responsive	Early trials		ASCO 2011 (abstr 10009)	RDientsmann	01/16	GIST		TRUE		Sorafenib (Pan-TK inhibitor)
PDGFRA wildtype	PDGFRA	MUT	PDGFRA::wildtype:.			Pan-TK inhibitor	Sunitinib	Responsive	Late trials		PMID:18955458	RDientsmann	01/16	GIST		TRUE		Sunitinib (Pan-TK inhibitor)
PDGFRA (D842V)	PDGFRA	MUT	PDGFRA:D842V			Pan-TK inhibitor	Sunitinib	Resistant	Late trials,Pre-clinical		PMID:22718859;PMID:16638875	RDientsmann	01/16	GIST		TRUE		Sunitinib (Pan-TK inhibitor)
PDGFRA (D842V)	PDGFRA	MUT	PDGFRA:D842V			FLT3 inhibitor	Crenolanib	Responsive	Early trials		ASCO 2016 (abstr 11010)	RDientsmann	12/16	GIST		TRUE		Crenolanib (FLT3 inhibitor)
PDGFRA overexpression	PDGFRA	EXPR	PDGFRA:over	Direct	Approved	Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical	Cell line	PMID:24086736	ARodriguez-Vida	09/15	R		TRUE		Sunitinib (Pan-TK inhibitor)
PDGFRA amplification	PDGFRA	CNA	PDGFRA:amp			[PDGFR inhibitor]	[]	No Responsive	Pre-clinical		PMID:23544171	RDientsmann		G		TRUE		PDGFR inhibitors
PDGFRA (V658A,P577S,R841K,H845Y,G853D)	PDGFRA	MUT	PDGFRA:V658A,P577S,R841K,H845Y,G853D			FLT3 inhibitor	Crenolanib	Responsive	Pre-clinical		PMID:24132921	RDientsmann		CM		TRUE		Crenolanib (FLT3 inhibitor)
PDGFRA-FIP1L1 fusion	PDGFRA	FUS	PDGFRA__FIP1L1		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	FDA guidelines		EMA	CRubio-Perez;DTamborero;RDientsmann		HES;ECL		TRUE	http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA fusion	PDGFRA	FUS	PDGFRA__.		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	FDA guidelines		EMA	CRubio-Perez;DTamborero;RDientsmann		MDS;MDPS		TRUE	http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA (552-596,631-668,814-854)	PDGFRA	MUT	PDGFRA:552-596,631-668,814-854		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	NCCN guidelines		NCCN guidelines	RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA (R748G,Y894C)	PDGFRA	MUT	PDGFRA:R748G,Y894C		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	NCCN guidelines		NCCN guidelines	RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA inframe deletion (I843)	PDGFRA	MUT	PDGFRA::consequence::inframe_deletion:I843.		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	NCCN guidelines		NCCN guidelines	RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA (T674I)	PDGFRA	MUT	PDGFRA:T674I			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Case report		PMID:12660384	RDientsmann		HES		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA wildtype	PDGFRA	MUT	PDGFRA::wildtype:.			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Resistant	Late trials		PMID:14645423;PMID:18955458	RDientsmann		GIST		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA (P577S,R841K,H845Y,G853D)	PDGFRA	MUT	PDGFRA:P577S,R841K,H845Y,G853D			BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	Pre-clinical		PMID:24132921	RDientsmann		CM		TRUE		Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDGFRA (552-596,631-668,814-854)	PDGFRA	MUT	PDGFRA:552-596,631-668,814-854		Approved	Pan-kinase inhibitor	Regorafenib	Responsive	NCCN guidelines		NCCN guidelines	RDientsmann		GIST		TRUE	Mutation exon 12,14,18	Regorafenib (Pan-kinase inhibitor)
PDGFRA (552-596,631-668,814-854)	PDGFRA	MUT	PDGFRA:552-596,631-668,814-854		Approved	Pan-TK inhibitor	Sunitinib	Responsive	NCCN guidelines		NCCN guidelines	RDientsmann		GIST		TRUE	Mutation exon 12,14,18	Sunitinib (Pan-TK inhibitor)
PDGFRB-COL1A1 fusion	PDGFRB	FUS	PDGFRB__COL1A1		Approved	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib	Responsive	FDA guidelines		EMA	CRubio-Perez;DTamborero;RDientsmann		MDS;MDPS		TRUE	http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)
PDPK1 amplification	PDPK1	CNA	PDPK1:amp			[PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:19602588	RDientsmann		BRCA		TRUE		PI3K pathway inhibitors
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			[AKT inhibitor]	[]	Responsive	Early trials		ASCO 2015 (abstr 2500)	RDientsmann	01/16	BRCA		TRUE		AKT inhibitors
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			[PI3K pathway inhibitor (alone or in combination)]	[]	Responsive	Pre-clinical		PMID:23136191;PMID:23475782;PMID:22392911	RDientsmann	01/16	L;COREAD		TRUE		PI3K pathway inhibitor (alone or in combination)s
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			[PI3K pathway inhibitor]	[]	Responsive	Case report		ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	RDientsmann	01/16	BLCA;HNC;L		TRUE		PI3K pathway inhibitors
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			[PI3K pathway inhibitor]	[]	Responsive	Early trials		PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	RDientsmann	01/16	BRCA;OV;CESC;ED		TRUE		PI3K pathway inhibitors
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			[PIK3CA inhibitor]	[]	Responsive	Early trials		AACR 2013 (abstr LB-64);ESMO 2013 (abstr P017)	RDientsmann	01/16	BRCA		TRUE		PIK3CA inhibitors
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			[PIK3CA inhibitor]	[]	Responsive	Case report		ASCO 2015 (abstr 2501)	RDientsmann	01/16	ST		TRUE		PIK3CA inhibitors
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			EGFR mAb inhibitor	Cetuximab	Resistant	Late trials		PMID:19223544;PMID:20619739	RDientsmann	01/16	COREAD		TRUE		Cetuximab (EGFR mAb inhibitor)
PIK3CA (E545*)	PIK3CA	MUT	PIK3CA:E545*			[BRAF inhibitor]	[]	Resistant	Case report		PMC3936420	DTamborero	03/16	CM		TRUE		BRAF inhibitors
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			[PI3K pathway inhibitor]	[]	Responsive	Case report		PMID:26787751;PMID:26763254	RDientsmann	07/16	HNSC		TRUE		PI3K pathway inhibitors
PIK3CA oncogenic mutation	PIK3CA	MUT	PIK3CA:.			[PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:19671762;PMID:21289267	RDientsmann		G;THCA		TRUE		PI3K pathway inhibitors
PIK3CA amplification	PIK3CA	CNA	PIK3CA:amp			[PI3K pathway inhibitor]	[]	Resistant	Pre-clinical		PMID:24366379	RDientsmann		BRCA		TRUE		PI3K pathway inhibitors
PIK3CA oncogenic mutation + ERBB2 amplification	PIK3CA;ERBB2	MUT;CNA	PIK3CA:.;ERBB2:amp			MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy	Everolimus;Trastuzumab;Chemotherapy	Responsive	Late trials		PMID:27091708	RDientsmann	01/16	BRCA		TRUE		Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)
PIK3CB oncogenic mutation	PIK3CB	MUT	PIK3CB:.			[AKT inhibitor]	[]	Responsive	Pre-clinical		PMID:23619167	RDientsmann	04/16	HNSC		TRUE		AKT inhibitors
PIK3CB oncogenic mutation	PIK3CB	MUT	PIK3CB:.			[MTORC1/2 inhibitor]	[]	Responsive	Pre-clinical		PMID:23619167	RDientsmann	04/16	HNSC		TRUE		MTORC1/2 inhibitors
PIK3CB (D1067Y)	PIK3CB	MUT	PIK3CB:D1067Y			[AKT inhibitor]	[]	Responsive	Pre-clinical		PMID:26759240	RDientsmann	04/16	BRCA		TRUE		AKT inhibitors
PIK3CB (D1067Y)	PIK3CB	MUT	PIK3CB:D1067Y			[MTORC1/2 inhibitor]	[]	Responsive	Pre-clinical		PMID:26759240	RDientsmann	04/16	BRCA		TRUE		MTORC1/2 inhibitors
PIK3CB (D1067Y)	PIK3CB	MUT	PIK3CB:D1067Y			[PI3K pathway inhibitor]	[]	Resistant	Case report		PMID:26759240	RDientsmann	04/16	BRCA		TRUE		PI3K pathway inhibitors
PIK3CB oncogenic mutation	PIK3CB	MUT	PIK3CB:.			[PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:23619167	RDientsmann		HNSC		TRUE		PI3K pathway inhibitors
PIK3R1 oncogenic mutation	PIK3R1	MUT	PIK3R1:.			[PI3K pathway inhibitor]	[]	Responsive	Case report		ASCO 2015 (abstr 11075)	RDientsmann	01/16	ED		TRUE		PI3K pathway inhibitors
PIK3R1 oncogenic mutation	PIK3R1	MUT	PIK3R1:.			[AKT inhibitor]	[]	Responsive	Pre-clinical		PMID:23166678	RDientsmann		G		TRUE		AKT inhibitors
PIK3R2 (A171V,N561D)	PIK3R2	MUT	PIK3R2:A171V,N561D			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:21984976;PMID:19962665	RDientsmann		ED		TRUE		MTOR inhibitors
PLCG2 (R665W,L845F)	PLCG2	MUT	PLCG2:R665W,L845F		Approved	BTK inhibitor	Ibrutinib	Resistant	Early trials		PMID:24869598	RDientsmann		CLL		TRUE		Ibrutinib (BTK inhibitor)
PML-RARA fusion	PML	FUS	PML__RARA		Approved	Retinoid	Tretinoin	Responsive	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	APML		TRUE		Tretinoin (Retinoid)
PML-RARA fusion	PML	FUS	PML__RARA		Approved	Retinoid;Chemotherapy	Tretinoin;Arsenic Trioxide	Responsive	FDA guidelines		FDA	RDientsmann		AML		TRUE	PML is the oncogene or rara??	Tretinoin + Arsenic Trioxide (Retinoid + Chemotherapy)
PML-RARA fusion	PML	FUS	PML__RARA	Indirect	Clinical Trials	PLK1 inhibitor	Volasertib	Responsive	Early trials		NCT02198482;NCT01662505	ECampo		AML		TRUE		Volasertib (PLK1 inhibitor)
POLEexonuclease domain mutation	POLE	MUT	POLE:268–471			[PD1 Ab inhibitor]	[]	Responsive	Case report		PMID:27001570;PMID:27683556;PMID:27159395	RDientsmann	06/16	G;ED		TRUE	Mutations in exonuclease domain. Domain coordinates from (PMID:23528559)	PD1 Ab inhibitors
PRKCH amplification + ABL1-BCR fusion	PRKCH;ABL1	CNA;FUS	PRKCH:amp;ABL1__BCR			MEK inhibitor;BCR-ABL inhibitor 1st gen&KIT inhibitor	Trametinib;Imatinib	Responsive	Pre-clinical		PMID:25186176	RDientsmann		CML		TRUE		Trametinib + Imatinib (MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor)
PTCH1 oncogenic mutation	PTCH1	MUT	PTCH1:.			MET inhibitor	Foretinib	Responsive	Pre-clinical		PMID:25391241	RDientsmann	01/16	MB		TRUE		Foretinib (MET inhibitor)
PTCH1 oncogenic mutation	PTCH1	MUT	PTCH1:.		Approved	[SMO inhibitor]	[]	Responsive	Pre-clinical		PMID:24651015 	DTamborero;RDientsmann	10/16	MB		TRUE		SMO inhibitors
PTCH1 oncogenic mutation	PTCH1	MUT	PTCH1:.		Approved	SHH inhibitor	Vismodegib	Responsive	FDA guidelines		PMID:19726763;PMID:19726761	RDientsmann		BCC;MB		TRUE		Vismodegib (SHH inhibitor)
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[PIK3CB inhibitor]	[]	Responsive	Case report		ASCO 2014 (abstr 2514)	RDientsmann	01/16	PRAD		TRUE		PIK3CB inhibitors
PTEN deletion	PTEN	CNA	PTEN:del			[PIK3CB inhibitor]	[]	Responsive	Case report		ASCO 2014 (abstr 2514)	RDientsmann	01/16	PRAD		TRUE		PIK3CB inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	RDientsmann	01/16	TH;G;L;OV;BRCA;CANCER;ED		TRUE		PI3K pathway inhibitors
PTEN deletion	PTEN	CNA	PTEN:del			[PI3K pathway inhibitor]	[]	Responsive	Pre-clinical		PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	RDientsmann	01/16	TH;G;L;OV;BRCA;CANCER;ED		TRUE		PI3K pathway inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[PI3K pathway inhibitor;AR antagonist]	[]	Responsive	Pre-clinical		PMID:21575859	RDientsmann	01/16	PRAD		TRUE		PI3K pathway inhibitor + AR antagonists
PTEN deletion	PTEN	CNA	PTEN:del			[PI3K pathway inhibitor;AR antagonist]	[]	Responsive	Pre-clinical		PMID:21575859	RDientsmann	01/16	PRAD		TRUE		PI3K pathway inhibitor + AR antagonists
PTEN deletion	PTEN	CNA	PTEN:del			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:21632463	RDientsmann	01/16	OV		TRUE		PI3K pathway inhibitor + MEK inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[PI3K pathway inhibitor;MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:21632463	RDientsmann	01/16	OV		TRUE		PI3K pathway inhibitor + MEK inhibitors
PTEN deletion	PTEN	CNA	PTEN:del			[MTOR inhibitor]	[]	No Responsive	Early trials		PMID:21788564;PMID:23238879	RDientsmann	01/16	ED		TRUE		MTOR inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[MTOR inhibitor]	[]	No Responsive	Early trials		PMID:21788564;PMID:23238879	RDientsmann	01/16	ED		TRUE		MTOR inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[AKT inhibitor]	[]	Responsive	Case report		PMID:22025163	RDientsmann	01/16	PA		TRUE		AKT inhibitors
PTEN deletion	PTEN	CNA	PTEN:del			[AKT inhibitor]	[]	Responsive	Case report		PMID:22025163	RDientsmann	01/16	PA		TRUE		AKT inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			MTOR inhibitor	Everolimus	Responsive	Early trials		PMID:23582881	RDientsmann	01/16	PRAD		TRUE		Everolimus (MTOR inhibitor)
PTEN deletion	PTEN	CNA	PTEN:del			MTOR inhibitor	Everolimus	Responsive	Early trials		PMID:23582881	RDientsmann	01/16	PRAD		TRUE		Everolimus (MTOR inhibitor)
PTEN deletion	PTEN	CNA	PTEN:del			MTOR inhibitor	Sirolimus	Responsive	Early trials		ASCO 2013 (abstr 2532)	RDientsmann	01/16	CANCER		TRUE		Sirolimus (MTOR inhibitor)
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			MTOR inhibitor	Sirolimus	Responsive	Early trials		ASCO 2013 (abstr 2532)	RDientsmann	01/16	CANCER		TRUE		Sirolimus (MTOR inhibitor)
PTEN deletion	PTEN	CNA	PTEN:del			[PD1 Ab inhibitor]	[]	Responsive	Early trials		PMID:26645196	RDientsmann	06/16	CM		TRUE		PD1 Ab inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[PD1 Ab inhibitor]	[]	Responsive	Early trials		PMID:26645196	RDientsmann	06/16	CM		TRUE		PD1 Ab inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[ATM inhibitor]	[]	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	BRCA		TRUE		ATM inhibitors
PTEN deletion	PTEN	CNA	PTEN:del			[EGFR mAb inhibitor]	[]	Resistant	Late trials		PMID:21163703;PMID:19398573	RDientsmann		COREAD		TRUE		EGFR mAb inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[EGFR mAb inhibitor]	[]	Resistant	Late trials		PMID:21163703;PMID:19398573	RDientsmann		COREAD		TRUE		EGFR mAb inhibitors
PTEN deletion	PTEN	CNA	PTEN:del			[PARP inhibitor]	[]	Responsive	Case report		PMID:21468130;PMID:20944090	RDientsmann		ED		TRUE	(low estrogen)	PARP inhibitors
PTEN oncogenic mutation	PTEN	MUT	PTEN:.			[PARP inhibitor]	[]	Responsive	Case report		PMID:21468130;PMID:20944090	RDientsmann		ED		TRUE	(low estrogen)	PARP inhibitors
PTEN biallelic inactivation	PTEN	BIA	PTEN:.		Clinical Trials	PIK3CA inhibitor	BYL719	Resistant	Case report		PMID:25409150	DTamborero		BRCA		TRUE		BYL719 (PIK3CA inhibitor)
PTEN biallelic inactivation	PTEN	BIA	PTEN:.		Approved	EGFR mAb inhibitor	Cetuximab	Resistant	Case report		Caris molecular intelligence	DTamborero		COREAD		TRUE		Cetuximab (EGFR mAb inhibitor)
PTEN biallelic inactivation	PTEN	BIA	PTEN:.			EGFR mAb inhibitor	Panitumumab	Resistant	Case report		Caris molecular intelligence	DTamborero		COREAD		TRUE		Panitumumab (EGFR mAb inhibitor)
PTEN deletion + BRAF oncogenic mutation	PTEN;BRAF	CNA;MUT	PTEN:del;BRAF:.			[BRAF inhibitor]	[]	Resistant	Pre-clinical		PMID:21317224;PMID:21725359	RDientsmann	01/16	CM		TRUE		BRAF inhibitors
PTEN oncogenic mutation + BRAF oncogenic mutation	PTEN;BRAF	MUT;MUT	PTEN:.;BRAF:.			[BRAF inhibitor]	[]	Resistant	Pre-clinical		PMID:21317224;PMID:21725359	RDientsmann	01/16	CM		TRUE		BRAF inhibitors
PTEN deletion + BRAF oncogenic mutation	PTEN;BRAF	CNA;MUT	PTEN:del;BRAF:.			[MEK inhibitor]	[]	Resistant	Pre-clinical		PMID:23039341	RDientsmann	01/16	CM		TRUE		MEK inhibitors
PTEN oncogenic mutation + BRAF oncogenic mutation	PTEN;BRAF	MUT;MUT	PTEN:.;BRAF:.			[MEK inhibitor]	[]	Resistant	Pre-clinical		PMID:23039341	RDientsmann	01/16	CM		TRUE		MEK inhibitors
PTEN deletion + BRAF oncogenic mutation	PTEN;BRAF	CNA;MUT	PTEN:del;BRAF:.			[BRAF inhibitor]	[]	Resistant	Pre-clinical		PMID:21317224;PMID:21725359	RDientsmann		CM		TRUE		BRAF inhibitors
PTEN oncogenic mutation + BRAF oncogenic mutation	PTEN;BRAF	MUT;MUT	PTEN:.;BRAF:.			[BRAF inhibitor]	[]	Resistant	Pre-clinical		PMID:21317224;PMID:21725359	RDientsmann		CM		TRUE		BRAF inhibitors
PTEN oncogenic mutation + ERBB2 amplification	PTEN;ERBB2	MUT;CNA	PTEN:.;ERBB2:amp			MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy	Everolimus;Trastuzumab;Chemotherapy	Responsive	Late trials		PMID:27091708	RDientsmann	01/16	BRCA		TRUE		Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)
PTPRD oncogenic mutation	PTPRD	MUT	PTPRD:.			[IGF1R inhibitor]	[]	Responsive	Case report		PMID:23800680	RDientsmann	12/16	S		TRUE		IGF1R inhibitors
RAC1 (P29S) + BRAF oncogenic mutation	RAC1;BRAF	MUT;MUT	RAC1:P29S;BRAF:.			[BRAF inhibitor]	[]	Resistant	Case report		PMID:25056119	RDientsmann	01/16	CM		TRUE		BRAF inhibitors
RAC1 (P29S) + BRAF oncogenic mutation	RAC1;BRAF	MUT;MUT	RAC1:P29S;BRAF:.			[BRAF inhibitor]	[]	Resistant	Case report		PMID:25056119	RDientsmann		CM		TRUE		BRAF inhibitors
RAD50 (L1237F) + ATM deletion	RAD50;ATM	MUT;CNA	RAD50:L1237F;ATM:del			TOPO1 inhibitor;CHK1/2 inhibitor	Irinotecan;CHK1/2 inhibitor	Responsive	Case report		PMID:24934408	RDientsmann	01/16	CANCER		TRUE		Irinotecan + CHK1/2 inhibitor (TOPO1 inhibitor + CHK1/2 inhibitor)
RAD51C oncogenic mutation	RAD51C	MUT	RAD51C:.			[PARP inhibitor]	[]	Responsive	Early trials		ASCO 2015 (abstr 5508)	RDientsmann	01/16	OV		TRUE		PARP inhibitors
RAD51C oncogenic mutation	RAD51C	MUT	RAD51C:.			[PARP inhibitor]	[]	Responsive	Early trials		ASCO 2015 (abstr 5508)	RDientsmann	04/16	OV		TRUE		PARP inhibitors
RAF1 fusion	RAF1	FUS	RAF1__.	Direct	Pre-clinical	[Pan-RAF inhibitor]	[]	Responsive	Pre-clinical	Cell line	PMID:20526349	ARodriguez-Vida	09/15	PRAD		TRUE		Pan-RAF inhibitors
RAF1 fusion	RAF1	FUS	RAF1__.	Indirect	Approved	MEK inhibitor	U0126	Responsive	Pre-clinical	Cell line	PMID:20526349	ARodriguez-Vida	09/15	PRAD		TRUE		U0126 (MEK inhibitor)
RAF1 overexpression	RAF1	EXPR	RAF1:over			Pan-TK inhibitor	Sorafenib	Responsive	Pre-clinical	Cell line	PMID:24375110	CdeTorres	10/16	OS		TRUE		Sorafenib (Pan-TK inhibitor)
RAF1 fusion	RAF1	FUS	RAF1__.			Pan-TK inhibitor	Sorafenib	Responsive	Pre-clinical		PMID:20526349	RDientsmann		PRAD		TRUE		Sorafenib (Pan-TK inhibitor)
RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation	RAF1;BRAF	MUT;MUT	RAF1:S257P,G361A,P261P;BRAF:.			[BRAF inhibitor]	[]	Resistant	Pre-clinical		PMID:23737487	RDientsmann		CM		TRUE		BRAF inhibitors
RB1 oncogenic mutation	RB1	MUT	RB1:.			[HDAC inhibitor]	[]	Responsive	Pre-clinical		PMID:18483379	RDientsmann	01/16	RB		TRUE		HDAC inhibitors
RB1 deletion	RB1	CNA	RB1:del			[HDAC inhibitor]	[]	Responsive	Pre-clinical		PMID:18483379	RDientsmann	01/16	RB		TRUE		HDAC inhibitors
RB1 overexpression	RB1	EXPR	RB1:over	Indirect	Pre-clinical	CDK4/6 inhibitor	PD-0332991	Responsive	Pre-clinical	Xenograft	PMID:23708653	ARodriguez-Vida	09/15	PRAD		TRUE		PD-0332991 (CDK4/6 inhibitor)
RB1 oncogenic mutation	RB1	MUT	RB1:.			[MDM2/MDMX inhibitor]	[]	Responsive	Pre-clinical		PMID:17080083;PMID:21515735	RDientsmann		RB		TRUE		MDM2/MDMX inhibitors
RB1 deletion	RB1	CNA	RB1:del			[MDM2/MDMX inhibitor]	[]	Responsive	Pre-clinical		PMID:17080083;PMID:21515735	RDientsmann		RB		TRUE		MDM2/MDMX inhibitors
RB1 oncogenic mutation	RB1	MUT	RB1:.	Indirect	Approved	Chemotherapy	Cisplatin	Responsive	Early trials		PMID:26238431	ARodriguez-Vida;RDientsmann		BLCA	BLCA	TRUE		Cisplatin (Chemotherapy)
RB1 deletion	RB1	CNA	RB1:del	Indirect	Approved	Chemotherapy	Cisplatin	Responsive	Early trials		PMID:26238431	ARodriguez-Vida;RDientsmann		BLCA	BLCA	TRUE		Cisplatin (Chemotherapy)
RET fusion	RET	FUS	RET__.			[RET inhibitor]	[]	Responsive	Pre-clinical		PMID:22327624;PMID:22327622	RDientsmann	01/16	LUAD		TRUE		RET inhibitors
RET-TPCN1 fusion	RET	FUS	RET__TPCN1			[RET inhibitor]	[]	Responsive	Pre-clinical		PMID:23056499	RDientsmann	01/16	TH		TRUE		RET inhibitors
RET (C634W,M918T)	RET	MUT	RET:C634W,M918T			[RET inhibitor]	[]	Responsive	Pre-clinical		PMID:23056499	RDientsmann	01/16	TH		TRUE		RET inhibitors
RET (C634W,M918T)	RET	MUT	RET:C634W,M918T			Pan-kinase inhibitor	Cabozantinib	Responsive	Pre-clinical		PMID:21470995	RDientsmann	01/16	TH		TRUE		Cabozantinib (Pan-kinase inhibitor)
RET fusion	RET	FUS	RET__.			Pan-kinase inhibitor	Cabozantinib	Responsive	Early trials,Case report		PMID:23533264;PMID:23584301;PMID:25366691;ASCO 2015 (abstr 8007);ENA 2015 (abstract LB-C17)	RDientsmann	01/16	LUAD		TRUE		Cabozantinib (Pan-kinase inhibitor)
RET (C634W,M918T)	RET	MUT	RET:C634W,M918T			Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical		PMID:21470995	RDientsmann	01/16	TH		TRUE		Sunitinib (Pan-TK inhibitor)
RET fusion	RET	FUS	RET__.			Pan-TK inhibitor	Vandetanib	Responsive	Early trials,Case report		PMID:23533264;PMID:23584301;PMID:25366691;ASCO 2015 (abstr 8007);ENA 2015 (abstract LB-C17)	RDientsmann	01/16	LUAD		TRUE		Vandetanib (Pan-TK inhibitor)
RET fusion	RET	FUS	RET__.			Pan-TK inhibitor	Nintedanib	Responsive	Case report		PMID:26787234	RDientsmann	06/16	LUAD		TRUE		Nintedanib (Pan-TK inhibitor)
RET-TPCN1 fusion	RET	FUS	RET__TPCN1			Pan-kinase inhibitor	Cabozantinib	Responsive	Pre-clinical		PMID:21470995	RDientsmann		THCA		TRUE		Cabozantinib (Pan-kinase inhibitor)
RET-TPCN1 fusion	RET	FUS	RET__TPCN1			Pan-TK inhibitor	Sunitinib	Responsive	Pre-clinical		PMID:21470995	RDientsmann		THCA		TRUE		Sunitinib (Pan-TK inhibitor)
RET (618,620,634,768,791,891,918,C634W,M918T)	RET	MUT	RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T		Approved	Pan-TK inhibitor	Vandetanib	Responsive	FDA guidelines		PMID:20065189;PMID:22025146	RDientsmann		THCA		TRUE		Vandetanib (Pan-TK inhibitor)
RET-TPCN1 fusion	RET	FUS	RET__TPCN1			Pan-TK inhibitor	Vandetanib	Responsive	Pre-clinical		PMID:21470995	RDientsmann		THCA		TRUE		Vandetanib (Pan-TK inhibitor)
RICTOR amplification	RICTOR	CNA	RICTOR:amp			[MTORC1/2 inhibitor]	[]	Responsive	Case report		PMID:26370156	RDientsmann	01/16	L		TRUE		MTORC1/2 inhibitors
RNF43 oncogenic mutation	RNF43	MUT	RNF43:.			[Porcupine inhibitor]	[]	Responsive	Case report		ENA 2015 (abstr C45)	RDientsmann	11/15	COREAD		TRUE		Porcupine inhibitors
ROS1 fusion	ROS1	FUS	ROS1__.			[HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:23533265	RDientsmann	01/16	LUAD		TRUE		HSP90 inhibitors
ROS1 (G2032R)	ROS1	MUT	ROS1:G2032R			Pan-kinase inhibitor	Cabozantinib	Responsive	Pre-clinical		PMID:25351743	RDientsmann	01/16	LUAD		TRUE		Cabozantinib (Pan-kinase inhibitor)
ROS1 fusion	ROS1	FUS	ROS1__.			ALK inhibitor	Crizotinib	Responsive	Case report		PMID:24875859	RDientsmann	01/16	IM		TRUE		Crizotinib (ALK inhibitor)
ROS1 fusion	ROS1	FUS	ROS1__.			ALK inhibitor	Crizotinib	Responsive	Early trials		PMID:25264305	RDientsmann	01/16	LUAD		TRUE		Crizotinib (ALK inhibitor)
ROS1 fusion	ROS1	FUS	ROS1__.		Clinical trials	ALK inhibitor	Crizotinib	Responsive	FDA guidelines		FDA	CRubio-Perez;EArriola		NSCLC		TRUE		Crizotinib (ALK inhibitor)
ROS1 (G2032R)	ROS1	MUT	ROS1:G2032R		Approved	ALK inhibitor	Crizotinib	Resistant	Case report		PMID:23724914;PMID:25688157	RDientsmann		LUAD		TRUE		Crizotinib (ALK inhibitor)
SERPINB3 oncogenic mutation	SERPINB3	MUT	SERPINB3:.			[CTLA4 inhibitor]	[]	Responsive	Early trials		PMID:27668655	RDientsmann	12/16	CM		TRUE		CTLA4 inhibitors
SETD2 deletion	SETD2	CNA	SETD2:del			[WEE1 inhibitor]	[]	Responsive	Pre-clinical		ENA 2014 (abstr 211)	RDientsmann		CANCER		TRUE		WEE1 inhibitors
SETD2 oncogenic mutation	SETD2	MUT	SETD2:.			[WEE1 inhibitor]	[]	Responsive	Pre-clinical		ENA 2014 (abstr 211)	RDientsmann		CANCER		TRUE		WEE1 inhibitors
SF3B1 (K700E,K666N)	SF3B1	MUT	SF3B1:K700E,K666N			[Spliceosome inhibitor]	[]	Responsive	Pre-clinical		ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	RDientsmann		CANCER		TRUE		Spliceosome inhibitors
SH2B3 deletion	SH2B3	CNA	SH2B3:del			[JAK inhibitor]	[]	Responsive	Pre-clinical		PMID:20404132	RDientsmann		MDPS		TRUE		JAK inhibitors
SH2B3 oncogenic mutation	SH2B3	MUT	SH2B3:.			[JAK inhibitor]	[]	Responsive	Pre-clinical		PMID:20404132	RDientsmann		MDPS		TRUE		JAK inhibitors
SLC29A1 oncogenic mutation	SLC29A1	MUT	SLC29A1:.			Chemotherapy	Gemcitabine	Resistant	Pre-clinical		PMID:21166756	ARodriguez-Vida	09/15	BLCA	BLCA	TRUE	SLC29A1 is HENT1 used symbol	Gemcitabine (Chemotherapy)
SMARCA1 oncogenic mutation	SMARCA1	MUT	SMARCA1:.			[EZH2 inhibitor]	[]	Responsive	Pre-clinical		PMID:26552009	RDientsmann	01/16	CANCER		TRUE		EZH2 inhibitors
SMARCA4 deletion	SMARCA4	CNA	SMARCA4:del			[EZH2 inhibitor]	[]	Responsive	Case report		ESMO 2015 (abstract 302)	RDientsmann	11/15	OV		TRUE		EZH2 inhibitors
SMARCA4 oncogenic mutation	SMARCA4	MUT	SMARCA4:.			[EZH2 inhibitor]	[]	Responsive	Case report		ESMO 2015 (abstract 302)	RDientsmann	11/15	OV		TRUE		EZH2 inhibitors
SMARCB1 deletion	SMARCB1	CNA	SMARCB1:del			[EZH2 inhibitor]	[]	Responsive	Case report		ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	RDientsmann	01/16	MRT		TRUE	INI1 gene symbol: SMARCB1	EZH2 inhibitors
SMARCB1 oncogenic mutation	SMARCB1	MUT	SMARCB1:.			[EZH2 inhibitor]	[]	Responsive	Case report		ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	RDientsmann	01/16	MRT		TRUE	INI1 gene symbol: SMARCB1	EZH2 inhibitors
SMARCB1 oncogenic mutation	SMARCB1	MUT	SMARCB1:.			[HDAC inhibitor]	[]	Responsive	Pre-clinical		PMID:26920892	RDientsmann	07/16	MRT		TRUE		HDAC inhibitors
SMARCB1 deletion	SMARCB1	CNA	SMARCB1:del		Clinical Trials	[EZH2 inhibitor]	[]	Responsive	Early trials		ESMO 2015 (abstract 302)	RDientsmann	11/15	MRT		TRUE		EZH2 inhibitors
SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	SMO	MUT	SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W			SHH inhibitor	Vismodegib	Resistant	Case report		PMID:25759020;PMID:25306392	DTamborero;RDientsmann	04/16	BCC		TRUE		Vismodegib (SHH inhibitor)
SMO (L225R,N223D,S391N,D338N,D473H,G457S,E518)	SMO	MUT	SMO:L225R,N223D,S391N,D338N,D473H,G457S,E518.			[SMO inhibitor]	[]	Resistant	Pre-clinical		PMID:24951114	DTamborero;RDientsmann		MB		TRUE		SMO inhibitors
SMO (D473H)	SMO	MUT	SMO:D473H			SHH inhibitor	Vismodegib	Resistant	Case report		PMID:19726788;PMID:25759019	RDientsmann		MB		TRUE		Vismodegib (SHH inhibitor)
SRSF2 oncogenic mutation	SRSF2	MUT	SRSF2:.			[Spliceosome inhibitor]	[]	Responsive	Pre-clinical		PMID:27135740	RDientsmann	06/16	AML		TRUE		Spliceosome inhibitors
STAG2 oncogenic mutation	STAG2	MUT	STAG2:.			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:24356817	RDientsmann		G		TRUE		PARP inhibitors
STK11 deletion	STK11	CNA	STK11:del			[SRC inhibitor;PI3K/MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:20541700	RDientsmann	01/16	LUAD		TRUE		SRC inhibitor + PI3K/MEK inhibitors
STK11 oncogenic mutation	STK11	MUT	STK11:.			[SRC inhibitor;PI3K/MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:20541700	RDientsmann	01/16	LUAD		TRUE		SRC inhibitor + PI3K/MEK inhibitors
STK11 (D194E)	STK11	MUT	STK11:D194E			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:21189378	RDientsmann	01/16	PA		TRUE		Everolimus (MTOR inhibitor)
STK11 deletion	STK11	CNA	STK11:del			Anti-diabetic	Phenformin	Responsive	Pre-clinical		PMID:23352126	RDientsmann	01/16	LUAD		TRUE		Phenformin (Anti-diabetic)
STK11 oncogenic mutation	STK11	MUT	STK11:.			Anti-diabetic	Phenformin	Responsive	Pre-clinical		PMID:23352126	RDientsmann	01/16	LUAD		TRUE		Phenformin (Anti-diabetic)
STK11 oncogenic mutation	STK11	MUT	STK11:.			[BET inhibitor]	[]	Resistant	Pre-clinical		PMID:23129625;PMID:24045185	RDientsmann	04/16	L		TRUE		BET inhibitors
STK11 deletion	STK11	CNA	STK11:del			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:19165201	RDientsmann		LUAD		TRUE		MEK inhibitors
STK11 oncogenic mutation	STK11	MUT	STK11:.			[MEK inhibitor]	[]	Responsive	Pre-clinical		PMID:19165201	RDientsmann		LUAD		TRUE		MEK inhibitors
STK11 deletion	STK11	CNA	STK11:del			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:19541609	RDientsmann		CANCER		TRUE		MTOR inhibitors
STK11 oncogenic mutation	STK11	MUT	STK11:.			[MTOR inhibitor]	[]	Responsive	Pre-clinical		PMID:19541609	RDientsmann		CANCER		TRUE		MTOR inhibitors
STK11 deletion + KRAS oncogenic mutation	STK11;KRAS	CNA;MUT	STK11:del;KRAS:.			MEK inhibitor;Chemotherapy	MEK inhibitor;Docetaxel	Resistant	Pre-clinical		PMID:22425996	RDientsmann	01/16	LUAD		TRUE		MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)
STK11 oncogenic mutation + KRAS oncogenic mutation	STK11;KRAS	MUT;MUT	STK11:.;KRAS:.			MEK inhibitor;Chemotherapy	MEK inhibitor;Docetaxel	Resistant	Pre-clinical		PMID:22425996	RDientsmann	01/16	LUAD		TRUE		MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)
SUZ12 deletion	SUZ12	CNA	SUZ12:del			[BET inhibitor]	[]	Responsive	Pre-clinical		PMID:25119042	RDientsmann		CANCER		TRUE		BET inhibitors
SUZ12 oncogenic mutation	SUZ12	MUT	SUZ12:.			[BET inhibitor]	[]	Responsive	Pre-clinical		PMID:25119042	RDientsmann		CANCER		TRUE		BET inhibitors
SYK amplification	SYK	CNA	SYK:amp			[SYK inhibitor]	[]	Responsive	Pre-clinical		PMID:16409295;PMID:19549911	RDientsmann		MCL;CLL		TRUE		SYK inhibitors
TMPRSS2 fusion	TMPRSS2	FUS	TMPRSS2__.			[DNA-PKc inhibitor]	[]	Responsive	Pre-clinical		PMID:21575865	RDientsmann	01/16	PRAD		TRUE		DNA-PKc inhibitors
TMPRSS2 fusion	TMPRSS2	FUS	TMPRSS2__.			[PARP inhibitor]	[]	Responsive	Pre-clinical		PMID:21575865	RDientsmann		PRAD		TRUE		PARP inhibitors
TOP2A amplification	TOP2A	CNA	TOP2A:amp			Chemotherapy	Anthracyclines	Responsive	Late trials		PMID:22864769	RDientsmann	01/16	BRCA		TRUE		Anthracyclines (Chemotherapy)
TP53 oncogenic mutation	TP53	MUT	TP53:.			[MDM2 inhibitor]	[]	Resistant	Early trials		PMID:23084521;ASCO 2015 (abstr 10564)	RDientsmann	01/16	LIP		TRUE		MDM2 inhibitors
TP53 (R248Q,R175H)	TP53	MUT	TP53:R248Q,R175H			[HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:26009011	RDientsmann	04/16	CANCER		TRUE		HSP90 inhibitors
TP53 oncogenic mutation	TP53	MUT	TP53:.			[WEE1 inhibitor]	[]	Responsive	Pre-clinical		PMID:25125259	RDientsmann		HNC		TRUE		WEE1 inhibitors
TP53 (R248Q,R175H)	TP53	MUT	TP53:R248Q,R175H			[HSP90 inhibitor]	[]	Responsive	Pre-clinical		PMID:26009011	RDientsmann		CANCER		TRUE	REMAP:R172H changed to R175H it was not the human mutation	HSP90 inhibitors
TP53 oncogenic mutation	TP53	MUT	TP53:.			CDK4/CDK6 inhibitor	Abemaciclib	Resistant	Early trials		PMID:27217383	RDientsmann	12/16	BRCA		TRUE		Abemaciclib (CDK4/CDK6 inhibitor)
TP53 deletion	TP53	CNA	TP53:del	Indirect	Clinical Trials	ATR inhibitor	AZD6738	Responsive	Early trials		NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	ECampo		BCL		TRUE		AZD6738 (ATR inhibitor)
TP53 oncogenic mutation	TP53	MUT	TP53:.	Indirect	Clinical Trials	ATR inhibitor	AZD6738	Responsive	Early trials		NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	ECampo		BCL		TRUE		AZD6738 (ATR inhibitor)
TP53 oncogenic mutation	TP53	MUT	TP53:.			Chemotherapy	Cisplatin	Resistant	Early trials		PMID:27646943	RDientsmann	12/16	FGCT;MGCT		TRUE		Cisplatin (Chemotherapy)
TP53 oncogenic mutation	TP53	MUT	TP53:.			Chemotherapy	Decitabine	Responsive	Early trials		PMID:27959731	RDientsmann	12/16	AML;MDPS		TRUE		Decitabine (Chemotherapy)
TP53 oncogenic mutation	TP53	MUT	TP53:.			Anthracycline antitumor antibiotic	Doxorubicin	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	BLCA		TRUE		Doxorubicin (Anthracycline antitumor antibiotic)
TP53 oncogenic mutation	TP53	MUT	TP53:.			Chemotherapy	Gemcitabine	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	BLCA		TRUE		Gemcitabine (Chemotherapy)
TP53 oncogenic mutation	TP53	MUT	TP53:.			Chemotherapy	Mitomycin C	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	BLCA		TRUE		Mitomycin C (Chemotherapy)
TP53 oncogenic mutation	TP53	MUT	TP53:.	Indirect	Clinical Trials	WEE1 inhibitor	MK-1775	Responsive	Early trials		NCT01357161;ASCO2015 (abstr 2507)	KKarube;RDientsmann		OV		TRUE		MK-1775 (WEE1 inhibitor)
TP53 oncogenic mutation	TP53	MUT	TP53:.			Amylin analogue	Pramlintide	Responsive	Pre-clinical		PMID:25409149	RDientsmann		THYM		TRUE		Pramlintide (Amylin analogue)
TP53 deletion	TP53	CNA	TP53:del			Amylin analogue	Pramlintide	Responsive	Pre-clinical		PMID:25409149	RDientsmann		THYM		TRUE		Pramlintide (Amylin analogue)
TPMT biallelic inactivation	TPMT	BIA	TPMT:.		Approved	Chemotherapy	Cisplatin	Increased Toxicity (Ototoxicity)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Cisplatin (Chemotherapy)
TPMT (A80P,Y240C,A154T,A167G)	TPMT	MUT	TPMT:A80P,Y240C,A154T,A167G		Approved	Chemotherapy	Cisplatin	Increased Toxicity (Ototoxicity)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Cisplatin (Chemotherapy)
TPMT splice acceptor variant	TPMT	MUT	TPMT::consequence::splice_acceptor_variant:.		Approved	Chemotherapy	Cisplatin	Increased Toxicity (Ototoxicity)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Cisplatin (Chemotherapy)
TPMT biallelic inactivation	TPMT	BIA	TPMT:.		Approved	Purine analog	Mercaptopurine	Increased Toxicity (Myelosupression)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Mercaptopurine (Purine analog)
TPMT (A80P,Y240C,A154T,A167G)	TPMT	MUT	TPMT:A80P,Y240C,A154T,A167G		Approved	Purine analog	Mercaptopurine	Increased Toxicity (Myelosupression)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Mercaptopurine (Purine analog)
TPMT splice acceptor variant	TPMT	MUT	TPMT::consequence::splice_acceptor_variant:.		Approved	Purine analog	Mercaptopurine	Increased Toxicity (Myelosupression)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Mercaptopurine (Purine analog)
TPMT biallelic inactivation	TPMT	BIA	TPMT:.		Approved	Guanine analog	Thioguanine	Increased Toxicity (Myelosupression)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Thioguanine (Guanine analog)
TPMT (A80P,Y240C,A154T,A167G)	TPMT	MUT	TPMT:A80P,Y240C,A154T,A167G		Approved	Guanine analog	Thioguanine	Increased Toxicity (Myelosupression)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Thioguanine (Guanine analog)
TPMT splice acceptor variant	TPMT	MUT	TPMT::consequence::splice_acceptor_variant:.		Approved	Guanine analog	Thioguanine	Increased Toxicity (Myelosupression)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Thioguanine (Guanine analog)
TSC1 oncogenic mutation	TSC1	MUT	TSC1:.			[MTOR inhibitor]	[]	Responsive	Early trials		PMID:23312829;PMID:21525172;PMID:20048174	RDientsmann	01/16	RA		TRUE		MTOR inhibitors
TSC1 oncogenic mutation	TSC1	MUT	TSC1:.	Indirect	Approved	MTOR inhibitor	Everolimus	Responsive	Early trials		PMID:22923433	RDientsmann	01/16	BLCA		TRUE	TSC1 or TSC2 mutated	Everolimus (MTOR inhibitor)
TSC1 deletion	TSC1	CNA	TSC1:del			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	RDientsmann	01/16	R		TRUE		Everolimus (MTOR inhibitor)
TSC1 oncogenic mutation	TSC1	MUT	TSC1:.			MTOR inhibitor	Everolimus	Responsive	Case report		PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	RDientsmann	01/16	R		TRUE		Everolimus (MTOR inhibitor)
TSC1 oncogenic mutation	TSC1	MUT	TSC1:.		Approved	MTOR inhibitor	Everolimus	Responsive	FDA guidelines		FDA	DTamborero	04/16	GCA		TRUE	Tuberous sclerosis complex in 80% of cases = mutations in TSC1 or TSC2	Everolimus (MTOR inhibitor)
TSC1 oncogenic mutation	TSC1	MUT	TSC1:.		Approved	MTOR inhibitor	Everolimus	Responsive	Case report		PMID:26859683	RDientsmann	06/16	S;ST		TRUE		Everolimus (MTOR inhibitor)
TSC1 (E17K)	TSC1	MUT	TSC1:E17K			MTOR inhibitor	Tensirolimus	Responsive	Case report		PMID:27016228	RDientsmann	07/16	ED		TRUE		Tensirolimus (MTOR inhibitor)
TSC1 oncogenic mutation	TSC1	MUT	TSC1:.		Approved	MTOR inhibitor	Everolimus	Responsive	FDA guidelines		FDA	ARodriguez-Vida	09/15	RA	RA	TRUE	TSC positive.Renal angilypoma is benign tumor	Everolimus (MTOR inhibitor)
TSC2 oncogenic mutation	TSC2	MUT	TSC2:.			[MTOR inhibitor]	[]	Responsive	Early trials		PMID:23312829;PMID:21525172;PMID:20048174	RDientsmann	01/16	RA		TRUE		MTOR inhibitors
TSC2 (Q1178*)	TSC2	MUT	TSC2:Q1178*	Indirect	Approved	MTOR inhibitor	Everolimus	Responsive	Case report		PMID:25295501	CRubio-Perez;RDientsmann	01/16	THCA		TRUE		Everolimus (MTOR inhibitor)
TSC2 oncogenic mutation	TSC2	MUT	TSC2:.	Indirect	Approved	MTOR inhibitor	Everolimus	Responsive	Early trials		PMID:22923433	RDientsmann	01/16	BLCA		TRUE	TSC1 or TSC2 mutated	Everolimus (MTOR inhibitor)
TSC2 oncogenic mutation	TSC2	MUT	TSC2:.		Approved	MTOR inhibitor	Everolimus	Responsive	FDA guidelines		FDA	ARodriguez-Vida;DTamborero	04/16	RA;GCA	RA	TRUE	TSC positive.Renal angilypoma is benign tumor	Everolimus (MTOR inhibitor)
TSC2 (E17K)	TSC2	MUT	TSC2:E17K			MTOR inhibitor	Tensirolimus	Responsive	Case report		PMID:27016228	RDientsmann	07/16	ED		TRUE		Tensirolimus (MTOR inhibitor)
TSC2 deletion	TSC2	CNA	TSC2:del			[SRC inhibitor]	[]	Responsive	Pre-clinical		PMID:24691995	RDientsmann		LAM		TRUE	Lymphangioleiomyomatosis (LAM) is a rare, progressive, systemic disease that typically results in cystic lung destruction	SRC inhibitors
TSC2 oncogenic mutation	TSC2	MUT	TSC2:.			[SRC inhibitor]	[]	Responsive	Pre-clinical		PMID:24691995	RDientsmann		LAM		TRUE		SRC inhibitors
TUBB3 overexpression	TUBB3	EXPR	TUBB3:over			Taxane	Paclitaxel	Resistant	Pre-clinical		PMID:23184177	ARodriguez-Vida	09/15	BLCA	BLCA	TRUE		Paclitaxel (Taxane)
U2AF1 oncogenic mutation	U2AF1	MUT	U2AF1:.			[FLT3 inhibitor]	[]	Responsive	Pre-clinical		PMID:27397505	RDientsmann	07/16	CANCER		TRUE		FLT3 inhibitors
UGT1A1 biallelic inactivation	UGT1A1	BIA	UGT1A1:.		Approved	TOPO1 inhibitor	Irinotecan	Increased Toxicity	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Irinotecan (TOPO1 inhibitor)
UGT1A1 (G71R,P229Q)	UGT1A1	MUT	UGT1A1:G71R,P229Q		Approved	TOPO1 inhibitor	Irinotecan	Increased Toxicity	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Irinotecan (TOPO1 inhibitor)
UGT1A1 biallelic inactivation	UGT1A1	BIA	UGT1A1:.		Approved	BCR-ABL inhibitor 2nd gen	Nilotinib	Increased Toxicity (Hyperbilirubinemia)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Nilotinib (BCR-ABL inhibitor 2nd gen)
UGT1A1 (G71R,P229Q)	UGT1A1	MUT	UGT1A1:G71R,P229Q		Approved	BCR-ABL inhibitor 2nd gen	Nilotinib	Increased Toxicity (Hyperbilirubinemia)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Nilotinib (BCR-ABL inhibitor 2nd gen)
UGT1A1 biallelic inactivation	UGT1A1	BIA	UGT1A1:.		Approved	VEGFR inhibitor	Pazopanib	Increased Toxicity (Hyperbilirubinemia)	FDA guidelines		FDA	DTamborero;CRubio-Perez	01/16	CANCER		TRUE		Pazopanib (VEGFR inhibitor)
VEGFA amplification	VEGFA	CNA	VEGFA:amp			Pan-TK inhibitor	Sorafenib	Responsive	Early trials		PMID:24687604	RDientsmann	01/16	HC		TRUE		Sorafenib (Pan-TK inhibitor)
VHL oncogenic mutation	VHL	MUT	VHL:.	Indirect	Approved	[VEGFR inhibitor]	[Sorafenib,Sunitinib,Bevacizumab,Axitinib]	Responsive	Pre-clinical	Retrospective analysis	PMID:18635227	ARodriguez-Vida	09/15	R		TRUE		VEGFR inhibitors (Sorafenib,Sunitinib,Bevacizumab,Axitinib,etc)
ZBTB16 undexpression	ZBTB16	EXPR	ZBTB16:under			[LHRH analogues or antagonist]	[]	Resistant	Pre-clinical		PMID:16637071	ARodriguez-Vida	09/15	PRAD	PR	TRUE		LHRH analogues or antagonists
ZNRF3 oncogenic mutation	ZNRF3	MUT	ZNRF3:.			[Porcupine inhibitor]	[]	Responsive	Pre-clinical		PMID:26023187	RDientsmann		COREAD		TRUE		Porcupine inhibitors
TERT promoters core	TERT	MUT	TERT::consequence::promoters_core:.			Macrocyclic analog	Eribulin	Responsive	Pre-clinical		PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	CRubio-Perez	02/17	GBM		TRUE		Eribulin (Macrocyclic analog)
